<?xml version="1.0" encoding="UTF-8"?>
<ONIXMessage release="3.0" xmlns="http://ns.editeur.org/onix/3.0/reference" >
<Header><Sender><SenderName>unglue.it</SenderName><EmailAddress>unglueit@ebookfoundation.org</EmailAddress></Sender><SentDateTime>20260627T165756Z</SentDateTime><MessageNote>Unglue.it Meta-analysis</MessageNote></Header><Product><RecordReference>it.unglue.work.647600.866050</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>866050</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>10th Anniversary of Biomedicines—Translational Laboratory and Experimental Medicine for the Sake of Neurological Diseases and Mental Illnesses</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Masaru Tanaka</PersonName><PersonNameInverted>Tanaka, Masaru</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>?-synuclein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>?-synucleinopathies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Activation Likelihood Estimation (ALE)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADHD model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>affective components</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>alcohol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Amygdala</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Amyotrophic lateral sclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>animal model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence (AI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Attention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism Spectrum Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>axon outgrowth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain derived neurotrophic factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain Injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain-Derived Neurotrophic Factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brainstem</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Central nervous system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cerebellum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebral infarction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebrovascular diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical evidence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical Trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognitive decline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conditioned medium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cuprizone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Death</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Demyelination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental pulp stem cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dentate Gyrus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnostic and Statistical Manual of Mental Disorders Fifth Edition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diaschisis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>directed forgetting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dizziness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dopamine (DA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dopamine transporter knockout (DAT-KO) rats</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dose effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>downregulate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug screen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug-naïve</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>duloxetine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysbiosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGFR pathway inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Electroencephalography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Emotions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enteric nervous system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>escitalopram</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Executive Function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>febrile seizure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>first-episode</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fMRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional NIRS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastrointestinal dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gaze perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gaze-cueing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genetic diversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glia cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>guanfacine (GF)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut–brain axis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hamilton Rating Scale for Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hippocampus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>homocysteine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imbalance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>induced pluripotent stem cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammasomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intentional forgetting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interleukin-6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemic stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ketamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kynurenine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kynurenine pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>latent dirichlet allocation (LDA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Local Field Potentials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Locomotion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lower back pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>major depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medial prefrontal cortex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Melatonin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mental illness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesial temporal lobe epilepsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitochondria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mitochondrial respiration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motoneuron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor disability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Multiple Sclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>near-infrared spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neural plasticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurocognitive mechanisms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegenerative disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurodegenerative Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurologic patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurological disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurons</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuropathology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroplasticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurotrophic factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NLRP3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NMDA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-invasive brain stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-motor symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>norepinephrine (NE)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open field test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osimertinib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcome measures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain catastrophizing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parkinson’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>paroxetine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral nervous system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacological response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PPMS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>remyelination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reperfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>respiratory chain complex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rodent models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rotarod test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sensation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Serotonin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sociability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spatial working memory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SPECT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal cord injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SPMS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stroke registry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Subventricular zone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Suicidal behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>superior temporal sulcus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supplementary motor area</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thalamus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapeutics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trajectory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>translational</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tryptophan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UBL3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vertebrobasilar insufficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vertigo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virus encephalitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>voltage gated sodium channel NaV1.1</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The 10th Anniversary of Biomedicines—Translational Laboratory and Experimental Medicine for the Sake of Neurological Diseases and Mental Illnesses features a collection of 21 groundbreaking papers commemorating a decade of pioneering research into the complexities of the human mind, neurological diseases, and mental illnesses. This reprint explores the complex interactions that occur within the human brain, including neuroplasticity, cognitive responses, and the influence of aging and pathological conditions on behavior. Researchers and clinicians have dedicated themselves to bridging the gap between laboratory discoveries and clinical applications, unraveling the mysteries of brain function and mental health, and proposing novel therapeutic approaches and potential advances in the field. This articles included in this Special Issue crucially elucidate the mechanisms that underpin neurological disorders and mental illnesses by investigating neural circuits, plasticity, and brain adaptation. From studying the brain's ability to recover after a stroke to investigating the relationship between neural activity and cognitive function, this collection of papers exemplifies the unwavering dedication and innovation of biomedicine. As we commemorate a decade of groundbreaking research, these findings pave the way for future studies that aim to enhance the lives of people suffering from neurological conditions and mental health illnesses.<br/><br/>Listed by <a href="https://unglue.it/work/647600/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466284/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.647192.865642</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865642</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>A Multidisciplinary Approach in Head and Neck Malignancies</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Marco Zeppieri</PersonName><PersonNameInverted>Zeppieri, Marco</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Tamara Ius</PersonName><PersonNameInverted>Ius, Tamara</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Filippo Flavio Angileri</PersonName><PersonNameInverted>Angileri, Filippo Flavio</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Antonio Pontoriero</PersonName><PersonNameInverted>Pontoriero, Antonio</PersonNameInverted></Contributor><Contributor><SequenceNumber>5</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Alessandro Tel</PersonName><PersonNameInverted>Tel, Alessandro</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>alcohol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ALK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anaplastic large-cell lymphoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Anatomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>awake surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>betel nut</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biopsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain Mapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain metastases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain tumors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotid blow out syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD-30</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>craniospinal irradiation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DTI MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Endoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extent of surgical resection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FLAIR infiltration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frail elderly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>geriatric assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glioblastoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hTERT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human papillomavirus (HPV)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IDH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intensity modulation radiation therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>irradiation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ki-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meckel’s cave</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MGMT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microsurgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>MUS000000</SubjectCode><SubjectHeadingText>Music</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuro-Oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuroanatomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NSCLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oropharyngeal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overall survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pilocytic astrocytoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pineal gland</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pineal parenchymal tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pineal region</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary central nervous system lymphoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary gliosarcoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>progression-free survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pseudocapsule</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative comparison</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-time neuropsychological testing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skull base surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Smoking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spheno-orbital meningiomas</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stereotactic radiosurgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical approaches</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thalamopeduncular syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thalamopeduncular tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transcranial Magnetic Stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transorbital surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment-effect modifier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor volume</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vessel graft</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vessel-depleted neck</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This comprehensive reprint, authored by leading experts in the field, investigates the different aspects of the developments in neuro-oncology, including diagnostic tools, imaging, treatment, and surgical strategies. From the prognostic significance of volumetric MRI evaluation in glioblastoma surgery to the transformative potential of the transorbital approach in neurosurgery, this reprint covers a wide array of topics which are crucial for optimizing patient outcomes. Advanced imaging modalities for pediatric thalamopeduncular tumors and the utility of radiologically defined sarcopenia in head and neck cancer patients are also discussed. Key molecular drivers of metastatic disease, such as EGFR mutations in lung cancer, and emerging treatment paradigms for rare entities like primary intracranial gliosarcoma and ALK-positive lymphomas are studied. Real-time neuropsychological testing during awake surgery and innovative surgical techniques for complex lesions like spheno-orbital meningiomas are also discussed. This reprint serves as an indispensable resource for neurosurgeons, oncologists, radiologists, and researchers who seek to stay abreast of the latest developments in neuro-oncology and enhance patient care.<br/><br/>Listed by <a href="https://unglue.it/work/647192/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466233/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.580406.776417</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>776417</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advancements in Sports Medicine</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jiwu Chen</PersonName><PersonNameInverted>Chen, Jiwu</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yaying Sun</PersonName><PersonNameInverted>Sun, Yaying</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACLR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aerobic training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>albumin-to-alkaline phosphatase ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>allografts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anchor pullout</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>balance exercises</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biologics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cartilage volume</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>degenerative lumbar diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>demineralized bone matrix</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elite football</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise testing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>femoroacetabular impingement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>femoroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gait retraining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gingivitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hamstring tendon with preserved tibial insertion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip arthroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>injury prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kinematics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>labrum repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>longitudinal capsulotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maximal aerobic capacity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical endurance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic marker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pullout strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resistance training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rotator cuff</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rotator cuff repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rotator cuff tear</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>running-related injuries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Shoulder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal fusion rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sports injuries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sports monitorization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vascular function</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This reprint focuses on the current progress in sports medicine, with a specific interest in surgery, exercise therapy, and multi-disciplinary research. With the advancement of society, more attention is paid to the quality of life, which emphasizes the importance of sports and exercise. Correspondingly, there is a great need for sports medicine. This issue collected novel findings on sports medicine in surgery, conservative therapy, and the application of exercise training in other disorders<br/><br/>Listed by <a href="https://unglue.it/work/580406/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/414229/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518983.695130</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695130</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advances in Autism Research</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Antonio Narzisi</PersonName><PersonNameInverted>Narzisi, Antonio</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2019-nCoV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>accuracy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>action observation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>action prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Adolescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adulthood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults and adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>affiliative behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alexithymia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Amygdala</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antibodies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AQ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>ART000000</SubjectCode><SubjectHeadingText>Art</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ASD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Asperger Syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attention deficit and hyperactivity disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attention to detail</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autism in adulthood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism Spectrum Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autism spectrum disorder (ASD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism Spectrum Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autistic traits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autistic-like features</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autonomic Nervous System</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian false-discovery probability (BFDP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behavioral intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Belief</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bipolar Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood–brain barrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BOT-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>broader autism phenotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabidiol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabidivarin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>central coherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebrospinal fluid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>challenging behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>challenging behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child and Adolescent Psychiatry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Communication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Comorbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>compulsion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>context</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cortisol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COSMIN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-cultural generalisability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dental care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental language disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental trajectories</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disruptive behavior disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dopamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Draw-a-Man</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drawings maturity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early intensive behavioral intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early intensive intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Early Intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Early Start Denver Model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EEG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Empathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Employment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Epilepsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ERP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Europe</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>executive functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Experience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eye tracking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>false positive report probability (FPRP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feeding problems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>First Year Inventory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frontal EEG alpha asymmetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GAD65</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastrointestinal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome-Wide Association Studies (GWAS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gilles de la Tourette</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grammatical comprehension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>group activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gulf</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-functioning autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-risk infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HMD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human figure drawings</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperactivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypothalamus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ICT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>identify</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Imitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immersive virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infant screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intellectual Disability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IVR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Joint attention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knowledge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Language</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>language acquisition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>language profiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>level 1 and level 2 screening tools</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Life sciences: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>literature review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Longitudinal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical procedures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mental health prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>migration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>moderators and mediators of intervention.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motion analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor performance skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mouse social behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodevelopment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurodevelopmental Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurosciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obsession</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxytocin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>p-cresol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PAI-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Parents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PEERS®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perspective-taking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>persuasive text writing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postural balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>precise medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preconception risk factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Preschool teachers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prevalence estimate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>priors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PRISMA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>problem behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Proprioception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Psychopathology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>régression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regressive autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reward response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RewP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Schizophrenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-awareness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Self-efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-motion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semantic features</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensitization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensorimotor integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory experience questionnaire (SEQ)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory responsiveness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>short sensory profile (SSP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Side effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sign language</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social Behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social skills intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social-cognitive development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stereotypical behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>study design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidal attempts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidal ideation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surveillance review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TAS-20</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telehealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>THC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Theory of Mind</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Toddlers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TSIA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>validity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video signal processing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Vision</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>visual impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wearable sensors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>word learning</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book represents one of the most up-to-date collections of articles on clinical practice and research in the field of Autism Spectrum Disorders (ASD). The scholars who contributed to this book are experts in their field, carrying out cutting edge research in prestigious institutes worldwide (e.g., Harvard Medical School, University of California, MIND Institute, King’s College, Karolinska Institute, and many others). The book addressed many topics, including (1) The COVID-19 pandemic; (2) Epidemiology and prevalence; (3) Screening and early behavioral markers; (4) Diagnostic and phenotypic profile; (5) Treatment and intervention; (6) Etiopathogenesis (biomarkers, biology, and genetic, epigenetic, and risk factors); (7) Comorbidity; (8) Adulthood; and (9) Broader Autism Phenotype (BAP). This book testifies to the complexity of performing research in the field of ASD. The published contributions underline areas of progress and ongoing challenges in which more certain data is expected in the coming years. It would be desirable that experts, clinicians, researchers, and trainees could have the opportunity to read this updated text describing the challenging heterogeneity of Autism Spectrum Disorder.<br/><br/>Listed by <a href="https://unglue.it/work/518983/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/8c/69/8c69931e5ee8924a7bff46ed21c65fb2.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368374/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.519120.695267</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695267</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advances in Autism Research</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Antonio Narzisi</PersonName><PersonNameInverted>Narzisi, Antonio</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2019-nCoV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>accuracy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>action observation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>action prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Adolescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adulthood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults and adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>affiliative behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alexithymia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Amygdala</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antibodies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AQ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>ART000000</SubjectCode><SubjectHeadingText>Art</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ASD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Asperger Syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attention deficit and hyperactivity disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attention to detail</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autism in adulthood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism Spectrum Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autism spectrum disorder (ASD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism Spectrum Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autistic traits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autistic-like features</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autonomic Nervous System</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian false-discovery probability (BFDP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behavioral intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Belief</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bipolar Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood–brain barrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BOT-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>broader autism phenotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabidiol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannabidivarin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>central coherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebrospinal fluid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>challenging behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>challenging behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child and Adolescent Psychiatry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Communication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Comorbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>compulsion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>context</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cortisol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COSMIN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-cultural generalisability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dental care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental language disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental trajectories</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disruptive behavior disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dopamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Draw-a-Man</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drawings maturity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early intensive behavioral intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early intensive intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Early Intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Early Start Denver Model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EEG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Empathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Employment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Epilepsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ERP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Europe</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>executive functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Experience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eye tracking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>false positive report probability (FPRP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feeding problems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>First Year Inventory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frontal EEG alpha asymmetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GAD65</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastrointestinal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome-Wide Association Studies (GWAS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gilles de la Tourette</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grammatical comprehension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>group activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gulf</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-functioning autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-risk infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HMD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human figure drawings</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperactivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypothalamus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ICT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>identify</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Imitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immersive virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infant screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intellectual Disability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IVR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Joint attention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knowledge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Language</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>language acquisition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>language profiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>level 1 and level 2 screening tools</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Life sciences: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>literature review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Longitudinal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical procedures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mental health prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>migration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>moderators and mediators of intervention.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motion analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor performance skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mouse social behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodevelopment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurodevelopmental Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurosciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obsession</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxytocin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>p-cresol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PAI-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Parents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PEERS®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perspective-taking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>persuasive text writing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postural balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>precise medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preconception risk factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Preschool teachers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prevalence estimate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>priors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PRISMA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>problem behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Proprioception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Psychopathology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>régression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regressive autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reward response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RewP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Schizophrenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-awareness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Self-efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-motion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semantic features</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensitization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensorimotor integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory experience questionnaire (SEQ)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory responsiveness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>short sensory profile (SSP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Side effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sign language</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social Behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social skills intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social-cognitive development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stereotypical behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>study design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidal attempts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidal ideation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surveillance review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TAS-20</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telehealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>THC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Theory of Mind</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Toddlers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TSIA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>validity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video signal processing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Vision</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>visual impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wearable sensors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>word learning</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book represents one of the most up-to-date collections of articles on clinical practice and research in the field of Autism Spectrum Disorders (ASD). The scholars who contributed to this book are experts in their field, carrying out cutting edge research in prestigious institutes worldwide (e.g., Harvard Medical School, University of California, MIND Institute, King’s College, Karolinska Institute, and many others). The book addressed many topics, including (1) The COVID-19 pandemic; (2) Epidemiology and prevalence; (3) Screening and early behavioral markers; (4) Diagnostic and phenotypic profile; (5) Treatment and intervention; (6) Etiopathogenesis (biomarkers, biology, and genetic, epigenetic, and risk factors); (7) Comorbidity; (8) Adulthood; and (9) Broader Autism Phenotype (BAP). This book testifies to the complexity of performing research in the field of ASD. The published contributions underline areas of progress and ongoing challenges in which more certain data is expected in the coming years. It would be desirable that experts, clinicians, researchers, and trainees could have the opportunity to read this updated text describing the challenging heterogeneity of Autism Spectrum Disorder.<br/><br/>Listed by <a href="https://unglue.it/work/519120/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a4/63/a4636ee47ec9182f6ba3f57043f263a7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368445/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492443.660232</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>660232</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advances in Diagnosis and Therapy of Neuroendocrine Neoplasms</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Eva Segelov</PersonName><PersonNameInverted>Segelov, Eva</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2017 WHO classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2019 WHO classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer-driven genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcinoid heart disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcinoid syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CommNETs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curative surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>follow-up</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>germline mutations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grading</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>guidelines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver metastases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-term functional outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignant castration-resistant prostatic cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MANEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medullary thyroid carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metronomic treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>midgut</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MiNENs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mixed adeno-neuroendocrine carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mixed non-neuroendocrine neuroendocrine neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modified Delphi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multidisciplinary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mutational mechanism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NETs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumours</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Notch</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic exocrine insufficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic NET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic neuroendocrine neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic neuroendocrine tumours</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parenchyma-sparing surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>QPIs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality performance indicators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>relapse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risk factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>second-line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small bowel NET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small bowel neuroendocrine tumours</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small cell lung carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>somatostatin analogues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Staging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>temozolomide</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue is dedicated to neuroendocrine neoplasms (NENs), a category of malignancy that demonstrates wide clinical heterogeneity, posing major challenges in diagnosis and management. There have been significant advances in the field of NEN genomics, pathology, imaging, and treatment over the past five years. NENs are examples of rare tumours (although their incidence and prevalence are increasing) where international collaborative efforts have allowed the generation of high-level evidence to guide optimal patient-centred care. This issue presents both reviews and original papers to provide comprehensive state-of-the-art understanding of this fascinating disease.<br/><br/>Listed by <a href="https://unglue.it/work/492443/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382549/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.567057.758684</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>758684</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advances in Molecular Genetics of Brain Tumors</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Nives Pećina-Šlaus</PersonName><PersonNameInverted>Pećina-Šlaus, Nives</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ivana Jovčevska</PersonName><PersonNameInverted>Jovčevska, Ivana</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>18F-FET PET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bevacizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BIRC3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BMP4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain tumours</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CAM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cancer Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cancer stem cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell proliferation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DCX</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Doublecortin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Drosophila</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug sensitivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DVL1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>EDU000000</SubjectCode><SubjectHeadingText>Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EZH2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional precision oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GBM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Genetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glioblastoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IDH mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IDH1 mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunofluorescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunohistochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intracranial meningioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>KCC2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microglia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular Targeted Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multicriterial analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NAD+ synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NES</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NF2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nicotinamide phosphoribosyltransferase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NKCC1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>olfactomedin-like 3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>OLIG2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PCNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PDZ domain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pediatric glioblastoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pentose Phosphate Pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PI3K</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pseudoprogression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiation necrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox household</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>schwannoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SH3PXD2A-HTRA1 fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single cell RNA-seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stemness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>temozolomide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TGFβ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JN Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment-related changes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>true progression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VEGF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wnt Signaling Pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-catenin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This reprint encompasses a number of articles that focus on the molecular blueprint of brain tumors. A collection of relevant papers in the rapidly expanding field of brain tumor molecular genetics broadens our knowledge about the biology of brain tumors, and inspires further studies that will improve the diagnosis and clinical management of brain tumors. Due to the great heterogeneity of brain tumors it is important to research and understand every aspect of their initiation, progression and metastasis in order to design better diagnostic and therapeutic approaches for their clinical management and patient benefit.<br/><br/>Listed by <a href="https://unglue.it/work/567057/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/76/84/7684ecaef03d584cf35aedf86fd7e890.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407079/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.562129.752130</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>752130</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Advances on Scoliogeny, Diagnosis and Management of Scoliosis and Spinal Disorders</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Theodoros B. Grivas</PersonName><PersonNameInverted>Grivas, Theodoros B.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>22q11.2 deletion syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adolescent idiopathic scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aetiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body height</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body posture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brace concepts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brace therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bracing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cobb angle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computed Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corrective exercises</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-sectional area</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cultural adaptation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curve morphology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>differentially expressed proteins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital photography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early onset scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>follow-up study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>home exercise program</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>idiopathic scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intraspinal anomaly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Italian Spine Youth Quality of Life Questionnaire</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iTRAQ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lateral spinal profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maturation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Motor Skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodynamic functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuromuscular scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>night time brace</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nighttime orthotic treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-operative treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ossification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>paraspinal muscles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathobiomechanics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalised approach</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical therapy modalities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physiotherapeutic scoliosis-specific exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>posterior approach</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>progressive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary function test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rett Syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rigid brace</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ring apophysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sclerostin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scoliometer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shared decision-making</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal appearance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal deformities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sports activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SRS-22</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surface topography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telerehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>truncal asymmetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wnt Signaling Pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-actin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-catenin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book contains research articles on the advances in the aetiology of idiopathic scoliosis (IS), the spinal growth related to the implementation of growth modulation for the surgical treatment of early-onset IS, the non-surgical treatment of IS using Physiotheraputic Scoliosis Specific Exercises, and braces. Additionally, it focuses on issues related to surgical treatment, issues related to body posture and the quality of life of this sensitive group of people. The high quality of published papers in this Special Issue of the JCM serve these objectives.<br/><br/>Listed by <a href="https://unglue.it/work/562129/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/396057/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.589424.787834</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>787834</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Anesthetic Management in Perioperative Period</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Patrice Forget</PersonName><PersonNameInverted>Forget, Patrice</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adverse effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aesthetic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>airway complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>airway management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ambulatory monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ambulatory surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anaesthetic techniques</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Analgesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial catheterization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>association analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bimaxillary surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blepharoplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Blood transfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer-free survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac index (CI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiac Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiopulmonary bypass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>catecholamines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell salvage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>central venous catheters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebral oxygen saturation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebral tissue oxygen saturation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cervicofacial oncologic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chloroprocaine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical data prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conscious sedation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Copeptin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary stents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>correlations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Critical Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>desflurane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dexamethasone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dexmedetomidine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diffusing capacity for carbon monoxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>echocardiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emergence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial demage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enhanced recovery after surgery (ERAS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidural Analgesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erector spinae plane block</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extubation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fast-and-frugal decision trees</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>fasting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fibula free flap</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluid management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Frailty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>general anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hematoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemodynamic monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemodynamics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hip Fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypotension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hysterectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iloprost</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>impedance cardiography (ICG)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infective endocarditis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intensive care unit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intraoperative Complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intrathecal analgesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intravenous infusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive blood pressure monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isoflurane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Laryngoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>left subclavian vein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LGEA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>local anesthetic toxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>local anesthetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>loco-regional anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnesium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>major abdominal surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>McGrath</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mechanical ventilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical decision making</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methylene blue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>midazolam</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MINS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>morbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple trauma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle strength dynamometer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle weakness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nasotracheal intubation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>near-infrared</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>near-infrared spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neostigmine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nerve block</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuromuscular blockade reversals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuromuscular scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuroprotection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NICCOMO</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>noncardiac surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obstructive sleep apnea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adult patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>one-lung ventilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opioid consumption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opioid free anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opioid reduced anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>organ failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxygenation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pediatrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peri-operative anaesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative patient management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative cognitive dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative delirium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative recovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pre-op</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>propensity score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoas muscle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulse wave transit time</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quadratus lumborum block</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rebound pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>residual neuromuscular blockade</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ristocetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robot-assisted surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic-assisted prostatectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ropivacaine infiltration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sedation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sevoflurane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shock</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sonography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal anaesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Spine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spondylosurgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stent to surgery time interval</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STOP BANG questionnaire</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>superior vena cava</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supplemental oxygen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical procedures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic vascular resistance index (SVRI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thoracotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thyromental height test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TIVA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total intravenous anaesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total intravenous anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total knee replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tourniquet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcranial Doppler</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transurethral resection of bladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transurethral resection of prostate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Traumatic Brain Injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>troponin I</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasoplegia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasoplegic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasopressin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video-assisted thoracic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>videolaryngoscope</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vital stability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>volatile anaesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>volatile anesthetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>von Willebrand factor</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>There are a variety of anesthetic management options during surgery, and these are constantly evolving. Both innovative and confirmatory research are important if the scientific community aims to develop and improve people’s quality of care. This reprint introduces new avenues and covers questions regarding innovative anesthetic techniques and unmet needs after surgery, paving the way for future improvements. It can be useful for both clinicians and clinical researchers, especially in light of the expansion of concepts like personalized care.<br/><br/>Listed by <a href="https://unglue.it/work/589424/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/420980/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.543860.727892</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>727892</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Anti-aging Nutrients with Health Beneficial Effects</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yoshinori Katakura</PersonName><PersonNameInverted>Katakura, Yoshinori</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aging related disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anthocyanins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>argan press-cake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Caco-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Caenorhabditis elegans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caffeine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cAMP/PKA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardamonin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cultural Studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DAF-16</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>denervation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exosome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exosomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food &amp; society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GABA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose and lipid metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut-brain interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hair cycle regulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Human health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IgA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal epithelial cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>JNK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>keratinocyte–hair follicle stem cell interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>l-serine deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Longevity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Low grade inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>luteolin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maslinic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microarray analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MITF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mitochondrial function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle atrophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Muscle strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural herbs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>olive peel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidative stress response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>p38 MAPK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phgdh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pro-inflammatory cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quercetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>raw-milk cheese</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regulatory T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>retinaldehyde dehydrogenase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SGLT1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SH-SY5Y</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tangeretin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telogen–anagen transition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telomerase reverse transcriptase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transporter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitellogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wnt/β-catenin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Recently, many kinds of foods and food-derived nutrients have been reported to show health-beneficial effects. In particular, some foods and food-derived nutrients have shown anti-aging effects on several organs and tissues, such as brain, muscle, skin, intestine, and so on. In some kinds of foods, the molecular basis of their functionalities (e.g., anti-brain aging, anti-sarcopenia, and anti-skin aging) and inter-tissue networks activated by these foods mediated by exosomes, cytokines, and immune cells have been clarified in detail.<br/><br/>Listed by <a href="https://unglue.it/work/543860/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/388555/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.564456.755055</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>755055</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Antibiotic Resistance</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Piera Anna Martino</PersonName><PersonNameInverted>Martino, Piera Anna</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AmpC β-lactamases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Animal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic resistance profiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial stewardship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Awareness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blaCTX-M</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Campylobacter spp.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Candida auris</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chickens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Chile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Climate Change</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CMY-2 type</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>common language</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Covid 19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Derby</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Domestic animals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>E. coli</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emerging pathogens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Enteritidis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Enterococcus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Environment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Escherichia coli</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extended-spectrum beta-lactamases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>farm animals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foodborne pathogens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Greece</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Human</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ISEcp1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Italy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>layer poultry farms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Livestock</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microbiology (non-medical)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Middle East</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multidrug-resistant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Natural Language Processing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nigeria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>One Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>One Heath</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pigs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>qualitative study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Rabbits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salmonella enterica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salmonella spp.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spa type</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Staphylococcus aureus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strategic action plan on antibiotic resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Suriname</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surveillance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Swedish stakeholder perceptions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>text data mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vancomycin resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole genome sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wild birds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wildlife</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Antibiotic resistance represents one of the most important challenges in the world and involves humans, animals and the environment.For this reason, it is increasingly important to focus our attention on the present scenarios and the future prospects relating to this problem. The One Health approach helps us and can provide the tools to consider the problem from different points of view, also providing alternative solutions to the use of the antibiotic itself.<br/><br/>Listed by <a href="https://unglue.it/work/564456/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/6d/04/6d048ebc1d603a5c0994222a4aa6d0ed.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/398346/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.589838.788248</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>788248</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Antioxidants in Animal Production, Reproduction, Health and Welfare</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Youssef A. Attia</PersonName><PersonNameInverted>Attia, Youssef A.</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Woo Kyun Kim</PersonName><PersonNameInverted>Kim, Woo Kyun</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Nesrein Hashem</PersonName><PersonNameInverted>Hashem, Nesrein</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Maria de Olivera</PersonName><PersonNameInverted>Olivera, Maria de</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abdominal fat color</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>active yeast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antinutrient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antioxidants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BAX</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian inference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BCL-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bee pollen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biochemical parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood biochemical constituents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood hematology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>boswellic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>broiler</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>broiler chickens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>broilers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caprine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcass traits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac injury markers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cecal health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cecal microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chicken</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>copper toxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cornelian cherry extract</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>correlation coefficients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cryopreservation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cyclic heat stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>date palm (pollen extract)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary protein level</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>doxorubicin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Duroc breed boars</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Eimeria tenella</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endurance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enzyme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feed efficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feeding time</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Fermentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fertility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fertility-related markers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fiber</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fipronil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>folic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fructooligosaccharide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose transporter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>growth performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haemato-biochemical parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heat stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hematological parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hematology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high temperature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histopathology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Holstein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laying hen performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver histology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lysozyme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meat fatty acid profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meat quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nano particles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nitric Oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nitrocompounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nitroethanol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nitropropanol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrient density</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Olive oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oocyst shedding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oregano essential oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oreochromis niloticus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidative biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathogens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PCNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenolic antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytogenic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytogenic feed additive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyphenolics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Polyphenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Poultry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prebiotic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>productive performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>propolis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quails</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rabbit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sea bass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selenium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Semen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semen additives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semen cryopreservation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sperm ultrastructure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spermatozoa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Spirulina</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Spirulina platensis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tannin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>temperature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TGF-β1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSV Zoology and animal sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trace element</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Turraea fischeri</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>undenatured type II collagen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin E</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>volatile fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zinc</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zoology &amp; animal sciences</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The exposure of animals to environmental stresses (restraint, bad housing conditions, irradiation, pollution, diseases, and heat stress) and endogenous stresses (metabolic and physiological disorders) can seriously disrupt the redox homeostasis, leading to impairments in animals’ health and overall performance. Under these circumstances, the self-antioxidant defense system may not be enough to neutralize ROS effects. In this context, the utilization of an exogenous source of antioxidants, mainly dietary sources, may present an effective and cost-effective solution. There are a plethora of substances, either naturally occurring or synthesized (organic acids, minerals, vitamins, hormones, and specific feed additives originating from plants such as essential oils and polyphenols), known for their antioxidant activity, that can be used to maintain adequate redox status in animals in order to preserve their well-being and/or productivity. This area of research still needs more investigations in order to clearly elucidate the effective antioxidant substances that could be used in practical applications, with an emphasis on their biological mechanisms during different physiological conditions and health statuses. We intend to bring together current research concerning the role of antioxidant substances either from natural sources or those synthesized for improving animal production, reproduction, health, and welfare.<br/><br/>Listed by <a href="https://unglue.it/work/589838/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421064/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.455883.616927</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>616927</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039217885</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Application of Bioinformatics in Cancers</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Chad Brenner</PersonName><PersonNameInverted>Brenner, Chad</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>activation induced deaminase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AID/APOBEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alternative splicing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biochemical engineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics tool</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker signature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biostatistics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biotechnology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain metastases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breast cancer detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breast cancer prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bufadienolide-like chemicals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer CRISPR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer-related pathways</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell-free DNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor DNA (ctDNA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical/environmental factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comorbidity score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computational Immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>concatenated deep feature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>copy number aberration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>copy number variation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Curation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curative surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>datasets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Decision support systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deep learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>denoising autoencoders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>differential gene expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diseases genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA sequence profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epigenetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erlotinib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>estrogen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extreme learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>false discovery rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feature extraction and interpretation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feature selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>firehose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Functional analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gefitinib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene inactivation biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene loss biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene signature extraction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genomic instability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GEO DataSets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Head and Neck Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health strengthening herb</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hierarchical clustering analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-throughput analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histopathological imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histopathological imaging features</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HNSCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hormone sensitive cancers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hTERT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>independent prognostic power</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intratumor heterogeneity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>knockoffs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>KRAS mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>locoregionally advanced</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microarray</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mitochondrial metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mixture of normal distributions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular mechanism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular subtypes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Monte Carlo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple-biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mutable motif</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neoantigen Prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network target</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurological disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>next generation sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>observed survival interval</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>omics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>omics profiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovarian cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overall survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pancreatic Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pathophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>precision medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>R package</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-organizing map</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-cell sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin cutaneous melanoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>somatic mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>star</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>steroidogenic enzymes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TCGA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TCGA mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology, engineering, agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telomerase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telomeres</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>The Cancer Genome Atlas</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Traditional Chinese Medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptional signatures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment de-escalation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor infiltrating lymphocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tumor microenvironment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>variable selection</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This collection of 25 research papers comprised of 22 original articles and 3 reviews is brought together from international leaders in bioinformatics and biostatistics. The collection highlights recent computational advances that improve the ability to analyze highly complex data sets to identify factors critical to cancer biology. Novel deep learning algorithms represent an emerging and highly valuable approach for collecting, characterizing and predicting clinical outcomes data. The collection highlights several of these approaches that are likely to become the foundation of research and clinical practice in the future. In fact, many of these technologies reveal new insights about basic cancer mechanisms by integrating data sets and structures that were previously immiscible.<br/><br/>Listed by <a href="https://unglue.it/work/455883/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/d4/a3/d4a3d2f66ebc814ea9bcd2e8becf80e7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20191120</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427611/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.519812.695959</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695959</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Bacterial Meningitis</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>James M. Stuart</PersonName><PersonNameInverted>Stuart, James M.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bacterial meningitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>burden</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Burkina Faso</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capsule</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebrospinal fluid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conjugate vaccine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conjugate vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corticosteroid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dexamethasone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Disability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enterovirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Epilepsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>etiologic diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>focal neurological deficit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genetic factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Global</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>global health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>global health estimates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>group B streptococci</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Group B Streptococcus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>H. influenzae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Haemophilus influenzae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hearing loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hydrocephalus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>impact of Hib conjugate vaccine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive bacterial infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive meningococcal disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive pneumococcal disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mathematical modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningococcal carriage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningococcal group</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningococcal urethritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningococcus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N. meningitidis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>national reference laboratory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neisseria meningitidis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal sepsis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurological sequelae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Niger</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nongroupable</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NTHi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PCV impact</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pneumococcal conjugate vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pneumococcal meningitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pneumococcus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-vaccine surveillance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rapid diagnostic test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>S. agalactiae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>S. pneumoniae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seizure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serotype distribution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serotypes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social and economic costs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Streptococcus agalactiae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Streptococcus pneumoniae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surveillance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>susceptibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TBM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tuberculous meningitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vaccine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vaccine impact</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WHO meningitis roadmap</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This timely collection of expert papers draws attention to the global burden of meningitis and the challenges faced by the WHO’s roadmap to defeat meningitis by 2030. The three main goals of the meningitis roadmap are to eliminate epidemics of bacterial meningitis, reduce cases and deaths from vaccine-preventable bacterial meningitis, and reduce disability and improve quality of life after meningitis of any cause. This book includes a wide range of original research and reviews on epidemiology and vaccination of bacterial meningitis that have direct relevance to advancing the goals of the roadmap.<br/><br/>Listed by <a href="https://unglue.it/work/519812/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/e9/f6/e9f6fb7f0080a78619ccea2eff53adee.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368774/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.525908.703711</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>703711</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Bayesian Design in Clinical Trials</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Paola Berchialla</PersonName><PersonNameInverted>Berchialla, Paola</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ileana Baldi</PersonName><PersonNameInverted>Baldi, Ileana</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adaptive designs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adaptive randomization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bayesian</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian designs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian inference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bayesian meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian trial design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>binary data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bridging studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>causal inference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cisplatin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical Trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clustering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>combination study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>distribution distance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dose escalation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dose-escalation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dose-finding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dose–response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>doubly robust estimation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>doxorubicin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early phase dose finding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frequentist validation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>futility rules</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>highest posterior density intervals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interim analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>latent Dirichlet allocation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modelling assumption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>normal approximation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>optimal dose combination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxaliplatin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peritoneal carcinomatosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phase I</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PIPAC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>poor accrual</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>posterior and predictive probabilities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>power-prior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive power</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prior distribution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prior elicitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>priors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>propensity score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rare disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sample Size</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sample size determination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social issues &amp; processes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stopping boundaries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>target allocation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment combinations</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In the last decade, the number of clinical trials using Bayesian methods has grown dramatically. Nowadays, regulatory authorities appear to be more receptive to Bayesian methods than ever. The Bayesian methodology is well suited to address the issues arising in the planning, analysis, and conduct of clinical trials. Due to their flexibility, Bayesian design methods based on the accrued data of ongoing trials have been recommended by both the US Food and Drug Administration and the European Medicines Agency for dose-response trials in early clinical development. A distinctive feature of the Bayesian approach is its ability to deal with external information, such as historical data, findings from previous studies and expert opinions, through prior elicitation. In fact, it provides a framework for embedding and handling the variability of auxiliary information within the planning and analysis of the study. A growing body of literature examines the use of historical data to augment newly collected data, especially in clinical trials where patients are difficult to recruit, which is the case for rare diseases, for example. Many works explore how this can be done properly, since using historical data has been recognized as less controversial than eliciting prior information from experts’ opinions. In this book, applications of Bayesian design in the planning and analysis of clinical trials are introduced, along with methodological contributions to specific topics of Bayesian statistics. Finally, two reviews regarding the state-of-the-art of the Bayesian approach in clinical field trials are presented.<br/><br/>Listed by <a href="https://unglue.it/work/525908/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/9e/dc/9edc52e83bc0d8309150671b390aeb34.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/369384/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.647787.866237</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>866237</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Body Image, Nutrition and Mental Health</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Hubertus Himmerich</PersonName><PersonNameInverted>Himmerich, Hubertus</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Khadijeh Mirzaei</PersonName><PersonNameInverted>Mirzaei, Khadijeh</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>active-duty military personnel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADIPO/LEP ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adipokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anorexia nervosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Athletes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bariatric surgery candidates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bipolar Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BMI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body appreciation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Body Image</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>depressive symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disgust</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eating disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Eating Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Emotion Regulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eye gaze</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Food</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GFRAL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy eating</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunohistochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>individual profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Interventions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lebanon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maladaptive eating behaviours</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metformin treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>military population</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-pharmacological</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrition labeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obesity treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral hygiene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral tissue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>PSY000000</SubjectCode><SubjectHeadingText>Psychology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Self-perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory sensitivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social media</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social media addiction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social media use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sociocultural and sport-related pressures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>technology-enabled interventions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thinness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Touch</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>university students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Veterans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight and shape concern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight bias internalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Weight loss intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight-related experienced stigmatization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>women health</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The Special Issue “Body Image, Nutrition, and Mental Health” examines and illuminates the complex relationships among body image, nutrition, and mental health. It covers the psychological and social risk factors of body image disturbances and associated disorders, biological aspects of appetite regulation and the metabolic syndrome, and therapeutic approaches for eating and weight disorders and their health consequences.<br/><br/>Listed by <a href="https://unglue.it/work/647787/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466303/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.1792701.2106866</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>2106866</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Botulinum Toxin for Urinary Tract Disease</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Heinrich Schulte-Baukloh</PersonName><PersonNameInverted>Schulte-Baukloh, Heinrich</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adverse effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bladder botulinum toxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>botox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Botox®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>botulinum toxin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>botulinum toxin A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BotulinumtoxinA detrusor injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic urine retention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>detrusor overactivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Detrusor wall thickness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>External sphincter injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Female urinary incontinence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>general anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>idiopathic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Idiopathic overactive bladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Injection paradigm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>local anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mechanosensitivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Minimally invasive therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>03</SubjectSchemeIdentifier><SubjectCode>N</SubjectCode></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Needle thickness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nerve</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurogenic bladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurogenic bladder dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurogenic detrusor overactivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>onabotulinumtoxinA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>OnabotulinumtoxinA intravesical injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overactive bladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Procedure considerations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Suburothelial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transurethral incision of the bladder neck</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transvaginal ultrasound guidance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trigone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Underactive bladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Urge incontinence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Urge urinary incontinence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Urgency urinary incontinence</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are more practical ways of distribution on the way? What acceptance problems or obstacles to long-term use might exist among patients or doctors? What are the risks? Has the therapy gained a foothold in the outpatient sector?<br/><br/>Listed by <a href="https://unglue.it/work/1792701/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2026</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/773069/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.531899.710898</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>710898</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Brain Function and Health, Sports, and Exercise</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Filipe Manuel Clemente</PersonName><PersonNameInverted>Clemente, Filipe Manuel</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ana Filipa Silva</PersonName><PersonNameInverted>Silva, Ana Filipa</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3-methoxy-4-hydroxyphenylglycol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>5-hydroxyindoleacetic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aerobic exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aerobic fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alternate uses test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Amygdala</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antisaccade</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Arousal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Attention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attentional bias</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attitudes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain Breaks®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiorespiratory fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebral oxygenation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>China</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>closed-skill exercises</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Convergent Thinking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>creativity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-over studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>depressive symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diffusion Tensor Imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>divergent thinking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early adulthood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Executive Function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise intensity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flexibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fractional anisotropy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>handgrip strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high altitude</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hippocampus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inhibitory Control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inhibitory performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insight problem-solving</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>international physical activity questionnaires</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lifestyle, sport &amp; leisure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-rope jumping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mediating effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mental health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor expertise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-randomized controlled trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oculomotor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>online platform</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open-skill exercises</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pleasure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>simultaneous training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Soccer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spatial cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sports</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>task-evoked pupil dilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::W Lifestyle, Hobbies and Leisure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video exercises</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vigor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Vision</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This reprint represents the articles published in the Special Issue “Brain Function and Health, Sports, and Exercise”. Fifteen articles were published, with topics covering the relationship between acute effects of exercise on cognitive function, as well as the influence of exercise on positive medium-term adaptations in populations as children, youth, adults and older. We think that the different approaches used in the different articles will help the readers to have a greater overview of the current research in brain and exercise.<br/><br/>Listed by <a href="https://unglue.it/work/531899/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/be/49/be49d4628546b85de3585ad6dc4491d8.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/374891/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.564684.755283</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>755283</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Chronic Fatigue Syndrome/Myalgic Encephalomyelitis</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Giovanni Ricevuti</PersonName><PersonNameInverted>Ricevuti, Giovanni</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Lorenzo Lorusso</PersonName><PersonNameInverted>Lorusso, Lorenzo</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>active exercise program</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Adolescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenergic receptors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autoantibodies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autoimmunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autonomic Function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autonomic Nervous System</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood analytics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain fog</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>c1q</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiopulmonary exercise test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CFS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic fatigue syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical Trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cluster analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complement system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>creatine kinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>creatinine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic criteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual task</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysbiosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EEG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrocardiogram</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrodermal activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise for well-being</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fast Fourier Transform</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Fatigue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fibromyalgia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flexibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>follow-up</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>G-protein-coupled receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Genetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heart Rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IgG deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IgG replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>impact on society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal permeability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Korea and Japan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LPS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ME/CFS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Measurement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic endotoxemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mitofusin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MMSE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MOcA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myalgic encephalomyelitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Myalgic Encephalomyelitis/Chronic Fatigue Syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxygen consumption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxygen–ozone therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ozone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PEM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postexertional malaise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ROC curve</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>routine blood tests</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>static balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TUG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular stiffness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasoregulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wellbeing</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue on CFS/ME collects 18 papers with an interdisciplinary view on the current demographic and epidemiological data and immunological characteristics of CFS/ME and examines the different pathogenic hypotheses, as well as giving information about the latest knowledge on diagnostic investigations, pharmacological, integrative, physical, cognitive-behavioral and psychological curative approaches.<br/><br/>Listed by <a href="https://unglue.it/work/564684/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/80/37/80378356d18715bf75fe7ad833881b92.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/398393/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492298.660087</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>660087</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Classical Swine Fever</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Fun-In Wang</PersonName><PersonNameInverted>Wang, Fun-In</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Chia-Yi Chang</PersonName><PersonNameInverted>Chang, Chia-Yi</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibody</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibody detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autophagy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>border disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bovine viral diarrhea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>China</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>classical swine fever</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Classical swine fever virus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>classical swine fever virus (CSFV)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complement inactivation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CSFV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>detergent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>E2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>E2 gene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>E2 subunit vaccine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flaviviridae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foetal immune response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>future perspectives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunobiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Japan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Jeju LOM strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laboratory diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LOM vaccine strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MLV-LOM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modified live vaccine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>omega value</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pathogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathogenicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>persistent congenital infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pestivirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogenetic tree</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogeny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>porcine reproductive and respiratory syndrome virus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>publication bias</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyroptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative PCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>replication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reporter virus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sample transport</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum neutralization test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sows</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>space–time analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spatio-temporal analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SPF pig</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subgenotype 2.1c</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subgenotype 2.1d</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Swine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trans-placental transmission</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transboundary diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transmission</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tween20</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viral replication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virulence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virus inactivation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virus shift</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wild boar</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book focuses on the “disease aspects” of classical swine fever (CSF). The epidemiological pattern of the reemergence of CSF from wild boars and its spread to neighboring domestic pigs provides useful information for policy makers. The recent advances in diagnostics and vaccines and how each type of vaccine should be appropriately used in various field situations provide useful information for practicing veterinarians and laboratory scientists, for example, whether the vaccine virus attenuated enough to not cross the placenta to avoid sequelae, how innocuous samples like serum should be cautiously treated to avoid risk of virus spread, how various genotypes of the CSF virus evolve and compete to survive in the field, and how the CSF virus molecularly manipulates normal cell biological processes for its own advantage to survive. Phylogenetic analyses help in tracing the origin of the CSF virus responsible for each outbreak. Overall, readers should be impressed by the capabilities of CFS in pigs. We hope that this book can be a useful reference for all colleagues, whether in CSF-free or CSF-affected parts of the world.<br/><br/>Listed by <a href="https://unglue.it/work/492298/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382414/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.647251.865701</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865701</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Clinical Application of Hemodialysis and Its Adverse Effects</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Shuzo Kobayashi</PersonName><PersonNameInverted>Kobayashi, Shuzo</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Takayasu Ohtake</PersonName><PersonNameInverted>Ohtake, Takayasu</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abdominal obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adsorptive therapies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AN69</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Atherosclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>buttonhole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C-reactive protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cannulation technique</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular events</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Copper</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dialysis membrane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyskalemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>end-stage renal disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expanded hemodialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>geriatric nutritional risk index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemodiafiltration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemodialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-flow access</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperkalemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypokalemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LDL-apheresis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lower-extremity revascularization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maintenance hemodialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular displacers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>morbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nutritional assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PAD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral artery disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical mobility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein-bound uremic toxins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein-energy wasting (PEW)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reduction dialysis frequency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rope ladder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subclavian steal syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>uremic toxins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>vaccination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular access</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zinc</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue focuses on several important themes related to hemodialysis treatment. It includes fourteen papers: one systematic review, two reviews, three communications, one brief report, and seven original research articles. These articles provide important new insights to many readers. Protein-bound uremic toxin clearance, special characteristics of dialysis membranes, and vascular access cannulation techniques have been reviewed. Nutritional assessment, significance of the trace element zinc, and the impact of COVID-19 infection in hemodialysis patients have been covered in communication articles. Original research articles address several important themes including risk factors for amputation and/or mortality in patients with lower extremity artery disease, vascular access flow and cervical artery circulation, dialysis tolerance and hemodialysis modality, physical mobility, malnutrition and insulin resistance in relation to metabolic syndrome, and the impact of dyskalemia on clinical outcomes in hemodialysis patients. We guest authors believe that these published papers will contribute to extending our knowledge and providing improved clinical care to patients on hemodialysis.<br/><br/>Listed by <a href="https://unglue.it/work/647251/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466241/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.646789.865239</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865239</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Clinical Application of Ultra-High Frequency Ultrasound: Emerging Trends</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Rossana Izzetti</PersonName><PersonNameInverted>Izzetti, Rossana</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Marco Nisi</PersonName><PersonNameInverted>Nisi, Marco</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aesthetic medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ankyloglossia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anorectal conditions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atopic dermatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B-mode</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bowel wall</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Breastfeeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>childhood-onset Sjögren’s syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>computer program</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corneometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnostic imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dupilumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>durometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysmenorrhea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elastography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exocrine glands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>filler</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycated hemoglobin (HbA1C)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-intensity focused ultrasound (HIFU)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hirschsprung’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histoanatomical morphometrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histopathology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyaluronic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intraoral ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>juvenile cystic adenomyosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>labial salivary glands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lacrimal glands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipohypertrophy (LH)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>major salivary glands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>major salivary glands ultrasonography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minor salivary glands</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>monoclonal antibodies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>onycopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral neoplasm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pediatric Sjögren’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pediatrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral nerve</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>03</SubjectSchemeIdentifier><SubjectCode>PG</SubjectCode></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>probe</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoriasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyoderma gangrenosum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shear wave</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sjögren’s disease (SjD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sjögren’s syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLEB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sucking function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic sclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKE Dentistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tongue movement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UHFUS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultra-high frequency ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultra-high-frequency ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultrahigh-frequency ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ultrasonography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultrasound echogenicity</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Ultra-high frequency ultrasound (UHFUS) is an emerging diagnostic technique in several medical fields due to its unique characteristic of providing a submillimeter resolution of anatomical structures. UHFUS was initially developed for pre-clinical settings, with the first clinical application reported only in the early 2000s. To date, an increasing number of applications have been described for the investigation of dermatological, vascular, musculoskeletal and oral diseases. Compared with other ultrasonographic techniques, UHFUS presents the major advantage of providing real-time imaging, along with being repeatable over time, which makes this technique suitable for all stages of disease work-up, from diagnosis to surgical planning and follow-up.There are excellent research opportunities in this field, summarized by the focus of this Special Issue, including the following: novel UHFUS applications and comparison with state-of-the-art techniques; reliability in the diagnosis, prognosis, surgical planning and follow-up of various pathological conditions; and the strengths and weaknesses in clinical and pre-clinical settings.<br/><br/>Listed by <a href="https://unglue.it/work/646789/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466184/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492476.660265</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>660265</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Clinical Medicine for Healthcare and Sustainability</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Teen-­Hang Meen</PersonName><PersonNameInverted>Meen, Teen-­Hang</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yusuke Matsumoto</PersonName><PersonNameInverted>Matsumoto, Yusuke</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Kuan-Han Lee</PersonName><PersonNameInverted>Lee, Kuan-Han</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute bacterial infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Addiction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>alcohol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic susceptibility testing (AST), evidence-based prescription</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial resistance (AMR), rapid diagnostics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bariatric surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioimpedance analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caffeine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiometabolic diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>catheter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ceftaroline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ceftriaxone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical deterioration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community-acquired pneumonia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complicated intra-abdominal infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complicated urinary tract infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computed Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>computerized</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conventional neural network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>convolutional neural networks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cost</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cost optimization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-sectional cohort study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>decision support</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deep learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental panoramic radiographs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic foot ulcer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>discordance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>doripenem</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early medical intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Electronic Health Records</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ensemble methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eravacycline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erythrodermic psoriasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Ethics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forensic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forensic medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Frailty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Healthcare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare and sustainability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare quotient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemodialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>home mechanical ventilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospital emergency department</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hospital Rapid Response Team</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypotension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>incidence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insurance medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intensive Care Units</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intra-abdominal infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Korea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laparoscopic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large for gestational age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laser assisted</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>LAW000000</SubjectCode><SubjectHeadingText>Law</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-axis injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Long-term oxygen therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Longitudinal studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrosomia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical records system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical referral system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Menopause</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mild Cognitive Impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimal clinically important difference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multimorbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>musculoskeletal disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>National Health Insurance Service data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-metastatic colorectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nursing Homes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Occupational medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults living in super-aging society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncologic outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Palliative Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-reported experience measures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral arterial disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pneumonia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-acute care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postprandial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preoperative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>propensity score matching</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Protection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychoactive substances</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality of care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Queuing theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled tria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rapid culture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resistance training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risk factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>season</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>secukinumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensitivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum urate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single surgeon experience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Smoking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Socioeconomic status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Specificity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidal plans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suicidal thoughts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical complication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sustainability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>symptom assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapeutics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapy of internal medicine diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trial sequential analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultrasound-guided injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>uric acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary tract infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>walking speed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>white matter hyperintensity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>xanthine dehydrogenase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>When the domestic government, the private sector, and people in various professional fields talk about long-term care issues, they all focus on creating a warm and home-like care institution. However, we actively emphasize the importance of community-based long-term care. For “aging in place”, the development of domestic non-institutional care is still in its infancy, and some long-term care needs must still be met through institutional care, and the facilitation of the extension or outreach of community-based care and respite service platforms for the development of community-based long-term care still rely on institutional care. The history of the development of long-term care in Taiwan is much shorter than that of Japan, Europe, the United States, and Canada. Despite years of hard work and rapid development, the long-term care resources needed to establish a complete system in terms of universalization, fairness, accessibility, and selectivity are not available. In the future, based on the soundness of institutional care, it hoped that outreach will move toward the goals of community care and aging in place. We hope the studies in this Special Issue will help further develop clinical medicine for healthcare and stainability.<br/><br/>Listed by <a href="https://unglue.it/work/492476/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382582/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.590180.788590</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>788590</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Clinical Pharmacology and Pharmacy of Antimicrobial Agents</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Dóra Kovács</PersonName><PersonNameInverted>Kovács, Dóra</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adsorption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adverse drug reaction (ADR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic combination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antifungals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Campylobacter ureolyticus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>campylobacteriosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>combination therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>contact killing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cystic fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>desorption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dosing regimen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>doxycycline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug-drug interaction (DDI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Escherichia coli</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food Microbiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glomerular filtration rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>habits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heterocyclic compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intensive care patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interstitial concentrations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LpxC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrolide antibiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbial pathogen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimum inhibitory concentration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Monte Carlo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Monte Carlo simulations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multi-drug resistant infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multi-organ failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multimorbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonlinear mixed-effects modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>organ failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Other branches of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxacillin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>P. aeruginosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pan-genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Patient Safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pH dependence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacodynamics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacokinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenolic compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polypharmacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyran</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-medication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum/plasma concentrations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small ruminant feed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical site infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synergistic effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>time-kill</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tissue concentrations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>translational modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Traumatology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triclosan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UDP-3-O-acyl-N-acetylglucosamine deacetylase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In this Special Issue, our aim was to collect studies on clinical pharmacology and pharmacy of antimicrobial agents from both human and veterinary medicine as the complex problem of AMR requires actions taken within the One Health approach that involve both fields. Studies covered here are about new or optimized usage of already authorized antimicrobials, as well as discoveries about new agents, new combinations of drugs, and drug repositioning. Pharmacodynamic, pharmacokinetic, and toxicological aspects of individual and combinational drug use are areas covered in this Special Issue.<br/><br/>Listed by <a href="https://unglue.it/work/590180/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421127/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492306.660095</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>660095</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Clinical Research on Diabetic Complications</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Didac Mauricio</PersonName><PersonNameInverted>Mauricio, Didac</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial stiffness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aspirin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>baPWV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bariatric surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>branched-chain amino acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>burnt-out diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotid plaque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cerebrovascular disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic kidney disease (CKD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dermal electrochemical conductance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic foot disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic foot syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic kidney disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic macroangiopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic microangiopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic neuropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic retinopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dialysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dipeptidyl peptidase 4 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dipeptidyl-peptidase IV inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>echogenic plaque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>end-stage renal disease (ESRD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fibroblast growth factor 23</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucagon-like peptide-1 receptor agonists</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose fluctuations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heart disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>History of engineering &amp; technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>incident diabetes mellitus (DM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>klotho</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microperimetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NMR spectroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-reported outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral artery disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plaque characteristics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reno-cardiovascular protection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sCD36</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sodium-glucose co-transporter 2 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sudomotor reflex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology, engineering, agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment satisfaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trial sequential analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Type 1 Diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 1 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vascular</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vascular Disease</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Refrigeration, air conditioning, and heat pumps (RACHP) have an important impact on the final energy uses of many sectors of modern society, such as residential, commercial, industrial, transport, and automotive.                    Moreover, RACHP also have an important environmental impact due to the working fluids that deplete the stratospheric ozone layer, which are being phased out according to the Montreal Protocol (1989).                                          Last, but not least, high global working potential (GWP), working fluids (directly), and energy consumption (indirectly) are responsible for a non-negligible quota of greenhouse gas (GHG) emissions in the atmosphere, thus impacting climate change.<br/><br/>Listed by <a href="https://unglue.it/work/492306/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466091/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.590675.789085</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>789085</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Clinical Research on Type 2 Diabetes and Its Complications</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Fernando Gómez-Peralta</PersonName><PersonNameInverted>Gómez-Peralta, Fernando</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acarbose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>advanced glycation end products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alpha-glucosidase inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ambulatory care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behaviour change intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood glucose monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Body Weight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone fragility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac autonomic neuropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chemotaxis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comorbidities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Comorbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complex intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>concomitant drugs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Continuity of Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronavirus infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CVD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developing country</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic peripheral neuropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic retinopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic sensorimotor polyneuropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dipeptidyl peptidase-4 inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Electrophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>empagliflozin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>end-stage kidney disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ethiopia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fracture risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gender</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucagon-like peptide-1 receptor agonist</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose transport</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose variability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycemic control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HbA1c</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospitalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperglycemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypoglycemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoglycemic agents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunosuppressants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in-hospital mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Korean National Health Insurance Corporation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liraglutide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microvascular complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miglitol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Monocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NAFLD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NASH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-alcoholic fatty liver disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-alcoholic steatohepatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obesity and diabetes mellitus type 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient participation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient profiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient transfer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pneumatosis intestinalis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>poststroke complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prednisone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>progression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulse wave velocity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>random forest</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reactive oxygen species (ROS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Readmission</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-world evidence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>secondary care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semaglutide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>sex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SGLT-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin autofluorescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stroke outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SURE study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Telemedicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urine albumin-creatinine ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VEGFR-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VEGFR-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>voglibose</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The huge prevalence of type 2 diabetes is a leading human and economic concern worldwide. The diagnosis code of type 2 diabetes includes multiple clinical phenotypes showing different degrees of obesity, fat distribution patterns, types of dyslipidemia, and characteristics of insulin resistance syndrome. In addition, subjects with type 2 diabetes could develop different clinical trajectories, with age being a critical factor in progression. The chronic complications of type 2 diabetes are a major cause of mortality and disability, and are ranked in the top places in western countries’ scores. The pathophysiological heterogeneity of type 2 diabetes is not captured by the current classifications and guidelines. The potential for diabetes progression and complications developing is different depending on the type 2 diabetes cluster, which is mostly regardless of the degree of glycemic control. However, the impact on quality and life expectancy with the current therapeutic approach is not always the same for every individual. Clinical research is the key to reducing the burden of diabetes. New basic, digital, and clinical  approaches are obtaining useful knowledge and designing more individualized interventions to prevent, track, and treat diabetic complications. This Special Issue is a clear reflection of this methodological evolution.<br/><br/>Listed by <a href="https://unglue.it/work/590675/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421232/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.564118.754712</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>754712</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Combined Nutrition and Exercise Interventions in Community Groups</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Carlos Vasconcelos</PersonName><PersonNameInverted>Vasconcelos, Carlos</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abdominal obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Adolescence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aerobic capacity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anthropometrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aquatic resistance training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behavior change theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Behaviour Change</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behaviour change techniques</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone mineral density</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brief intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiometabolic health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiorespiratory fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cohort study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>College students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal cancer screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community-based</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community-based intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cooperative Extension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Counseling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cultural Studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>culturally sensitive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diet quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diet quality index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary habits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>factor analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>father’s parenting practices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feasibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food &amp; society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food insecurity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>formative research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>France</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit and vegetable intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>geriatric rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Guam</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health Behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health behaviour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health belief model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health program</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health promotion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health service</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy eating</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospital setting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hunger and health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypertriglyceridemic waist phenotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Information-Motivation-Behavioral Skills Model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Latino fathers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low and middle income and countries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>measurement equivalence/invariance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meta-regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Metabolic Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mHealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>milk intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>moderate-to-vigorous physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Motor Skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrition education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritionists</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Participatory research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preschool children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reproductive age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>service evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Structural Equation Modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tailored intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>web-based intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight gain prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Weight loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Women</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Young adults</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Diet and physical activity are two key modifiable lifestyle factors that influence health across the lifespan (prevention and management of chronic diseases and reduction of the risk of premature death through several biological mechanisms). Community-based interventions contribute to public health, as they have the potential to reach high population-level impact, through the focus on groups that share a common culture or identity in their natural living environment. While the health benefits of a balanced diet and regular physical activity are commonly studied separately, interventions that combine these two lifestyle factors have the potential to induce greater benefits in community groups rather than strategies focusing only on one or the other. Thus, this Special Issue entitled “Combined Nutrition and Exercise Interventions in Community Groups” is comprised of manuscripts that highlight this combined approach (balanced diet and regular physical activity) in community settings. The contributors to this Special Issue are well-recognized professionals in complementary fields such as education, public health, nutrition, and exercise. This Special Issue highlights the latest research regarding combined nutrition and exercise interventions among different community groups and includes research articles developed through five continents (Africa, Asia, America, Europe and Oceania), as well as reviews and systematic reviews.<br/><br/>Listed by <a href="https://unglue.it/work/564118/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/17/fe/17fec03688f03bd4391da74adbfd520b.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/398290/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.519875.696053</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>696053</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Commercial Banking</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Christopher Gan</PersonName><PersonNameInverted>Gan, Christopher</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antiques &amp; collectables</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Asia-Pacific</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bank capital</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bank competition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bank performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bank risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bank risks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>banks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bayesian model-averaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Capital</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capital adequacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capital regulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Competition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Data envelopment analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Deposit insurance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynamic panel models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Efficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foreign bank entry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>H-statistics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Indian banking sector</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lifestyle, sport &amp; leisure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>net interest income</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-interest income</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Panel Data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pooled regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regulations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>revenue diversification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risk-taking behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risks</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The existence of financial intermediaries is arguably an artifact of information asymmetry. Beyond simple financial transactions, financial intermediation provides a mechanism for information transmission, which can reduce the degree of information asymmetry and consequently increase market efficiency. During the process of information transmission, the bank is able to provide unique services in the production and exchange of information. Therefore, banks have comparative advantages in information production, transmission, and utilisation. This book provides an overview of commercial banking and includes empirical methods in banking such risk and bank performance, capital regulation, bank competition and foreign bank entry, bank regulation on bank performance, and capital adequacy and deposit insurance.<br/><br/>Listed by <a href="https://unglue.it/work/519875/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/bf/06/bf06d397c7549e197adf5b5c38b98194.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368799/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492421.660210</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>660210</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Computational Methods for the Analysis of Genomic Data and Biological Processes</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Francisco A. Gómez Vela</PersonName><PersonNameInverted>Vela, Francisco A. Gómez</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Federico Divina</PersonName><PersonNameInverted>Divina, Federico</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Miguel García-Torres</PersonName><PersonNameInverted>García-Torres, Miguel</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>binding sites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioinformatics analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CAMTA1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CBF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chilling stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chou’s 5-steps rule</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromatin interactions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clustering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computational biology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computational intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Convolution Neural Network (CNN)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CRISPR-Cas9</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Data mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deep learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>differential genes expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>differentiation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA N6-methyladenine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DREB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ensembles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eQTL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fine-mapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene co-expression network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene ontology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene-set enrichment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome architecture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIGD2A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-fat diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infiltration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infiltration tactics optimization algorithm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Long Short-Term Memory (LSTM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machine-learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microarray</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mRNA expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>murine coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathways</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>potential therapeutic targets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Power</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Proteomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quercetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reactome Pathways</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA N6-methyladenosine site</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-cell clone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Systems Biology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Text Mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcription factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transcriptomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>viral infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>yeast genome</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In recent decades, new technologies have made remarkable progress in helping to understand biological systems. Rapid advances in genomic profiling techniques such as microarrays or high-performance sequencing have brought new opportunities and challenges in the fields of computational biology and bioinformatics. Such genetic sequencing techniques allow large amounts of data to be produced, whose analysis and cross-integration could provide a complete view of organisms. As a result, it is necessary to develop new techniques and algorithms that carry out an analysis of these data with reliability and efficiency. This Special Issue collected the latest advances in the field of computational methods for the analysis of gene expression data, and, in particular, the modeling of biological processes. Here we present eleven works selected to be published in this Special Issue due to their interest, quality, and originality.<br/><br/>Listed by <a href="https://unglue.it/work/492421/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382527/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492655.660444</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>660444</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Corporate Bankruptcy Prediction</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Błażej Prusak</PersonName><PersonNameInverted>Prusak, Błażej</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Artificial Neural Networks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>audit expectation gap</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bagging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bankruptcy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bankruptcy model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bankruptcy prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bankruptcy risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>boosting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chapter 11</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>citation mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>company performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corporate bankruptcy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corporate failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>credit risk modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Czech Republic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>decision trees</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>default</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ensemble classifiers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>European large companies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>financial distress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>financial ratios</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Forecasting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forecasting methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fuzzy sets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insolvency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ISA 701</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>key audit matters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>literature review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>manufacturing insolvency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Materiality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>models predicting financial distress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neural networks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>payment defaults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phases of economic cycle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Poland</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>principal component analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rating systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regression count</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scoring models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stacking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>support vector machine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tax arrears</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Bankruptcy prediction is one of the most important research areas in corporate finance. Bankruptcies are an indispensable element of the functioning of the market economy, and at the same time generate significant losses for stakeholders. Hence, this book was established to collect the results of research on the latest trends in predicting the bankruptcy of enterprises. It suggests models developed for different countries using both traditional and more advanced methods. Problems connected with predicting bankruptcy during periods of prosperity and recession, the selection of appropriate explanatory variables, as well as the dynamization of models are presented. The reliability of financial data and the validity of the audit are also referenced. Thus, I hope that this book will inspire you to undertake new research in the field of forecasting the risk of bankruptcy.<br/><br/>Listed by <a href="https://unglue.it/work/492655/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382761/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.531761.710760</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>710760</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>COVID-19: Current Challenges and Future Perspectives</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Peter Leggat</PersonName><PersonNameInverted>Leggat, Peter</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>John Frean</PersonName><PersonNameInverted>Frean, John</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Lucille Blumberg</PersonName><PersonNameInverted>Blumberg, Lucille</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Africa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alcohol-related liver disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiretroviral therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attitudes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bangladesh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bowel perforation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chagas Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cirrhosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CMV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive bias</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coinfections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19 vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytokine release syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytokine storm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>D-Dimer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic reasoning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Differential Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emergency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Environmental medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EpiCollect5</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Ethics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fecal calprotectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>general practitioners</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Harare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health care workers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare personnel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare worker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare workers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heart transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatitis B and C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IL-6 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>impact</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>India</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Influenza</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kaletra</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kenya</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knowledge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lilongwe</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lopinavir/ritonavir</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Malaria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malawi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MDR-TB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical doctor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MERS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nairobi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>necrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nepal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonalcoholic steatohepatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Operational research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Other branches of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overview</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pandemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pandemics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perceptions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Philippines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasmodium falciparum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-acute COVID-19 syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preparedness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>presumptive tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Public Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-time operational research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reinfection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>research capacity building</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>respiratory viruses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhinovirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>severe acute respiratory syndrome coronavirus 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>severity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SORT IT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TB treatment outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thrombosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tocilizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Tuberculosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zimbabwe</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and the disease now affects nearly every country and region. Caused by SARS-CoV-2, COVID-19 presents significant challenges to health systems and public health in both hemispheres as well as to the economies of each country. The morbidity and mortality due to infections caused by SARS-CoV-2 have been significant despite the short duration since its discovery and initially overwhelmed many hospitals and clinics. It influences everyone, and countermeasures have been dramatic in their impact on employment, social systems, and mental health. This Special Issue provides an avenue for authors from various disciplines to provide feedback on our responses and preparedness to COVID-19 globally as well as to disseminate critical information about the SARS-CoV-2 virus and the associated COVID-19 pandemic. It consists of 22 peer-reviewed papers that cover worldwide perspectives encompasses the following: Original articles about COVID-19 (including epidemiology, modelling, clinical data, treatment, prevention, countermeasures, impacts on tropical regions, response, and preparedness);Original articles about SARS-CoV-2 (microbiology, virology, transmission, pathology, and vaccinology);Perspectives about COVID-19 and SARS-CoV-2 (comparisons with past coronavirus outbreaks, impactful local initiatives, novel responses, and commentaries);Reviews on COVID-19 (based on systematic and narrative reviews);and Innovations (vaccine development, drug trials, and original countermeasures).<br/><br/>Listed by <a href="https://unglue.it/work/531761/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/4d/52/4d52c766c4d19b8fcd1c2f832e29cdbf.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/374848/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.537946.719754</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>719754</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Crosstalk between Depression, Anxiety, and Dementia: Comorbidity in Behavioral Neurology and Neuropsychiatry</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Masaru Tanaka</PersonName><PersonNameInverted>Tanaka, Masaru</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Animal-Assisted Intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial properties</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behavioral and psychological symptoms of dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cerebral blood flow</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Default Mode Network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disability level</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Down’s syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug response monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyslipidemias</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>executive control network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FFAR4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>G protein-coupled receptors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gender medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GPR120</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy life expectancy (HALE)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPA axis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPG axis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inositol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kiss1 receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kisspeptin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>late-life depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LC-MS/MS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Locomotion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-chain fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>longitudinal study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Major Depressive Disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>morbidity/mortality paradox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple reaction monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Multiple Sclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodegenerative disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurodegenerative disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nucleus Accumbens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutraceutical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional psychiatry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Omega-3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalized medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pet-robot intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasma protein biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyunsaturated fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-stroke depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Psilocybin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychiatric disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resting-state functional magnetic resonance imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salience network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Schizophrenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systolic blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue highlights the most recent research on depression, anxiety and dementia, with attention to comorbidity in a range of diseases. The symptoms of depression, anxiety and dementia are the most common comorbid manifestations present in patients suffering from neurodegenerative and psychiatric diseases. Together, these illnesses constitute an extremely complex and challenging research field due to their inherent multifactorial causative factors, heterogeneous pathogenesis, and mental and behavioral manifestations. This Special Issue covers laboratory, clinical and statistical studies on the crosstalk between depression, anxiety, dementia, Alzheimer’s disease, multiple sclerosis, schizophrenia, diabetes mellitus, Down’s syndrome, and/or compulsive disorders. It contains contributions from 71 authors, has been reviewed by 25 referees, and edited by three academic editors and one managing editor.<br/><br/>Listed by <a href="https://unglue.it/work/537946/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381226/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.519884.696062</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>696062</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Current Advances on Non-Melanoma Skin Cancer</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Constantin Caruntu</PersonName><PersonNameInverted>Caruntu, Constantin</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>actinic cheilitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>actinic keratosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>basal cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Calcitriol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcinogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cutaneous squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic test accuracy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epigenetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hedgehog pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vivo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lip neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lncRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Merkel cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methylaminolevulinate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MicroRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-melanoma skin cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>novel therapeutic approaches</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>photochemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reflectance confocal microscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>signaling pathways</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology, engineering, agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telomerase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telomeres</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Ultraviolet radiation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin D receptor</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The book is devoted to the design, application and characterization of thin films and structures, with special emphasis on optical applications. It comprises ten papers—five featured and five regular—authored by scientists all over the world. Diverse materials are studied and their possible applications are demonstrated and discussed—transparent conductive coatings and structures from ZnO doped with Al and Ga and Ti-doped SnO2, polymers and nanosized zeolite thin films for optical sensing, TiO2 with linear and nonlinear optical properties, organic diamagnetic materials, broadband optical coatings, CrWN glass molding coatings, and silicon on insulator waveguides.<br/><br/>Listed by <a href="https://unglue.it/work/519884/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a7/a1/a7a1d4ff9015381ea80be680a8e2b012.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368805/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491750.659538</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659538</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Dental Implant Materials 2019</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>In-Sung Yeo</PersonName><PersonNameInverted>Yeo, In-Sung</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abutment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial mouth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone remodeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone–implant interface</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CAD/CAM all-ceramic restoration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cellular responses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ceramics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chewing simulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental implant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental implant neck design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental implants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental implant–abutment connection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental implant–abutment design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dental materials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Fatigue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>finite element analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluoride</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fracture load</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fracture strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>implant connection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>implant-abutment connection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liner treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-term healing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marginal bone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>material testing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mechanical stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mechano-regulation theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>monolithic zirconia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multi-unit abutment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osseointegration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peri-implant bone loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peri-implant probing depth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peri-implantitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>photofunctionalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>removal torque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resin cement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RVYFFKGKQYWE motif</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>settling effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shear strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>short-term healing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>static loading</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Surface modification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surface treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tensile bond strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TiO2 nanotube</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tissue differentiation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Titanium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>titanium base</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Torque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultraviolet light</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitronectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zirconia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zirconia abutment</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Dental implant materials are advancing in the fusion of various scientific fields. Surface modification technologies for implants have been applied to titanium at the micro-level for about four decades. Now, implant surfaces are being topographically and chemically modified at both the micro- and nano-level. The modification techniques are altering other metals and ceramics, making these materials more biocompatible. Materials for abutments in dental implant systems appear to depend on implant–abutment connection structures. Biomechanical factors, such as friction and preload, influence the development of the abutment materials. Additionally, the surfaces of the abutment materials are important in the soft-tissue attachment, which is being actively investigated. As dental implants have to be functional in human bodies for a long time, numerous materials are being clinically tested as implant-supported restorations. The Special Issue, “Dental Implant Materials 2019”, introduces the creative works of scientists on the current advancements in the field of materials for implant dentistry.<br/><br/>Listed by <a href="https://unglue.it/work/491750/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381877/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.646575.865025</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865025</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights, Mechanisms, and Pharmacotherapies</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ming-Jui Hung</PersonName><PersonNameInverted>Hung, Ming-Jui</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adiponectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>angina</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial stiffness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Atherosclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood viscosity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>case report</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chest width</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary artery disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dabigatran</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic kidney disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>east Asian traditional medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ejection fraction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exosomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Framingham score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fufang danshen dripping pill</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GLP-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heart Failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heart Rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>herbal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperglycemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>idarucizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>integrative medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leptin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphocyte-to-C-reactive protein ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neutrophil-to-lymphocyte ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obesity paradox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral artery disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet-to-lymphocyte ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulse wave velocity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reversal agents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subendocardial viability ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJD Cardiovascular medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>three-dimensional anthropometrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vasospasm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>waist circumference</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Cardiovascular diseases (CVD) are the leading causes of mortality in patients with diabetes, and many factors, including hypertension, contribute to this high prevalence of CVD. The current evidence regarding these diseases is quickly expanding, especially in the vascular mechanisms that predispose someone to both conditions. Furthermore, several novel therapies, such as sodium glucose co-transporter 2 inhibitors, have recently beenshown to have benefits against CVD in patients with type 2 diabetes. With these reasons in mind, the need for updated clinical studies in these fields to optimize the outcomes of patients with diabetes, hypertension, and cardiovascular diseases arises. Finally, as we know that diabetes, hypertension, and especially CVD are associated with severity and mortality in patients with COVID-19 infection, we also invited colleagues around the world to report their clinical insights with these comorbidities and COVID-19 in order to provide support in this fundamental area during the pandemic.<br/><br/>Listed by <a href="https://unglue.it/work/646575/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466153/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.535135.716318</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>716318</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Diabetology: Feature Papers 2021</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Peter Clifton</PersonName><PersonNameInverted>Clifton, Peter</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACE2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autoimmune Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>banting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>best</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood glucose monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carpal tunnel syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic kidney disease (CKD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>collip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>continuous blood glucose sensors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-associated mucormycosis (CAM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetic Keto Acidosis (DKA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetic nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferroptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FINDRISC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>focus groups</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Healthcare Professionals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin pumps</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>limited-resource countries (LRC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MacLeod</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Metabolic-Stress-Associated Interactome (MSAI)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>middle-aged population</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucormycosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N-acetyl-β-d-glucosaminidase (NAG)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>olfactory neurovascular niche</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic β-cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patients’ experiences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>power doppler signal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox-iron stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regulatory T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-management of type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serine proteases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TMPRSS2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Type 1 Diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>young-adults</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>As Editor-in-Chief of the journal Diabetology, I am pleased to announce the Special Issue “Diabetology: Feature Papers 2021” is now published in book format. Diabetology (ISSN 2673-4540) is an international, peer-reviewed scientific open access journal that provides an advanced forum for studies related to epidemiology, etiology, pathophysiology, pathogenesis, management, complications, and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. In this Special Issue, “Feature Papers”, we aim to publish outstanding contributions in the main fields covered by the journal, which will make a great contribution to the community. This book covers the whole spectrum of diabetology from risk screening, risk markers, pathways of disease in type 1 diabetes and insulin treatment, and management of the disease and comorbidities.<br/><br/>Listed by <a href="https://unglue.it/work/535135/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/379374/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491958.659747</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659747</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Diagnosis and Treatment of Small Bowel Disorders</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Anastasios Koulaouzidis</PersonName><PersonNameInverted>Koulaouzidis, Anastasios</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Wojciech Marlicz</PersonName><PersonNameInverted>Marlicz, Wojciech</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adult Stem Cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adverse events</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomedical optical imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capsule endoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>celiac disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>collagenous colitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colon cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crohn’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cystic fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysbiosis index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enteropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fecal calprotectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional gastrointestinal disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Gastroenterology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut brain axis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperspectral imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammatory Bowel Disease (IBD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical diagnostic imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microscopic colitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucosal healing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Multispectral Imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prebiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Probiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Serology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small bowel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small-bowel bulge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small-bowel mass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical site infections (SSIs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synbiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video capsule endoscopy</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Over the last few decades, remarkable progress has been made in understanding the aetiology and pathophysiology of diseases and many new theories emphasize the importance of the small bowel ‘ecosystem’ in the pathogenesis of acute and chronic illness. Emerging factors such as microbiome, stem cells, innate intestinal immunity and the enteric nervous system along with mucosal and endothelial barriers have key role in the development of gastrointestinal and extra-intestinal diseases. Therefore, the small intestine is considered key player in metabolic disease development, including diabetes mellitus, and other diet-related disorders such as celiac and non-celiac enteropathies. Another major field is drug metabolism and its interaction with microbiota. Moreover, the emergence of gut-brain, gut-liver and gut-blood barriers points toward the important role of small intestine in the pathogenesis of common disorders, such as liver disease, hypertension and neurodegenerative disease. However, the small bowel remains an organ that is difficult to fully access and assess and accurate diagnosis often poses a clinical challenge. Eventually, the therapeutic potential remains untapped. Therefore, it is due time to direct our interest towards the small intestine and unravel the interplay between small-bowel and other gastrointestinal (GI) and non-GI related maladies.<br/><br/>Listed by <a href="https://unglue.it/work/491958/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382081/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.532043.711042</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>711042</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Laurent Kodjikian</PersonName><PersonNameInverted>Kodjikian, Laurent</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aflibercept</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aflibercept monotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>age-related macular degeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>age-related macular degeneration (AMD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-vascular endothelial growth factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-VEGF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-VEGF treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti–vascular endothelial growth factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AREDS2-HOME study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bevacizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brolucizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cataract surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>choriocapillaris</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>choroidal neovascularisation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>choroidal neovascularization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comparative therapies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Delphi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>effectiveness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emerging treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epithelial tear</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exudation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fellow eye</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food supplement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ForeseeHome AMD Monitoring System®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>good baseline visual acuity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hereditary retinal dystrophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intravitreal anti-vascular endothelial growth factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-term FU</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macula-off rhegmatogenous detachment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macular neovascularization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meta-regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meteorin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neovascular age-related macular degeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neovascular age-related macular degeneration (nAMD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oct-angiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Optical Coherence Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>optical coherence tomography angiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polypoidal choroidal vasculopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pro re nata regimen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quiescent macular neovascularization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ranibizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reading acuity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-world evidence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Retina</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>retinal deep perifoveal capillary plexus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sorsby</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sorsby’s fundus dystrophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STARS®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>superficial perifoveal capillary plexus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>switch therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapeutic innovation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treat and extend</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treat-and-extend</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment change</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment Outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment-naive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular endothelial growth factor (VEGF)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>visual acuity</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life.<br/><br/>Listed by <a href="https://unglue.it/work/532043/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a8/3b/a83b6c8452cae0b801e1b8a1736d7b7f.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/374944/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.590410.788820</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>788820</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Diet Quality and Risk of Cardiometabolic and Diabetes</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Giuseppe Pepa</PersonName><PersonNameInverted>Pepa, Giuseppe</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adult</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Body Composition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiometabolic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiometabolic risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Compliance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DASH diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diet quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary energy density</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary habits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary inflammation index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epidemiology study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foods groups</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fully automated</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high blood glucose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Humans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isorhamnetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Korean genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macronutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Margarine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mediterranean Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Micronutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NASH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NHANES</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidative balance score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytosterols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quercetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selenium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social issues &amp; processes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Structural Equation Modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>web-based intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Weight loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Young adults</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Cardiometabolic risk factors and type 2 diabetes are the largest contributors to the global disease burden and disease-related mortality. Visceral obesity drives the progression of multiple cardiometabolic risk factors and type 2 diabetes, and behavioral lifestyle weight loss interventions are important strategies for the prevention of these metabolic alterations. Despite the consistent evidence that the greater the body weight loss, the greater the preventive effect on cardiometabolic risk factors or diabetes, too radical strategies might be unfeasible on a large scale, and the long-term maintenance of weight reduction following restricted calorie diets represents a major challenge. Changes in diet composition acting on nutrient quality independently of changes in energy intake may be effective in cardiometabolic and diabetes risk prevention, offering a more feasible and safe alternative treatment to energy restriction. The aim of the present Special Issue is to summarize recent evidence on "Diet Quality and Risk of Cardiometabolic and Diabetes". More specifically, the impact of diet quality in terms of micro- or macronutrient composition, beyond the effect of diet restriction, on the prevention of cardiometabolic and diabetes risk as well as diabetes management, will be discussed. Personalized quality dietary interventions for cardiometabolic health and diabetes prevention, as well as possible underlying mechanisms, will also be addressed in this Special Issue.<br/><br/>Listed by <a href="https://unglue.it/work/590410/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421176/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.564613.755212</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>755212</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Dietary Curcumin and Health Effects</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Roberta Masella</PersonName><PersonNameInverted>Masella, Roberta</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Francesca Cirulli</PersonName><PersonNameInverted>Cirulli, Francesca</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adipose Tissue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adverse effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anticancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>APOE4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive nutraceutical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioavailability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemoprevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comet assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Complementary Therapies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curcuma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>curcumin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyslipidemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fetal Development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fish Oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glioblastoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycogen synthase kinase-3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory bowel disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Islet amyloid polypeptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>micelles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular signaling mechanism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutriepigenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phytotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Polyphenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postpartum depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy Complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Preterm Birth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proctocolitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized control trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>senolytics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subjective memory complaints</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>turmeric</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The Special Issue provides twelve contributions, of which three original articles, seven narrative reviews, one systematic review, and one meta-analysis that, altogether, offer a multifaceted and multidisciplinary overview that allows to draw a picture as intriguing and fascinating as possible on the benefits of curcumin and also to suggest potential fields of activities still to be explored. Among the biological activities exerted by curcumin, the anti-oxidative and anti-inflammatory properties reported in many studies make it a potential effective tool in preventing and counteracting chronic-degenerative diseases, very often associated with obesity and aging, such as cardiovascular diseases, T2D, metabolic dysfunctions, neurodegenerative diseases, and cancer, all of them characterized by the presence of oxidative and inflammatory processes. The main concerns that arise from the evaluation of the preventive/therapeutic effects of curcumin are, first of all, the still small number of randomized placebo-control studies available; in addition,  small sample sizes have generally been considered, and different protocols and different formulations as well as different routes of administration of curcumin have been used. Thus, it is quite difficult to compare the results and to provide a standard protocol for the use of this promising natural compound. For these reasons, and taking in account the growing use of curcumin by the general population, further investigations to confirm and expand current findings are mandatory and research on curcumin and its effects on human health have to be fostered and promoted.<br/><br/>Listed by <a href="https://unglue.it/work/564613/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/db/84/db8453a06b37244feb017ffd4a2f9861.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/398376/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.456292.617437</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>617437</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039217045</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Dietary Intake and Type 2 Diabetes</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Omorogieva Ojo</PersonName><PersonNameInverted>Ojo, Omorogieva</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>25-OH-D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aldosterone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>almond</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AMPK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>appendicular fat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>appendicular lean</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aronia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bariatric surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Body Composition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbohydrate counting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbohydrate restricted diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic conditions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cohort study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dairy products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DASH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes reversal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes specific formula</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diet quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary management approaches</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>energy restricted diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enteral nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enteral tube feeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fasting blood glucose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feces</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fish</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fish Oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>folk medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Food</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>free fatty acids (FFA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gestational diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Ginseng</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycaemic control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycaemic index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycated haemoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycated hemoglobin A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycemic control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycemic index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hedychium coronarium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high fat diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high-density lipoprotein cholesterol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperglycemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>incretins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin dosage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin secretion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interleukin-6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isomaltulose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Japanese</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lactic acid bacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipid parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipid profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>longitudinal analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low carbohydrate diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low energy diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low-carbohydrate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macronutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Micronutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mushroom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional supplement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nuts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peanut</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyunsaturated fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein and fat counting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PUFA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomised controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rosemary extract</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Short Chain Fatty Acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>standard formula</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>streptozotocin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subjective appetite</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sucromalt</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T2DM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tempeh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total body fat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total body lean</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trace elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triglyceride</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Type 1 Diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vegetable oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>very-low-calorie</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin D deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Women</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zinc intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zinc status</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The prevalence of diabetes is on the increase in the UK and worldwide, partly due to changes in lifestyle which predispose individuals to overweight and obesity. It is estimated that about 90% of the currently diagnosed adults have type 2 diabetes, and based on the World Health Organisation (WHO) report, about 422 million adults were living with diabetes in 2014 compared with 108 million in 1980; this condition caused about 1.5 million deaths in 2012. In the United States of America, it is estimated that about 30.3 million adults are living with diabetes, with a further 1.5 million new diabetes cases diagnosed every year, representing an increasing prevalence of this condition. Diabetes represents a major public health challenge, despite advances in technology and the pharmaceutical industry. These problems may be in the form of acute or long-term complications. Therefore, in order to attenuate the problems of diabetes, management strategies usually include lifestyle changes such as increased physical activity and dietary interventions. Studies which evaluate the role of nutrition in the management of type 2 diabetes often involve human and animal models as these approaches enable us to have a broader and more in-depth understanding of the condition. In some cases, diabetes may co-exist with other conditions, such as stroke, and these may present unique challenges with regard to nutritional interventions. This Special Issue aims to evaluate the risk factors associated with type 2 diabetes and the role of the diet in the management of people with this condition. This evidence is drawn from both human and animal studies.<br/><br/>Listed by <a href="https://unglue.it/work/456292/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/02/ee/02eebb0439515f984ce8e68b1316d12c.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20191205</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427606/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.647027.865477</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865477</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Dietary Supplements in Cardiovascular and Metabolic Diseases</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Bruno Trimarco</PersonName><PersonNameInverted>Trimarco, Bruno</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Gaetano Santulli</PersonName><PersonNameInverted>Santulli, Gaetano</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>1-deoxynojirimycin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2-aminoethanesulfonic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>20-HETE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>6 min walk test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artichoke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>astaxanthin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bergamot</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bergamot polyphenolic fraction (BPF)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbonyl</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiometabolic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemokine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cholesterol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic fatigue syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coenzyme Q10</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>crossover clinical trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytokine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary supplement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary supplements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNJ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>energy drinks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flow-mediated dilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>furegrelate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucosamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>handgrip strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HET0016</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypercholesterolemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>indomethacin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipid accumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malondialdehyde (MDA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitochondria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitochondrial dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Morus alba</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mulberry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myalgic encephalomyelitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NADH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nitric Oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonrestorative sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NS-398</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutraceutical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutraceutical compound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutraceutical supplementation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nutraceuticals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral supplement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parsley</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pentosidine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>persistent symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PLS regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Polyphenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-acute COVID-19 syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prebiotic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proprotein convertase subtilisin/kexin type 9 (PCSK9)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein carbonyl</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reactive oxygen species (ROS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>red yeast rice (RYR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rosemary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salt loading</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>savory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SGLT2 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>short-chain fatty acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SHRSP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SQ-29,548</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supplements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tauric acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Taurine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thromboxane-A2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trimethylamine n-oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>water-soluble tomato concentrate</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue begins with two preclinical studies on bergamot fruit extract (Citrus bergamia) showing reductions in oxidative stress and dyslipidemia both in vitro and in vivo. Additionally, a review explores the potential therapeutic use of combining SGLT2 inhibitors with plant extracts. In another in vivo study, humanized mice supplemented with L-carnitine and essential oil emulsions exhibited prebiotic effects on gut microbiota, reducing plasma trimethylamine N-oxide (TMAO) levels and increasing fecal short-chain fatty acids (SCFAs). Preclinical studies also examined the impact of copper nanoparticles on oxidative stress and vascular relaxation, and assessed the quality of herbal teas and dietary supplements, revealing deficiencies in their nutraceutical content. Two reviews highlight the health benefits of astaxanthin and taurine. Clinical studies include a retrospective analysis linking glucosamine usage to increased cardiovascular risk in osteoarthritis patients, and a trial demonstrating the efficacy of L-Arginine plus vitamin C supplementation in long-COVID patients. The issue concludes with three placebo-controlled trials: one showing Coenzyme Q10 plus NADH benefits on fatigue and quality of life in chronic fatigue syndrome patients, another revealing the antioxidant effects of water-soluble tomato concentrate in healthy adults, and a third highlighting the positive impact of bergamot polyphenolic fraction phytosome, artichoke extracts, Q10 phytosome, and zinc on lipid profiles, inflammation, NAFLD, and endothelial reactivity in hypercholesterolemic individuals.<br/><br/>Listed by <a href="https://unglue.it/work/647027/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466216/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.590085.788495</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>788495</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Dietary, Lifestyle and Children Health</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Zhiyong Zou</PersonName><PersonNameInverted>Zou, Zhiyong</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adiposity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arsenic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>baby food</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birth cohort</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birth weight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birthweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Breastfeeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cadmium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardio-metabolic risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiorespiratory fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caregiver perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CCDI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child and Adolescent Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>child-nutrition disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>childhood asthma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>children and adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>children health prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>children safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>children’s health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>China</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cholesterol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cohort</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complementary feeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cultural Studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>D-chiro-inositol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>determinants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diet quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diet quality questionnaire</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary diversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary fat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyslipidemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eating habits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electronic devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fast food</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food &amp; society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food contaminant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food groups</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food marketing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit and vegetable intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit and vegetables</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit consumption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gestational diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>global dietary recommendations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycomacropeptide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>growth trajectories</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy lifestyle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Household</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infant feeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inositol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intrauterine growth restriction (IUGR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Japan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>KIDMED test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Kindergarten</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>latent class analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Lead</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leptin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle behaviors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malnutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mealtime regularity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mediation analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mediterranean</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mediterranean Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Menus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mercury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Metagenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>monounsaturated fatty acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myo-inositol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurodevelopment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrition therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional errors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>obesity phenotypes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overnutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parents’ educational level</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parents’ occupational level</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>policy research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyunsaturated fatty acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>potassium intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prebiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediabetic state</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preschool children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preterm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preterm neonate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prospective study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>puberty timing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal damage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Riksmaten Adolescents Diet Diversity Score (RADDS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Rural Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screeners</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sedentary behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sedentary behaviour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sentinel foods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-child status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soy food</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Split-Dalmatia County</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Swedish Healthy Eating Index for Adolescents 2015 (SHEIA15)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thailand</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBC Cultural and media studies::JBCC Cultural studies::JBCC4 Cultural studies: food and society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxic elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>young child</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Food quality, including dietary quality and diversity, is as essential to human health as air is to human life. In addition, other healthy lifestyle factors, including a healthy body mass index, regular exercise, no smoking, and sufficient sleep duration, are associated with a lower incidence of chronic non-communicable diseases and longer life expectancy. More importantly, maternal healthy lifestyle factors are also associated with a substantially reduced risk of chronic diseases in their offspring. Childhood is a critical period for the development of a healthy lifestyle and the prevention of chronic diseases in adulthood. However, the prevalence of childhood obesity is increasing and unhealthy lifestyles are becoming an epidemic, posing a potential future burden of adult chronic disease. The aim of this Special Issue is to identify and assess dietary factors, including dietary diversity and specific nutrients/phytochemicals, as well as other healthy lifestyle factors, in the prevention and management of childhood chronic diseases. Additionally, we want to identify gaps and tools that could help with the assessment of children’s health. We wanted to encourage all researchers who work in this field to submit original research, reviews, systematic reviews, and meta-analyses to this Special Issue to broaden our knowledge and pave the way for new research directions.<br/><br/>Listed by <a href="https://unglue.it/work/590085/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421114/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.656389.877986</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>877986</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Effects of Learning Environments on Student Outcomes</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Myint Swe Khine</PersonName><PersonNameInverted>Khine, Myint Swe</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Academic Learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>academic performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arts-based interventions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>associations with outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>asynchronous learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Blended learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemistry education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>citizenship education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitivism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community of inquiry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>constructivist approach</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cronbach’s alpha</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>EDU000000</SubjectCode><SubjectHeadingText>Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>educational design research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>educational gardens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Educational Research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elementary science education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>engagement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Environmental education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>environmental learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>higher education students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Historical perspectives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>improving environments</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive species</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>learning environment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>learning environments</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>learning sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meaningful learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Movement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>MUS000000</SubjectCode><SubjectHeadingText>Music</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>native flora</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>online learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>online time</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacy education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PhET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>place-based education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant biodiversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>questionnaires</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reliability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serial mediation model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>simulation-based learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social and emotional learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>student engagement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>student-centred learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>student-to-student interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Teacher Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>teaching methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JN Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JN Education::JND Educational systems and structures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>United Theory of Acceptance and Use of Technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>What Is Happening In this Class? (WIHIC)</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In recent years, there has been a surge of interest in school and curriculum reform worldwide. Educators and policymakers now recognize that success hinges on understanding the intricate connections between student learning, social and emotional factors, and the learning environment. Researchers have delved into the effects of the learning environment on student outcomes, exploring topics such as students’ and teachers’ perceptions, attitudes toward specific subjects, and cognitive achievements in diverse, multicultural settings. Additionally, studies have investigated how 21st-century learning environments enhance students’ experiences. This volume provides a contemporary overview of the impact of learning environments on student outcomes. The articles within explore scientific insights, thought-provoking ideas, innovative approaches, and future-oriented scenarios across all levels of schooling—from primary to tertiary education, including out-of-school and online environments. The articles in this special issue draw on theoretical frameworks and best practices from intervention studies, learning-based experiments, and qualitative, quantitative and mixed-methods approaches.<br/><br/>Listed by <a href="https://unglue.it/work/656389/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/472527/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.522767.699696</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>699696</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>eHealth in Chronic Diseases</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Irene Torres-Sanchez</PersonName><PersonNameInverted>Torres-Sanchez, Irene</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Marie Carmen Valenza</PersonName><PersonNameInverted>Valenza, Marie Carmen</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>alcohol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apps</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Balance disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blended care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood glucose self-monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Brazil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Caregivers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>China</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic conditions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic disease management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic low back pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic musculoskeletal pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic non-communicable diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic obstructive pulmonary disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>collaboration at distance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Communication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comprehensive medication review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>content analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coordination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COPD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COPD patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary heart disease (CHD)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Disease Management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>educational content</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eHealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Elderly care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electronic health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evaluation methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>falls</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feasibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fishbowl discussion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functionality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycosylated hemoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health communication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health literacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthcare delivery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>horse simulator riding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory bowel disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innovation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interdisciplinary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interdisciplinary care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>internet intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>media use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medically underserved area</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medication therapy management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mHealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mixed Methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mixed-methods design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobile applications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mobile Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nurse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>online community</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Participatory Design</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Patient experience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient perspective</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient portal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient reported outcome measures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient reported outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacist</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physical Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Primary Health Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Qualitative research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>remote care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>remote monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rheumatology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Satisfaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Self-management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Smoking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social Support</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>suboptimal health status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Substance-Related Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supportive interventions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical aortic valve replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T2DM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telehealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Telemedicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telemonitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>time trend</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcatheter aortic valve replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>unified health system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urban</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>usefulness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Videogames</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>web-based</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book provides a review of the management of chronic diseases (evaluation and treatment) through eHealth. Studies that examine how eHealth can help to prevent, evaluate, or treat chronic diseases and their outcomes are included.<br/><br/>Listed by <a href="https://unglue.it/work/522767/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/04/a7/04a716ff42cb2ac583be7a4e723edb6e.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/369229/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.564646.755245</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>755245</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Endocrine and Neuroendocrine Cancers</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Alfredo Berruti</PersonName><PersonNameInverted>Berruti, Alfredo</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Vito Amoroso</PersonName><PersonNameInverted>Amoroso, Vito</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Nicola Fazio</PersonName><PersonNameInverted>Fazio, Nicola</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenocortical cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenocortical tissues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anaplastic thyroid carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>avelumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcitonin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Checkpoint inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Consensus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>crcinoid crisis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ctDNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Delphi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases &amp; disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DOTATOC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EMT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epithelial markers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>everolimus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastroenteropancreatic neuroendocrine neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene carriers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GEP-NET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemodynamic instability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune checkpoint inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ipilimumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ki67 labeling index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ki67 proliferation index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medullary thyroid cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MEN2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesenchymal markers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic paraganglioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic pheochromocytoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular profiling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular targeted therapies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular Targeted Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mTOR inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>near infrared-labelled octreotide analog</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine neoplasm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nivolumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>octreotide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic neuroendocrine tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-derived xenograft</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pembrolizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PET/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PRRT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence-free survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>somatostatin analogs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>somatostatin receptor-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TPH inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor spheroids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumors associated macrophages</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Endocrine and neuroendocrine tumors originate from endocrine cells but are heterogeneous in terms of clinical presentation, disease outcome, and treatments available. This Special Issue addresses specific aspects of pre-clinical, clinical, and translational research and clinical management of these diseases with the aim of providing novel insights, addressing current unmet needs, and discussing future treatment perspectives.<br/><br/>Listed by <a href="https://unglue.it/work/564646/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/83/d5/83d5094b8cc4487f08126a90c81b62d2.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/398385/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.556117.745001</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>745001</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783031181610</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><ProductFormDetail>E101</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>EU Cohesion Policy Implementation - Evaluation Challenges and Opportunities</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Carla Henriques</PersonName><PersonNameInverted>Henriques, Carla</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Clara Viseu</PersonName><PersonNameInverted>Viseu, Clara</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Central government</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Central government policies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Data envelopment analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DEA models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Eastern Europe</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>economic growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Energy Efficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ERDF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>European regional development funds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>European Structural and Investment Funds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>European Union policy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Implementation of EU funds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>information and communication technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low-carbon economy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machine learning models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Political Economy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Politics &amp; government</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Public administration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research and Innovation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Small and mid-sized enterprises</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>smart specialization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JP Politics and government</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JP Politics and government::JPP Public administration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JP Politics and government::JPQ Central / national / federal government::JPQB Central / national / federal government policies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KC Economics::KCG Economic growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KC Economics::KCP Political economy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KJ Business and Management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Youth</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This open access book discusses evaluation challenges and opportunities of the European Union cohesion policy implementation.<br/><br/>Listed by <a href="https://unglue.it/work/556117/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/eb/76/eb762bef74d1fc6ce403fb531b3edac7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Springer</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/489092/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/391036/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.459413.621498</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>621498</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783030477011</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Evidence-based Positron Emission Tomography</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Giorgio Treglia</PersonName><PersonNameInverted>Treglia, Giorgio</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Luca Giovanella</PersonName><PersonNameInverted>Giovanella, Luca</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical &amp; internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic radiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diseases &amp; disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>endocrinology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Internal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medical imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurology &amp; clinical neurophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nuclear medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open access</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Other branches of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJC Diseases and disorders::MJCL Oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJD Cardiovascular medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJG Endocrinology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKR Nuclear medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKS Medical imaging::MKSH Medical imaging: radiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This open access book summarizes the findings of recent evidence-based articles (meta-analyses) on the use of positron emission tomography (PET) for various clinical indications. It is divided into five main sections, starting with an introduction to PET and meta-analysis. In turn, the second part addresses evidence-based PET in oncology, providing a broad overview of its use for different types of tumours. The remaining sections are focused on the use of PET in cardiology, in infectious and inflammatory diseases, and in neurology, respectively. Given its scope and the wealth of information it provides, the book will be an invaluable tool for clinicians with various specialties, as well as international scientific societies interested to the recent evidence-based data about PET.<br/><br/>Listed by <a href="https://unglue.it/work/459413/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/4f/0d/4f0d29c62070bf8610dd6c71c06cc895.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Springer Nature</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/264761/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.567119.758746</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>758746</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Explainable Artificial Intelligence in Stroke from the Clinical, Rehabilitation and Nursing Perspectives</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jie Jia</PersonName><PersonNameInverted>Jia, Jie</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yan Hu</PersonName><PersonNameInverted>Hu, Yan</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Dingguo Zhang</PersonName><PersonNameInverted>Zhang, Dingguo</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>18F-fluorodeoxyglucose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>active rehabilitation training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automated system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood flows</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain–computer interface</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain–computer interfaces</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>computer vision technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>convolutional neural networks (CNNs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deep learning method</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disorders of consciousness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DTI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EEG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electromyographic bridge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Executive Function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>facial expression recognition (FER)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>facial paralysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fugl-Meyer Assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gait</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Hand</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hand function rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hand rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hand rehabilitation robot</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hemiplegia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxic ischemic encephalopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immersive virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laser speckle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic connectivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor attempt (MA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor function assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Motor Imagery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor task</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-invasive brain stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Organic Chemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overlapping time window</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral magnetic stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>positron emission tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-stroke cognitive impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postural control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>repetitive transcranial stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rTMS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensorimotor rhythm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sensors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spasticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stroke rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>upper extremity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>upper limb</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>upper limb rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vision transformer (ViT)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable devices</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>As we know, strokes are one of the world's leading causes of death, and the cruel aspect of a stroke is that it leaves people with severe functional disability and/or cognitive impairment. Strokes have a significant impact on economies worldwide, as it is estimated that about 10% of the male population and 8% of the female population are affected by them. Such people need personal help in their everyday life and must be materially supported by social services. With the advancement of medicine, artificial intelligence, and new technologies have been developing rapidly and are gradually applied in diseases of the nervous system, increasingly helping diagnosis, treatment, rehabilitation, and prognosis of disease.This Special Issue has collected the 14 papers on artificial intelligence and new technologies in strokes, including in the aspects of diagnosis, treatment, prognosis, rehabilitation, and nursing. We welcome your reading.<br/><br/>Listed by <a href="https://unglue.it/work/567119/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/13/fa/13fadb28ebb3d392a78a5b48c27978ae.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407090/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.647395.865845</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865845</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Feature Papers in Medical Statistics and Data Science Section</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Pentti Nieminen</PersonName><PersonNameInverted>Nieminen, Pentti</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACE2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>algorithmic fairness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alpha and theta EEG band ratios</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AlphaFold2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automated detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>automated meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Automation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>big data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioinformatic analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C7</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Camelyon17</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotid intima-media thickness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>childhood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical outcome assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colon adenocarcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CpG DNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>craniovertebral angle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data imputation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data missingness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data preprocessing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data presentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Data science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deep learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dope</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Electronic Health Records</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>event detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genomic factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperbaric oxygen therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kaplan–Meier estimator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laboratory diagnostics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>logrank test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machine-learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical diagnostics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>membrane bilayer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mental workload</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Metagenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MMP3 and TESC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>model explainability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Modeller</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nephrology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuronal network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>OpenPose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ordinal variables</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outlier removal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parkinson’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patches</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalized medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein structures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrent neural networks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>requirements engineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research Synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RGB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2 vaccines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Shapley-based feature selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-cell RNA-seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spike protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>standardized regression coefficient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>statistical feature selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Statistics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structural models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MB Medicine: general issues::MBN Public health and preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tragus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Type 1 Diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weighted trajectory analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WSI</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Recent years have witnessed an increase in the use of advanced data analysis methods in biomedical, clinical, and epidemiological research. The aim of this reprint is to highlight the practical aspects of new data analysis methods and to provide insights into the challenges in biostatistics and data science. By considering recent developments in medical technology, the reprint includes novel approaches in the field of medical statistics and data science, covering meta-analysis, the assessment of clinical outcomes, machine learning, medical diagnostics, and genomic factors.<br/><br/>Listed by <a href="https://unglue.it/work/647395/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466258/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.589858.788268</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>788268</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Functional Nanoparticles for Environmental Contaminants Removal and Agricultural Application</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yu Shen</PersonName><PersonNameInverted>Shen, Yu</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3-sulfhydryl-1-propane sodium (MPS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biochar nanoparticle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotenoid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chinese cabbage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chinese soft-shelled turtles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chitosan nanoparticles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chlorophyll concentration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coatings</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colloidal biochar</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>controlled-release</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conventional fertilizers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CuNPs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>degradation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electron-transfer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Environmental economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epididymis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fenton-like</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>final germination percentage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hexaconazole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnetic fluorescent nanosensor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>manufactured nano-objects (MNOs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesoporous silicas</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metal nanoparticles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Microorganism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N doping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nano-agrochemicals (NAgs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nano-scale materials (NSMs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanocarrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanoparticle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanoplastics (NPs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanoscale schwertmannite</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonradical oxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrient concentration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>organic fertilizer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PAHs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peroxymonosulfate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>photo-responsibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pre-adsorption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>root length</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selective recognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shoot length</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>silver ion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sperm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinach</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfamethoxazole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tomato</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Toxicity</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This is a reprint for the Special Issue "Functional Nanoparticles for Environmental Contaminants Removal and Agricultural Application." in Coatings; this reprint includes 12 articles and 1 general review.<br/><br/>Listed by <a href="https://unglue.it/work/589858/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421067/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.1589536.1880195</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>1880195</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Healthcare Goes Digital</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Daniele Giansanti</PersonName><PersonNameInverted>Giansanti, Daniele</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Analgesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arrhythmia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Atrial Fibrillation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>big data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CAWI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chatbots</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>China online healthcare platforms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic disease management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic neck pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community-acquired pressure injuries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conversational agents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-regional healthcare choices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital health tools</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital psychotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Disability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Gynecology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Healthcare Technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>home radiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hospital</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>indicators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Informatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large language models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal health care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mental health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mHealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-communicable diseases (NCDs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nursing clinical data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nursing Homes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>office hysteroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>online medical service</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient mobility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient resource</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient satisfaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-centered outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patients’ perspectives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perinatal health care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plastic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>positive psychotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Postoperative care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Psychotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resilience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Saudi Arabia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Self-efficacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>signaling theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>smartwatch</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stress reduction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Suicide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>telerehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virtual music therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>voice assistants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Weight loss</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Digital healthcare is rapidly evolving through AI, mobile health, electronic health, telemedicine, and wearable technologies, transforming patient care, workflow efficiency, and personalized medicine. This reprint of the Special Issue presents research and reviews on virtual interventions, mobile apps, chatbots, and wearable devices, highlighting innovations, challenges, and future directions in modern healthcare delivery. It explores patient-centered approaches, remote monitoring, and the potential of emerging technologies to improve accessibility, outcomes, and clinical decision-making.<br/><br/>Listed by <a href="https://unglue.it/work/1589536/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2025</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/710674/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.571224.763906</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>763906</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Human Biomonitoring in Health Risk Assessment</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Christophe Rousselle</PersonName><PersonNameInverted>Rousselle, Christophe</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adipose Tissue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Benzene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>benzophenone-3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biological monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomonitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bisphenol A (BPA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bisphenol S (BPS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bisphenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bystanders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcinogenicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chlorpyrifos</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19 Pandemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dimethylformamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DMF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Endocrine Disruptors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>European Human Biomonitoring Initiative (HBM4EU)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exhaled breath condensate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>general population</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>guidance value</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HBM-GV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HBM4EU</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human biomonitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human biomonitoring (HBM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human biomonitoring guidance value (HBM-GV)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Internal exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lockdown</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lung Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malondialdehyde</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>margin of safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MDA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medical Toxicology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mercury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meta-regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylmercury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mineralogical analysis of broncho-alveolar lavages</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mixture risk assessment (MRA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nanoparticles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>occupational exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>occupational health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>operators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>organophosphorus flame retardants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ortho-toluidine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Other branches of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>paints production</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>partition coefficients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PBPK modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>persistent organic pollutants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pesticide exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pesticide risk assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pesticides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physiologically based pharmacokinetic modelling (PBPK)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reference range</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reference values</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reprotoxic effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>residents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TiO2 powders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toxicokinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tree-grown produce</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urban traffic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary mass-balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UV filters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Workers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Workplace</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Europe’s zero-pollution agenda should depart from an understanding of how the European citizens’ bodies are polluted by synthetic chemicals and prioritize the reduction of the chemical body burden and associated health impacts. In this context, Human Biomonitoring (HBM) is an important and valuable tool for assessing the internal exposure of humans resulting from aggregated exposure to chemicals. Though many obstacles still hinder the use of HBM data, the growing availability of HBM data offers an opportunity for improving and refining Human Risk Assessment. This Special Issue intends to illustrate, using case studies, how HBM data could be used to better estimate internal exposure and resulting risks. Case studies on exposure from consumer products (cosmetic products, non-food products, etc.) or exposures via food or water in the general population or among workers contributed to better identifying the obstacles hindering a broader use of HBM data in RA. A better understanding of population exposure and the exposure of vulnerable groups against health-based human biomonitoring guidance values also provides the basis for effective risk management to reduce impacts on health. I would like to thank all the authors for submitting their original contributions to this Special Issue. We greatly appreciate the support of all the reviewers who spent time evaluating and improving the quality of the manuscripts. I would also like to thank the editors of Toxics for their kind invitation and Selena Li of the Toxics Editorial Office for her invaluable support.<br/><br/>Listed by <a href="https://unglue.it/work/571224/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a3/26/a326540bb68e49a6a0edde5f66ee78a9.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407383/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.457601.619250</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>619250</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039284085</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Human Health Engineering</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Jean-Marie Aerts</PersonName><PersonNameInverted>Aerts, Jean-Marie</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adaptive control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adaptive model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADHD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>air-trapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>airflow limitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>airway resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alveolar pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ankle angular velocity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ankle torque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antagonistic actuator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artefact correction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>back loading</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bicycle helmet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bicycle helmets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood pressure estimation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body-plethysmography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcaneal spur</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>choreoathetosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic obstructive pulmonary disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cohort studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cold-induced-vasoconstriction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cold-induced-vasodilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computed Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>contour of shoe insole</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>control parameter reference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>control system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>convective and evaporative heat loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COPD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cyberaddiction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>decision tree</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>distal skin temperature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>driver drowsiness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynamic model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynamic modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyskinetic cerebral palsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dystonia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly person</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrocardiographic signal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emotional reaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Emphysema</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise testing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feature engineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>finite element simulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FitzHugh–Nagumo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forced expiration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>four-wheeled rollator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fractional calculus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>freestyle skiing aerials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gait characteristics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gradient artefact</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hard-margin support vector machines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>harmonization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head-shaped phantom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health information</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heart model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hill muscle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Information technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insole foot area</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intensive care unit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interface formats</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Internet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kano-TRIZ design theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>knee joint</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifting technique</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ligament</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-term effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machine leaning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnetorheological brake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mHealth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>missing data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobility scale</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Model Predictive Control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mortality prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>movement disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple imputations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>musculoskeletal modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>New Technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nomophobia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Novel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthosis control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxygen uptake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain minimum compressive pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalized model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>photoplethysmogram</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pneumatic artificial muscle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>powered mobility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulse oximeter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulse wave</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Quality function deployment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation Robotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>relaxation oscillator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reliability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>remoteness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Shoulder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>simultaneous EEG–fMRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sliding mode control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>smart wearables</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>smartphone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soft walking assistive robot</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>specific airway conductance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spherical phantom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Spine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spirometry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>squat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stance assistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stoop</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>streaming algorithm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>streaming data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>support-vector-machine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SVM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>swarm optimization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thermal comfort</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thermal manikin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thermal sensation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thermoregulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>usability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>validity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Van der Pol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VO2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>walking speed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wearable Device</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Weight loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>work-related musculoskeletal disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Youth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zonal performance characteristics</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In this Special Issue on human health engineering, we invited submissions exploring recent contributions to the field of human health engineering, which is the technology used for monitoring the physical or mental health status of individuals in a variety of applications. Contributions focused on sensors, wearable hardware, algorithms, or integrated monitoring systems. We organized the different papers according to their contributions to the main aspects of the monitoring and control engineering scheme applied to human health applications, including papers focusing on measuring/sensing physiological variables, contributions describing research on the modelling of biological signals, papers highlighting health monitoring applications, and finally examples of control applications for human health. In comparison to biomedical engineering, the field of human health engineering also covers applications on healthy humans (e.g., sports, sleep, and stress) and thus not only contributes to develop technology for curing patients or supporting chronically ill people, but also more generally for disease prevention and optimizing human well-being.<br/><br/>Listed by <a href="https://unglue.it/work/457601/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=TTHWDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200312</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465801/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.522841.699770</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>699770</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Hypoxia-Inducible Factors</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Kiichi Hirota</PersonName><PersonNameInverted>Hirota, Kiichi</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acetylsalicylic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adipose-derived cell supension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adipose-derived stem cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atherosclerotic plaque rupture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bibliome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood-derived therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ChIP-seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clopidogrel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COX-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug anticoagulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Enrichment analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene2pubmed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GPR146</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIF-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIF-PH inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia preconditioned plasma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia preconditioned serum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia sensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia-inducible factor 1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ILC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphangiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphatic regeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Macrophages </SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>matrix metalloproteinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Monocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neutrophils</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NOACs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral anticoagulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Oxygen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peripheral blood cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet rich plasma (PRP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>public database</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA-Seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>signature genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcription factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VEGF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>xanthine oxidase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Oxygen is an essential molecule in the production of adenosine triphosphate (ATP) in cells, and a lack of energy due to O2 deficiency makes the maintenance of biological functions and human life improbable. Since oxygen functions as the final electron acceptor in the series of ATP synthesis reactions in conjunction with oxidative phosphorylation in mitochondria, its deficiency causes the oxidation of a series of coenzymes, such as nicotinamide and flavin adenine dinucleotide, and the reduction in oxygen molecules to water molecules (H2O). Persistent deficiency has been believed to cause a loss of biological functions, even resulting in death. This classical view of oxygen has been completely revised over the last 20 years. Mammals do not have a mechanism for biosynthesizing oxygen in their bodies. In higher organisms such as vertebrates, which possess many organs, oxygen in the body is always “scarce,”; therefore, the dominant view is that organisms have evolved mechanisms to respond to the lack of this essential molecule (hypoxia), and actively use it to maintain bodily integrity. Anatomically complex, higher multicellular organisms are equipped with specialized mechanisms to enable all cells to obtain sufficient oxygen. The respiratory system consists of lungs, which provide oxygen to be transferred to hemoglobin in red blood cells, the diaphragm, other respiratory support muscles, and neuroepithelial cells that sense the partial pressure of oxygen. The cardiovascular system consists of red blood cells, an oxygen-carrying medium, the heart, the transport engine, blood vessels, and transport channels. The proper development and preservation of these systems requires the harmonious expression of thousands of genes. The transcription factor responsible for this gene expression is hypoxia-inducible factor 1 (HIF-1).   In this Special Issue, we invited research and review papers on various areas of oxygen biology research that focused on the fundamental understanding of HIF signaling pathways and related gene expression profiling, as well as pharmacogenomic biomarkers, molecular targets driving the regulation of human physiology and pathophysiology, and validation in animal models. We have published six original papers and three review articles in this Special Issue. We hope that this Special Issue will reflect the current exciting research concerning HIFs and their applications in medicine and health science.<br/><br/>Listed by <a href="https://unglue.it/work/522841/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/55/73/5573edb72dd3bfd23639e0634e690bd7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/369241/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492032.659821</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659821</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>In Vitro Digestibility in Animal Nutritional Studies</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Pier Giorgio Peiretti</PersonName><PersonNameInverted>Peiretti, Pier Giorgio</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ammonia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ankom DaisyII incubator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimethanogenic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Beef cattle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>camelina co-products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cereals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical composition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical inhibition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coenzyme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>common vetch</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>condensed tannins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corn distillers dried grains with solubles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>degradation rates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diet composition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digestibility assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ensiling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enzyme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>essential oils</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>faecal inoculum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>faeces</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feedstuff evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fermentability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fermentation kinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fermentation parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fibrous byproducts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>field peas</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forage quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gas collection technique</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gas production</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gas production technique</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gas volume</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Global warming</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>goats</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Grain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grazing ecology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>halogenated compound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hydro-thermic treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro digestibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro fermentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro gas production</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro organic matter degradability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro rumen fermentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inoculum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kale</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lactation stages</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macroalgae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methane</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methane production</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methanogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methanogenic inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbial bases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbial community</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbial populations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbial responses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitscherlich equation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NDF digestibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neural Network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nitrocompounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrient digestibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritive value</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>odd- and branched-chain fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pepsin digestibility assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>03</SubjectSchemeIdentifier><SubjectCode>PH</SubjectCode></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pH stat method</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pig fecal inoculum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant inhibitory compound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyethylene glycol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Poultry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein sources</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rumen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rumen degradability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rumen fermentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rumen fluid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rumen liquid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rumen microbial fermentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rumen-undegraded protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ruminant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ruminants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seaweeds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soybean hulls</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>straw</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Streptomyces griseus protease test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>substrate degradation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>swede</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synergies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>varietal effect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>volatile fatty acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>volatile fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zoology &amp; animal sciences</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book addresses various aspects of in vitro digestibility: • Application of meta-analyses and machine learning methods to predict methane production; • Methane production of sainfoin and alfalfa; • In vitro evaluation of different dietary methane mitigation strategies; • Rumen methanogenesis, rumen fermentation, and microbial community response; • The role of condensed tannins in the in vitro rumen fermentation kinetics; • Fermentation pattern of several carbohydrate sources; • Additive, synergistic, or antagonistic effects of plant extracts; • In vitro rumen degradation and fermentation characteristics of silage and hay; • In vitro digestibility, in situ degradability, and rumen fermentation of camelina co-products; • Ruminal fermentation parameters and microbial matters to odd- and branched-chain fatty acids; • Comparison of fecal versus rumen inocula for the estimation of NDF digestibility; • Rumen inoculum collected from cows at slaughter or from a continuous fermenter; • Seaweeds as ingredients of ruminant diets; • Rumen in vitro fermentation and in situ degradation kinetics of forage Brassica crops; • In vitro digestibility and rumen degradability of vetch varieties; • Intestinal digestibility in vitro of Vicia sativa varieties; • Ruminal in vitro protein degradation and apparent digestibility of Pisum sativum; • In vitro digestibility studies using equine fecal inoculum; • Effects of gas production recording system and pig fecal inoculum volume on kinetics; • In vitro methods of assessing protein quality for poultry; and • In vitro techniques using the DaisyII incubator.<br/><br/>Listed by <a href="https://unglue.it/work/492032/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382155/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.554363.742833</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>742833</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Integrative, Complementary and Alternative Medicine (CAM) in Healthcare</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Manoj Sharma</PersonName><PersonNameInverted>Sharma, Manoj</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Kavita Batra</PersonName><PersonNameInverted>Batra, Kavita</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Acupuncture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Amnesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aromatherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>behavioral and psychological symptoms of dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breech</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>children’s TKM use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic obstructive pulmonary disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complementary and alternative medicine (CAM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>doll-therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Florida</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Global Coherence Initiative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Healthcare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HeartMath</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>integrative medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interconnectedness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Labor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>manual therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal and prenatal health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metaanalysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mild Cognitive Impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor symptom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>moxibustion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multi-theory model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>national survey TKM usage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neroli oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parents’ perception of TKM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parkinson’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sunscreen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematicreview</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>traditional Korean medicine (TKM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin E</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This compendium describes the multimodal interventions in the field of integrative, complementary, and alternative medicine, which combines biological, behavioral, social, and environmental domains rather than merely treating the disease. Research emphasizing the understanding of connections between organs and body systems is the main focus of this text.<br/><br/>Listed by <a href="https://unglue.it/work/554363/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/41/79/41790a70b3d022c4ecd48995c007130a.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/390872/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.646697.865147</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865147</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Knee Arthroplasty: Therapeutic and Management Strategies</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Christian Carulli</PersonName><PersonNameInverted>Carulli, Christian</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>all-polyethylene tibia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotics and implant retention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>arteriosclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bilateral</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bilateral knee replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biomaterials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardio-ankle vascular index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cementless</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>debridement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gap balancing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haemophilia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemophilia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hemostatic matrix</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>implant survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>influencing factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>instability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knee</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knee Arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lateral laxity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leg axis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leg axis alignment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leg axis angles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-term results</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>loosening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metal-backed tibia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>numeric rating scale</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>of medial laxity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteophytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidized zirconium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative blood management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periprosthetic joint infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>planning software</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>revision knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic arm-assisted total knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic arm–assisted total knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>staged bilateral knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>staged bilateral total knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>survivorship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKJ Neurology and clinical neurophysiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thrombin-based hemostatic agent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Total knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total knee replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>two-stage</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In recent decades, knee arthroplasty has been one of the most evolving branches of orthopaedic surgery. Very few historical surgical techniques, biomaterials, implantation philosophies, and postoperative approaches are maintained; however, most have been fully implemented, and clinical outcomes, such as patients’ postoperative perceptions, have been associated with new paradigms. Nowadays, knee arthroplasty may be considered an “ultra-specialty on specialty” due to the many brand-new aspects arising from its clinical and surgical issues. Thus, this Special Issue on “Knee Arthroplasty: Therapeutic and Management Strategies” includes several modern aspects representing a new vision of this simple but complex surgery. The articles included in this Special Issue propose specific preoperative evaluations and risk factor analyses, the adoption of peculiar surgical techniques or computerized/robotic devices, the use of modern implants and biomaterials, the innovative management of postoperative infections, postoperative strategies, and the evaluation of long-term results. Well-known authors from various countries have contributed to this collection with their expertise and leadership, sharing the highly technical capacity while also providing a clear exposition of these modern aspects that have made and will continue to make knee arthroplasty a highly dynamic sector of orthopaedic art.<br/><br/>Listed by <a href="https://unglue.it/work/646697/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466175/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518755.694902</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>694902</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Malignant Mesothelioma</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Daniel L. Pouliquen</PersonName><PersonNameInverted>Pouliquen, Daniel L.</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Joanna Kopecka</PersonName><PersonNameInverted>Kopecka, Joanna</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Asbestos</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>asbestos exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BAP1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer-specific mutations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbon nanotubes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcinogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CDKN2A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor DNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dendritic Cells </SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA damage response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug repurposing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epigenome-wide analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epithelioid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extrapleural pneumonectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fatty acid-binding protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FDG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>first line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hippo pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunogenicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunohistochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infiltrating immune cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Interaction Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laminin subunit beta-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liquid biopsies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lurbinectedin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphocyte-to-monocyte ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrophage-capping protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignant mesothelioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignant pleural mesothelioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesothelioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mesothelium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MPM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MTAP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NF2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PET-CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plasma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pleural effusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pleural mesothelioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pleurectomy decortication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein-protein interactions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Proteomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PTCH1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox-sensitive factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sarcomatoid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selenium-binding protein 1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SETD2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Systems Biology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapy response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tumor microenvironment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor suppressor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor-associated macrophages</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VATS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WDPM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>well-differentiated papillary mesothelioma</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Malignant mesothelioma (MM) is a rare and aggressive cancer, related to chronic inflammation and oxidative stress caused mainly by exposure to asbestos. Although this mineral has been banned for decades in many countries, epidemiologists predict the MM epidemic will last past 2040, raising many concerns in public health given its late diagnosis, dismal prognosis, and lack of current efficient therapies.To deal with this situation, important breakthroughs have recently been made in the understanding of MM’s complex biology and the carcinogenic process of the different patterns of the disease. Examples of these include the development of new biomarkers and the deciphering of gene–environment interactions, molecular mechanisms of invasiveness, deregulated pathways, altered expression of miRNAs, DNA damage repair, or metabolic profile. From now on, MM’s aggressive and chemoresistant character appears linked to a polyclonal malignancy, and heterogeneity in molecular alterations.Given these improvements, new therapeutic targets are being explored to solve the double challenge faced by clinicians. The first is to reduce tumor development and its wasting consequences as soon as possible, without resistance and with limited toxicity. The second is to stimulate the recognition of tumor cells by the induction of a specific immune response. This Special Issue will highlight all these aspects.<br/><br/>Listed by <a href="https://unglue.it/work/518755/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/a3/b1/a3b1000901205eb58a7b7bb95d06a1a7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368269/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.389286.531365</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>531365</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783631577189</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Meta-Analyse angewandter Gleichgewichtsmodelle des internationalen Agrarhandels</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Sebastian Hess</PersonName><PersonNameInverted>Hess, Sebastian</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>ger</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Agrarhandel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Agrarhandels</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>agricultural science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Agriculture &amp; Farming</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Agriculture &amp; related industries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Analyse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>angewandter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Development economics &amp; emerging economies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economic Theory &amp; Philosophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gleichgewichtsmodell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gleichgewichtsmodelle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gleichsgew</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hess</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Industry &amp; industrial studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>International economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Internationalen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematical models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Primary industries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Produce trade</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Response Surface</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology, engineering, agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KC Economics::KCA Economic theory and philosophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KC Economics::KCL International economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KC Economics::KCM Development economics and emerging economies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WTO Doha Runde</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Quantitative partielle- oder allgemeine Gleichgewichtsmodelle stellen in der angewandten Ökonomie ein wichtiges Instrument zur Politikfolgenabschätzung dar. Aus wissenschaftlicher Sicht wird an diesen Modellen ihre mangelnde Transparenz sowie ihre Abhängigkeit von empirisch wenig gesicherten Parametern und Annahmen kritisiert. Mittels einer Meta-Analyse werden daher Studien untersucht, welche Politikfolgen der laufenden WTO-Verhandlungen (Doha-Runde) simuliert haben. Als zentrales Ergebnis zeigt sich, dass die erhebliche Varianz innerhalb simulierter regionaler Einkommensveränderungen durch vergleichsweise wenige, ermittelbare Variablen zu einem hohen Anteil erklärt werden kann. Die Ergebnisse der Meta-Regression können daher als Orientierungshilfe bei Vergleich und Bewertung existierender sowie zukünftiger Simulationsstudien dienen.<br/><br/>Listed by <a href="https://unglue.it/work/389286/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/53/3f/533fa193e9349053cd9f15a20982a351.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Peter Lang Gmbh, Internationaler Verlag Der Wissenschaften</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2008</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/289933/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.572823.766049</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>766049</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Micronutrients in Maternal and Infant Health</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Yunxian Yu</PersonName><PersonNameInverted>Yu, Yunxian</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B vitamins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birth outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birth weight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BKMR models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>childhood growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-exposure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Congenital Heart Defects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Copper</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cord blood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cord serum 25(OH)D level</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cultural Studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food &amp; society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>free thyroxine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>free triiodothyronine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>full-term infant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene polymorphism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gestational diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gestational diabetes mellitus (GDM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hemoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human milk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypertensive disorders of pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iron supplementary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lactation stage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large-for-gestational-age (LGA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lasso regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LBW</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LGA/macrosomia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Manganese</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal hemoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal hemoglobin concentration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal birth weight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nickle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonlinear association</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>passive smoking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Preeclampsia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prospective cohort study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prospective study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantile g-computation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reduced rank regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>repeated measurements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>restricted cubic spline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>retinol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>selenium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SGA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SGA/LBW</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small-for-gestational-age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SNPs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spontaneous abortion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subtypes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBC Cultural and media studies::JBCC Cultural studies::JBCC4 Cultural studies: food and society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thyroid-stimulating hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trace elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary selenium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin D deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin E</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zinc</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Maternal and infant nutrition has been on the global agenda as central to health, sustainable development, and progress in low- and middle-income countries. Micronutrients, which play a major role in the metabolism of macronutrients, cellular metabolism, and organ development of the fetus, are important for maintaining pregnancy and fetal growth. Besides, during pregnancy, there is an elevated demand for micronutrients, the excess or deficiency of which can result in an increased risk of pregnancy complications and adverse birth outcomes. As China is a rapidly developing country with a large population, micronutrient status and its influence on maternal and infant health have always been a concern. This Special Issue aimed to estimate the influence that micronutrients can have on maternal and infant health, which provides evidence for clinical interventions and government nutrition-related policies. Additionally, this Special Issue provides study directions for research on micronutrients among pregnant women and infants. In this Special Issue, original research articles and reviews were welcomed. Research areas include, but are not limited to, the following: Micronutrient status of pregnant women and infants; Relationship between micronutrients and pregnancy complications as well as birth outcomes.<br/><br/>Listed by <a href="https://unglue.it/work/572823/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/39/1c/391cdaf233cce586d759bcc9c9523f43.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407473/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.537856.719664</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>719664</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>MicroRNA and Cancer</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Paola Tucci</PersonName><PersonNameInverted>Tucci, Paola</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2′-O-methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adipokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B-CLL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioinformatics analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brain tumour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cancer stem cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer stem cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ccRCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colon cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cyclooxygenase-2 (COX-2)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deformability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometrial cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>estrogens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exosome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperinsulinemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypoxia inducible factor 1-alpha (HIF-1α)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune checkpoint inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin-like growth factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignant melanoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medulloblastoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic melanoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microRNA (miRNA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MicroRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>migration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-584-5p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR526b</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR655</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA-transcription factor network</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Non-Small Cell Lung Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>normal B-cell development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovarian cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PARP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PI3K/AKT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plasma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>progression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prostaglandin E2 receptor 4 (EP4)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pseudouridylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Régulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>replication stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum LDH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Smoking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>snoRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stem Cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stemness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subgroups</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>YKT6</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>MicroRNAs (miRs) are small noncoding RNAs that function as post-transcriptional regulators of gene expression and have important roles in almost all biological pathways. Deregulated miR expression has been detected in numerous cancers, where miRs act as both oncogene and tumor suppressors. Due to their important roles in tumorigenesis, miRs have been investigated as prognostic and diagnostic biomarkers and as useful targets for therapeutic intervention. From a therapeutic point of view, two modalities can serve to rectify gene networks in cancer cells. For oncomiRs, a rational means is downregulation through antagomirs. Moreover, observations of the pathological reductions in tumor-suppressive miRs have inspired the concept of “miR replacement therapy” to enhance the amount of these miRs, thereby restoring them to normal levels. However, the clinical applicability of miR-based therapies is severely limited by the lack of effective delivery systems. Therefore, to understand the role of this new class of regulators, we need to identify the mRNA targets regulated by individual miRs as well as to develop specific, efficient, and safe delivery systems for therapeutic miRs.<br/><br/>Listed by <a href="https://unglue.it/work/537856/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381223/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.398786.543679</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>543679</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783038976608</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Mobile Learning</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Maria Uther</PersonName><PersonNameInverted>Uther, Maria</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3-level evaluation framework</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Achievement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attitude</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>audio interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diffusion of models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital capabilities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital literacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>EDU000000</SubjectCode><SubjectHeadingText>Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>educational technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>English language teaching</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FRAME model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Higher Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>instructional approaches</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iPads</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>language learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>m-learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobile device</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobile devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobile learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobile technologies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>smartphone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subjective perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>technology integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JN Education</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Mobile learning has become one of the more influential aspects of the field of educational technology, given the ubiquity of modern mobile devices and proliferation of educational applications or ‘apps’. Within this volume, there are a range of studies and reviews which cover a breadth of current topics in the field, namely user motivations for using mobile learning, issues in evaluation, as well as domain-specific considerations (e.g., use within language learning or audio-based applications). Together, these studies represent the synthesis of a range of methods, approaches, and applications that highlight benefits and areas of future growth of mobile technologies and how they can be useful and most effective in education.<br/><br/>Listed by <a href="https://unglue.it/work/398786/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/56/36/5636df9b9a025ab3007e645f09f99a02.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20190325</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465394/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.542204.725825</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>725825</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Modern Problems of Scientometric Assessment of Publication Activity</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Oleg V. Mikhailov</PersonName><PersonNameInverted>Mikhailov, Oleg V.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>academic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>author-suggested weighted citation index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bibliometric</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bibliometric indicators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bibliometric measure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Citation Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conference accreditation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conference impact factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conference indicator</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emerging country</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Higher Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Human capital</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kazakhstan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lotka’s law</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patent analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>publication trend</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>research collaboration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>research productivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Russian professors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scholarly publications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scientific activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scientific contribution of individual</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scientometric indexes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scientometric indicators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scientometric politics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scientometrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social issues &amp; processes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sociological polls</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sustainable development goals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trends</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Universities</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>As is known, an objective assessment of scientific activity is one of the most difficult problems, in terms of the relationship within itself as well as with society. However, for many decades, the significance of scientists’ contribution to the development of the corresponding branch of science was assessed by the scientific community only by meaningful qualitative criteria, wherein the principle and mechanism of such an assessment was actually intuitive and defied quantitative description. That is why the urgent task was undertaken to create a system for evaluating scientific activity based on some objective indicators of the activity of a particular scientist; in search of such criteria, in the 1970s–1980s, the term “citation index” appeared. Although a close examination of this indicator revealed its limitations and in a number of cases even inadequacy in assessing scientific activity, it has nevertheless since the 1990s gained very wide popularity in the scientific community. This has contributed to the emergence of numerous works aimed at finding new and ideal indicators for assessing publication activity (so-called bibliometric indices). To date, several dozen such indices have been proposed, the most significant of which was the so-called Hirsch index or h-index. Nevertheless, despite the incredibly significant advances in this specific area of sociology, the above problem is still far from resolved. In this regard, the key task of this Special Issue is to familiarize its readers with the latest achievements both in the search for new, more advanced bibliometric indicators and in the improvement of existing ones.<br/><br/>Listed by <a href="https://unglue.it/work/542204/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI Books</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/386792/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518527.694674</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>694674</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Monitoring and Assessment of Environmental Quality in Coastal Ecosystems</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Sílvia C. Gonçalves</PersonName><PersonNameInverted>Gonçalves, Sílvia C.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bay of Bengal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>beach litter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Benefit transfer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioaccumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coastal pollution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crustaceans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economics, finance, business &amp; management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ecosystem services</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Endocrine Disruptors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Environmental economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>environmental monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fuzzy modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infrared thermography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inverse distance weighting (IDW)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine environmental pollution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine fish</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marine sediment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meta-regression function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mugil cephalus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ordinary kriging (OK)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PFNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radioactive materials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spatial predictions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Takagi–Sugeno</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::K Economics, Finance, Business and Management::KC Economics::KCV Economics of specific sectors::KCVG Environmental economics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trace metals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UAV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UGV</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Coastal ecosystems are dynamic, complex, and often fragile transition environments between land and oceans. They are exclusive habitats for a broad range of living organisms, functioning as havens for biodiversity and providing several important ecological services that link terrestrial, freshwater, and marine environments. Humans living in coastal zones have been strongly dependent on these ecosystems as a source of food, physical protection against storms and advancing sea, and a range of human activities that generate economic income. Notwithstanding, the intensification of human activities in coastal areas of the recent decades, as well as the global climatic changes and coastal erosion processes of the present, have had detrimental impacts on these environments. Maintaining the structural and functional integrity of these environments and recovering an ecological balance or mitigating disturbances in systems under the influence of such stressors are complex tasks, only possible through the implementation of monitoring programs and by assessing their environmental quality.  In this book, distinct approaches to environmental quality monitoring and assessment of coastal environments are presented, focused on abiotic and biotic compartments, and using tools that range from ecological levels of organization to the sub-organismal and the ecosystem levels.<br/><br/>Listed by <a href="https://unglue.it/work/518527/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/41/2e/412ea32641270aeaf403750b5707fb2f.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368162/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.589512.787922</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>787922</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Multidisciplinary Approach to Oral Cancer: The Way to Improve Expectancy and Quality of Life</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Carlo Lajolo</PersonName><PersonNameInverted>Lajolo, Carlo</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Gaetano Paludetti</PersonName><PersonNameInverted>Paludetti, Gaetano</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Romeo Patini</PersonName><PersonNameInverted>Patini, Romeo</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adjuvant therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell trajectory inference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental caries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DMFt</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Drug Discovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>esophageal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>esophagectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fibula free flap</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flap reconstruction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>free fibula flap</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gender distribution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Head and Neck Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunosuppression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>insomnia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interincisal opening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>jaw</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mandibular reconstruction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mandibulectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>matrigel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MIO</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mouth opening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Myogel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neoadjuvant chemoradiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nomograms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonsarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>OCSCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral cancer survivors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral Candida spp.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral candidiasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral mucositis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoradionecrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overall survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-specific implant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periodontitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>precise medication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary closure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychiatric profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiochemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ramus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-cell RNA-seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sleep disturbance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>survival outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>survivorship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tongue cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tooth extraction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trismus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>University of Washington Quality of Life Questionnaire</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular mimicry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zebrafish</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The growing improvement of medical sciences in the diagnosis and treatment of head and neck oncological diseases has produced a significant increase in the life expectancy of affected patients. it is therefore necessary to direct new energies towards understanding and protecting the quality of life of cancer patients. This reprint presents the fruit of the research protocols of numerous groups around the world on the topics of life expectancy and quality of life of patients suffering from head and neck cancer.<br/><br/>Listed by <a href="https://unglue.it/work/589512/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/420997/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492194.659983</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659983</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Neonatal Nutrition for Inflammatory Disorders and Necrotizing Enterocolitis</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Misty Good</PersonName><PersonNameInverted>Good, Misty</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bloodstream infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breast milk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breast-feeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Breastfeeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breastmilk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colostrum administration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Communication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cultural Studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>donor breast milk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>donor human milk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>donor milk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enteric pathogens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exosome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extracellular vesicle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food &amp; society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>formula</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>formula feeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastroschisis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycosaminoglycans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Hormones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human milk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human milk banks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human milk fortifier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immature intestine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal adaptation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal atresia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestinal resection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intestine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>late onset sepsis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long chain polyunsaturated fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>milk analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>milk fat globule</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Necrotizing enterocolitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>newborn</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NICU parent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osmolality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parenteral nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient empowerment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>premature infants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>premature neonates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prematurity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preterm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preterm infant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>product labeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>short bowel syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spontaneous intestinal perforation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>very low birth weight</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Nutrients Special Issue focuses on neonatal nutritional advances for inflammatory disorders affecting infants such as necrotizing enterocolitis (NEC). Nutrition can significantly impact the development of certain diseases that afflict infants. This Special Issue aims to bring together the latest research on the role of nutrition in preventing or impacting neonatal disorders. Specifically, this Special Issue focuses on the role of breast milk or donor breast milk and the various components in milk that have been demonstrated to protect against NEC and other inflammatory diseases. This issue provides a comprehensive composite of the advances in nutritional strategies that can modulate or prevent neonatal intestinal disorders.<br/><br/>Listed by <a href="https://unglue.it/work/492194/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382312/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.305678.437226</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>437226</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9782889451784</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E101</ProductFormDetail><ProductFormDetail>E116</ProductFormDetail><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Neuroimaging and Neuropsychology of Meditation States</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Barbara Tomasino</PersonName><PersonNameInverted>Tomasino, Barbara</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Franco Fabbro</PersonName><PersonNameInverted>Fabbro, Franco</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Attention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Expertise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fMRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meditation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuropsychology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>PSY000000</SubjectCode><SubjectHeadingText>Psychology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JM Psychology</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Neurophysiological and psychological modifications induced by meditation practice have been consistently addressed by neuroscience. Training meditation practice induced plasticity (Barinaga, 2003; Knight, 2004), and as a consequence several benefit for mental and physical health (Davidson &amp; McEwen, 2012), and cognitive performance. One goal of meditation is to achieve the light of consciousness observing with equanimity (the right distance) clouds of the mind wandering. This Frontiers Research Topic brings together studies from groups of authors whose research focus on neuropsychological systems involved in meditation demonstrating how meditation activates and can modify brain areas, cognitive mechanisms and well-being.<br/><br/>Listed by <a href="https://unglue.it/work/305678/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=vCEwDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>Frontiers Media SA</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2017</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">epub file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/444425/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">mobi file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/315389/</WebsiteLink></Website><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/313240/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.647623.866073</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>866073</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>New Approaches and Technologies in Orthodontics</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Letizia Perillo</PersonName><PersonNameInverted>Perillo, Letizia</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Vincenzo Grassia</PersonName><PersonNameInverted>Grassia, Vincenzo</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Fabrizia d'Apuzzo</PersonName><PersonNameInverted>d'Apuzzo, Fabrizia</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3D superimposition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>accuracy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aligner</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alveolar bone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>angle Class III</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>animal studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>apnea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arch length</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arch length discrepancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone anchored</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brackets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CAD/CAM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Candida albicans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CBCT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cephalogram</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Class II malocclusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>class III malocclusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clear aligners</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cleft</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clustering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>color mapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cone-beam computed tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dental Plaque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dentofacial orthopedics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital orthodontic measurement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fixed retainers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>functional appliances</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gingival crevicular fluid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infrared spectroscopies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insertion site</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interceptive orthodontics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interobserver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intraoral scanned digital model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intraoral scanner</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Invisalign®</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lip bumper</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malocclusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mandible</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mandibular incisor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mandibular retrognathism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Materials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>matrix metalloproteinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maxillary transverse deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maxillofacial growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maxillofacial protraction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>measurement method</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mechanosensing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>micro implant-assisted rapid palatal expansion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>midpalatal suture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mini-implants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>morphometrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mouth breathing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nasal obstruction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>occlusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>optimal timing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orovestibular tooth movement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthodontic retention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthodontic tooth movement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthodontic treatments</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Orthodontics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthopedic therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthopedic treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoclastogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overbite</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overjet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>palatal expansion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PAR index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periodontal ligament</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periodontitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phenotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>principal component analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>profile shape</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Raman spectroscopies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Recovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rejection rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Saliva</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>segmentation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skeletal expansion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>superimposition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surface model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Teenagers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKG Pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Three-dimensional imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>three-dimensional superimposition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tooth wear</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tooth width</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment efficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>unilateral cleft lip and palate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vibrational spectroscopies</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The aim of this Special Issue was to update readers with the latest research in different areas of orthodontics, with an emphasis on diagnostic and therapeutic advances to widen our knowledge and support scientific and clinical activities. In recent years, new diagnostic and treatment approaches in orthodontics have emerged, and researchers and practitioners must stay current with these innovations. Artificial intelligence (AI) development has advanced, allowing experts to provide better alternatives to patients, make more precise diagnoses, and reduce treatment costs and time frames. New technologies and procedures, such as intraoral scanners, digital models, and measurements, along with the increasing use of CBCT, have slowly grown, enhancing overall patient care, treatment plan management, and prevention, particularly in the early stages. Currently, impacted teeth, facial deformities, OSA, and other oral disorders or pathologies may be detected more quickly, allowing for more direct and timely communication and enhancing patient compliance. Furthermore, technology has enabled the accurate timing and positioning of many types of orthodontic devices, such as functional appliances and mini-screws, and the ability to determine which factors are connected to the orthodontic treatment movement (OTM). The literature is regularly expanding, allowing doctors to provide more effective and less onerous therapies for each patient.<br/><br/>Listed by <a href="https://unglue.it/work/647623/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466286/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491999.659788</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659788</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>New Technologies for the Treatment of Coronary and Structural Heart Diseases</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Alberto Polimeni</PersonName><PersonNameInverted>Polimeni, Alberto</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2D transesophageal echocardiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3D transesophageal echocardiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>accelerated atherosclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACURATE neo</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute coronary syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute myocardial infarction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>angioplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antiplatelet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aortic stenosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aortic valvuloplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Atherosclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bifurcations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bilateral internal mammary artery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioresorbable scaffold</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioresorbable vascular scaffold</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>borderline lesions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac computed tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac magnetic resonance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac magnetic resonance imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiac Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiogenic shock</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotid intima-media thickness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cholesterol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic total occlusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical implications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>computerized tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Congenital heart disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary artery bypass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary artery bypass grafting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary artery disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary calcium scoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronary CT angiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>da Vinci</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>distal radial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug eluting stents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug-eluting stent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual antiplatelet therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FDG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>feature tracking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorodeoxyglucose positron emission tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heart Failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>late gadolinium enhancement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>left atrial appendage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>left main</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>longitudinal axis strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnetic resonance angiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mechanical circulatory support</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myocardial deformation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonsignificant lesions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>off-pump coronary artery bypass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>on-pump coronary artery bypass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open heart</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Optical Coherence Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Percutaneous coronary intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>percutaneous coronary interventions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>progenitor cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>re-occlusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Regeneration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>right heart catheterization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SAPIEN 3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SAVR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>severe aortic stenosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>snuffbox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>statins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stem Cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stent bioresorbable</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stent thrombosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sternotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structural heart disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subclinical coronary artery disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surveillance coronary angiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tagging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>target vessel failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TAVI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TAVR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcatheter aortic valve replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ulnar</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WATCHMAN occlusive device</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>young patients</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>There has been significant progress in the field of interventional cardiology, from the development of newer devices to newer applications of technology, resulting in improved cardiovascular outcomes. The goal of this Special Issue is to update practicing clinicians and provide a comprehensive collection of original articles, reviews, and editorials. To this end, we invited state-of-the-art reviews, including reviews of new technology and therapeutics, as well as original research in this area to be considered for inclusion in this issue. Examples include the history and evolution of interventional techniques, reviews of specific devices and technologies for coronary artery disease (i.e., stent technology, atherectomy devices, coronary physiology, intracoronary imaging, and robotics), structural heart diseases (i.e., ASD: atrial septal defect; LAAC: left atrial appendage closure; MC: MitraClip; PFO: patent foramen ovale; TAVI: transcatheter aortic valve implantation), advances in the management of challenging coronary anatomy, new biomarkers of cardiovascular disease (noncoding RNAs, etc.), and interventional techniques in the management of heart failure, peripheral arterial diseases, and pulmonary embolism. This Special Issue presents the most recent advances in the field of coronary and structural heart diseases as well as their implications for future patient care.<br/><br/>Listed by <a href="https://unglue.it/work/491999/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382122/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518789.694936</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>694936</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Junji Uchino</PersonName><PersonNameInverted>Uchino, Junji</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adjuvant Chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>daily practice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA polymerase beta</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>docetaxel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGFR-TKI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endocrine disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epidermal growth factor receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Expanded Access Program</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FDG-PET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genomic diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose transporter 1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIP1R</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune checkpoint inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune checkpoint inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune-related adverse events</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interstitial lung disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>KRAS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple cancers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nivolumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Non-Small Cell Lung Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-small-cell lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nonsmall cell lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NSCLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nucleotide-diphosphate kinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oligometastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osimertinib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-1 blockade</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-1 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1 expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phase I/II trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platinum-based first-line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>previously treated patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognostic factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary pleomorphic carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RAD51B methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiology and other imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-world data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rechallenge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>responsiveness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>retrospective analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RUNX1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>S-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salvage Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stage IIIA-N2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T790M</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TP53 mutations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor-bearing patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tyrosine kinase inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>unresectable</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-catenin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.<br/><br/>Listed by <a href="https://unglue.it/work/518789/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/6c/59/6c595c6b0aef0397d48e008e2f8e331f.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368282/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.573090.766316</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>766316</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Novel Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Cosmin Mihai Vesa</PersonName><PersonNameInverted>Vesa, Cosmin Mihai</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Simona Gabriela Bungau</PersonName><PersonNameInverted>Bungau, Simona Gabriela</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abietane diterpenoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADMET</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>common carotid artery occlusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyslipidemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ejection fraction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>empagliflozin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial nitric oxide synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GIP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GLP-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucagon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Heart Failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hsa-miR-193b-3p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HUVEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>incretins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Leptin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>levopimaric acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LY3298176</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>morbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuroprotection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nicotinamide mononucleotide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peroxisome proliferator activated receptor gamma coactivator 1 alpha</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PFK15 synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quinopimaric acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>retinal ischemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>retinal ischemia/reperfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sacubitril/valsartan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sphingolipids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sphingomyelinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>statin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>summit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sunitinib L-malate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SURMOUNT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SURPASS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synergy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thromboxane prostanoid receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tirzepatide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasorelaxation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-glucosidase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The purpose of this reprint based on the Special issue "Molecules in Diabetes Melitus, Dyslipidemia and Cardiovascular Disease”, IJMS journal, MDPI, is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease.<br/><br/>Listed by <a href="https://unglue.it/work/573090/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/90/95/9095e0d9d2d88a7fdfefdd5ead03a6f7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407536/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.590821.789231</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>789231</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Nursing and COVID-19 Ⅱ</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Richard Gray</PersonName><PersonNameInverted>Gray, Richard</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Sonia Udod</PersonName><PersonNameInverted>Udod, Sonia</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>basic psychological need satisfaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Burnout</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>care ethics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>care homes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caregiving</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>changes in outlook</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Community nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>confinement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coping strategies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Coronavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronavirus disease 2019 (COVID-19)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>correctional nurses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19 ambulatory care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19 Pandemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crisis management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>crisis response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cross-cultural</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cultural competence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>depression symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Emergency Medical Services</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>end-of-life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>episodic memories</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>female nurses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>female stereotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frontlines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gender bias</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gender Equity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Health Workforce</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in-action review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infectious diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>influencing factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>insomnia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Item Response Theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Job stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>junior nurses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Long-term care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Measurement invariance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mental health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mental status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Minority</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mitigation measures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mixed Methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>narratives</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>novel infectious disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nurse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nurse management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nurses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nursing Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nursing records</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nursing skills</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nursing staff</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nursing students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>occupational health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Palliative Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pandemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pandemics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient isolation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perceived autonomy support</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personal protection equipment (PPE)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-traumatic growth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Post-traumatic stress disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>potentially morally injurious event (PMIE)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary healthcare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prison</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>professional identity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>professional roles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protective equipment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychological security</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosocial burden</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosocial risk scale</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Public Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Qualitative research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>qualitative study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>relational capital</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>relational care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>resilience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-determination theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Self-disclosure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sexism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Spain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>spirituality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>survey</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>topic modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcultural</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transformational experience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>turnover intentions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultra-Orthodox</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Validation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Volunteers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wellbeing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WHO-5 Well-Being Index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>willingness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>work conditions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>work meaning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Workforce</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Nurses represent the highest number of healthcare workers globally and have played a critical role in the COVID-19 pandemic. This reprint highlights the issues and challenges faced by nurses practicing in hospital and community settings during the COVID-19 pandemic. The manuscripts herein focus on nurses in various areas of practice, including nurse managers, highlighting the impact, experience, and reality of providing care during the crisis. Interventions and strategies to support practice environments and the mental health and wellbeing of the nursing workforce were identified. Evidence from these manuscripts shed light on how nurse leaders can provide relevant, coordinated, and consistent organizational and leadership support to better establish a safe and healthy work environment that protects and fosters the mental health and wellbeing of all nursing personnel. The pandemic exacerbated the already demanding quality of work environments for nurses, as well as their mental health and wellbeing, thereby inducing a global nursing shortage; therefore, improving these factors, which ultimately influence nurse retention, is critical. We trust that sharing the lived experiences of nurses during the COVID-19 pandemic can enable us to leverage their expertise in meeting the complex care needs of patients, including COVID-19 patients, while improving the care needed by nurses in their working environments, alongside preparing for future pandemic waves.<br/><br/>Listed by <a href="https://unglue.it/work/590821/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/421260/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.458817.620754</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>620754</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039286621</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Nutrients Intake and Hypertension</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Francesco Fantin</PersonName><PersonNameInverted>Fantin, Francesco</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adhesion molecule</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amino acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arterial stiffness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Atherosclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Calcium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular remodeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental programming</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electrolytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Endothelium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fish meal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fish protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fructose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hesperidin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high blood pressure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Humans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>l-NAME</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnesium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mediterranean Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Menopause</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nitric Oxide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nitrite</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ojeoksan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parathyroid function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyphenol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Post Exercise Hypotension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Potassium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulse wave velocity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal sympathetic nerve activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renin-angiotensin-aldosterone system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reprogramming</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rest raw material</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salt intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salt-sensitivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sodium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sodium intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sympathetic activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tea secondary metabolites</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasodilation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Weight loss</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Hypertension is a major health problem worldwide, increasing cardiovascular (CV) risk and mortality. Together with pharmacological treatments, non-pharmacological approaches, such as nutrient intake modifications, play an important role in optimizing treatment. A link has been demonstrated between hypertension and body weight as well as dietary habits. The aim of this Special Issue is to improve the understanding of the relationships between some nutrients and hypertension, and of the effects of different dietary approaches on hypertension regulation from different points of view.<br/><br/>Listed by <a href="https://unglue.it/work/458817/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://encrypted.google.com/books?id=mbfjDwAAQBAJ&amp;printsec=frontcover&amp;img=1&amp;zoom=1</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20200513</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/311311/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.571359.764041</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>764041</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Nutrition in Chronic Conditions</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Omorogieva Ojo</PersonName><PersonNameInverted>Ojo, Omorogieva</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Amanda Adegboye</PersonName><PersonNameInverted>Adegboye, Amanda</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>almonds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bahrain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>beta-hydroxybutyrate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biochemical measurement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BMI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone turnover markers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Childhood obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic heart failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Kidney Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>coffee</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cohort study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cost savings</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cultural Studies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diabetes mellitus type 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dietary fiber</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary habits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Economic Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extract of Ginkgo biloba (EGb)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Food &amp; society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycated haemoglobin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycemic control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycemic index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glycemic load</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gm16551</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut microbiome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>H19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>handgrip strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Helicobacter pylori</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospital outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory bowel disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulinaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ketogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lncRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malnutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical nutrition therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Micronutrients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mild Cognitive Impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NAFLD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional support</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral anti-diabetic agents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pandemic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PBLs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalised lifestyle intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant-based foods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postprandial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prebiotics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Proteinuria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>socio-demographic factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::G Reference, Information and Interdisciplinary subjects::GP Research and information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBC Cultural and media studies::JBCC Cultural studies::JBCC4 Cultural studies: food and society</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tree nuts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triglyceridaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Zinc deficiency</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The effects of nutrition on chronic conditions, such as diabetes, obesity, heart disease, and stroke, continue to generate interest among researchers. This is because diet is a modifiable risk factor. The composition of diet, including the proportions and types of macronutrients and micronutrients, is a major contributor to chronic diseases. The beneficial effects of nutritional interventions on chronic conditions have been well documented, although differences remain among researchers concerning their overall impact. The evaluations of the role of nutrition in chronic conditions draw on diet’s effects on body weight, body composition, glycemic, and insulin excursions, and vascular remodeling. The effect of diet in modulating gut microbiota dysbiosis is also an evolving area of research. This reprint, entitled “Nutrition in Chronic Conditions”, aims to examine the effect of nutrition in the development, care, and management of chronic conditions. This reprint includes 11 original studies conducted in high- and middle-income countries, 3 systematic reviews with meta-analysis, and 3 literature reviews. The topics covered in the reprint include: the effects of diet on (1) insulin and glucose metabolism; (2) gut health; (3) brain and cognitive impairment; (4) infections, chronic conditions, malnutrition, and all-cause mortality; (5) obesity and dietary variables in post-menopausal women; (6) non-alcoholic fatty liver disease in mice, specifically with the consumption of coffee; and (7) chronic conditions and COVID-19 infection.<br/><br/>Listed by <a href="https://unglue.it/work/571359/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/c6/7f/c67f1031ae2d795608b193906e8aa89c.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407426/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.562068.752069</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>752069</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Nutrition, Diet Quality, Aging and Frailty</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Cristiano Capurso</PersonName><PersonNameInverted>Capurso, Cristiano</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Catherine Féart</PersonName><PersonNameInverted>Féart, Catherine</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Activities of Daily Living</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aged</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Alzheimer’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amyloid beta-peptides</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Animal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-ageing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breakfast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Carbohydrates</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cognitive impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cohort study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-sectional study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dairy products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary diversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary inflammatory index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Disease Models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eating habits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food groups</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Frailty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Functional foods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glucose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperhomocysteinemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lifespan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Malnutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mediterranean dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>memory and learning tests</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meta-regression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle mass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutrient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nutrition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical frailty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>QoL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self-assessed chewing ability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serum albumin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin ageing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin B deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Westernized dietary pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole grain</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In the last century, the average life expectancy at birth increased from roughly 45 years in the early 1900s to more than 80 years of age at present. However, living longer is often related to different levels of frailty. There is no curative treatment for frailty—the interventions that have been described as effective to slow or delay the onset of frailty are physical activity and nutritional interventions. Maintaining adequate nutrition status is important to reduce the risk of chronic diseases, many of which are age-related. On the other hand, frailty itself may have a negative effect on eating and, thus, on the nutritional status. This Special Issue, "Nutrition, Diet Quality, Aging and Frailty", addresses the existing knowledge on nutrition regarding the causative factors of frailty and disease due to aging, i.e., strategies for delaying the pathological effects of aging. It consists of twelve peer-reviewed papers covering original research, protocol development, methodological studies, narrative or systematic reviews, and meta-analyses, to better understand these complex relationships.<br/><br/>Listed by <a href="https://unglue.it/work/562068/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/e2/b1/e2b19f56dbc9af860413593619fa0a38.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/396043/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491719.659507</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659507</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Oral Health and Environmentally Related Factors Associated with General Health and Quality of Life</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Gaetano Isola</PersonName><PersonNameInverted>Isola, Gaetano</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Romeo Patini</PersonName><PersonNameInverted>Patini, Romeo</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ACE2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>age determination by teeth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>age estimation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>applied model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Applied Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atomic force microscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autoclave</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caries</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cephalometric analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic periodontitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clear aligners</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cohort</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cone beam computed tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Corrosion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cranial base</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>craniofacial orthopedic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dental measurements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital dentistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>digital orthodontics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endodontic sterilization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endodontics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>facial skeleton</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>facial typology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fixed appliances</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forensic dentistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>geometric morphometric analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gingival biotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Korea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>myeloperoxidase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NiTi alloy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral pathology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthodontic diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthodontic retainers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthopantomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain perception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>panoramic radiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periodontitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>photobiomodulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Portuguese population</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>relapse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sex determination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sexual dimorphism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>three-dimensional facial scans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tonsillectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VAS (visual analog scale) scale</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The relationship of oral disease to overall disease is certainly not a new concept. For centuries, the role of oral infection and inflammation in contributing to diseases elsewhere in the body has been studied and reported. During the last few decades, a series of intriguing reports from many countries have increased the current interest in the role of oral health and disease in contributing to general health and systemic conditions. Is it possible that oral and periodontal disease is a risk factor for cardiovascular and other systemic diseases? Since this question was first posed, a phenomenal body of work has been directed at understanding how oral periodontal disease might affect distant sites and organs and, thus, have an effect on overall health. Recent studies of the human microbiome using DNA sequencing technologies have revealed new insights into the possible mechanisms that help to explain how oral infections can occur in distinct sites such as atheromas, the colon, and reproductive tissues.<br/><br/>Listed by <a href="https://unglue.it/work/491719/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381846/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.573378.766606</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>766606</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Orthopedics and Trauma in Children</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Axel A. Horsch</PersonName><PersonNameInverted>Horsch, Axel A.</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Maher A. Ghandour</PersonName><PersonNameInverted>Ghandour, Maher A.</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Matthias Christoph M. Klotz</PersonName><PersonNameInverted>Klotz, Matthias Christoph M.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adolescent idiopathic scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amputation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autografts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>avascular necrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cerebral palsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chiari</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>closed reduction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>combined osteotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>complication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>concentric circle sign</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conservative treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>definition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DEFSO</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental dysplasia of the hip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>developmental hip dysplasia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnostic imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>distal femoral extension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>distal forearm fractures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dorsiflexion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysplasia of the hip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>equinus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ewing sarcoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extraosseous</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>femoral osteotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>femur</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foam splint</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forearm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hemiplegia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip asymmetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip dislocation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip dysplasia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip luxation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip reconstructive surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hip ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ilium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intramedullary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Legg–Calvé–Perthes disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lower Extremity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lumbar spine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>morbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MPFL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>musculoskeletal disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nail</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Navigation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurogenic dislocation of the hip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neurologic injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-operative treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>O-arm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open reduction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthopedic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthotic management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patellofemoral instability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pediatric</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pediatric injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pediatric trauma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pedicle screws</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic asymmetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic osteotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pemberton</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pes equinus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plantarflexion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>positive anterior tilt angle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>posterior spinal fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postsurgical pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prospective randomized clinical trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proximal tibia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiographic follow-up</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radius</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Remodeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>return to sport</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Scheuermann kyphosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>scoliosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shortening osteotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skeletal maturity height</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spica cast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spinal fusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Spine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spine growth prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spondylolisthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>supracondylar humerus fractures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thoracic spine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trampoline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trampoline fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trauma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ulna</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>varisation derotation osteotomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vascular injury</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Discover the complexities of pediatric orthopedics in this comprehensive reprint book. Pediatric orthopedics present unique challenges in diagnosis and treatment, necessitating the expertise of skilled specialists. Congenital, developmental, and acquired orthopedic issues, including infectious, neuromuscular, nutritional, neoplastic, psychogenic, and traumatic conditions, are explored. With a focus on evidence-based recommendations, this book addresses the management of orthopedic deformities in children by considering different clinical scenarios. From upper and lower limb injuries to severe trauma, readers will gain insights into decision-making processes for reconstruction or amputation. As a valuable resource for orthopedic surgeons, pediatricians, and healthcare professionals, this reprint fills knowledge gaps to optimize patient care.<br/><br/>Listed by <a href="https://unglue.it/work/573378/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/9c/0d/9c0d6871007cb116936c87550f4d1c11.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407595/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.567783.759410</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>759410</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Osteoporosis and Related Bone Metabolic Disease</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Heinrich Resch</PersonName><PersonNameInverted>Resch, Heinrich</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3D printing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adverse events</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomaterial scaffolds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone fragility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone microstructural deterioration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone microstructure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone mineral density</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carcinoma in situ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CKDMBD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cortical porosity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crohn’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>denosumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DXA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fractal-based analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fracture risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fragility fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gaucher disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucocorticoid treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high resolution peripheral quantitative computed tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imaging methods</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imminent fracture risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>initiation timing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Life sciences: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lyso-Gb1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Men</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Menopause</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metformin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>National Health Insurance Research Database</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurosciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>OPG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoporosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>premature ovarian insufficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoriasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoriatic arthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RANKL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>second fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stress fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strontium ranelate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Testosterone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TRAP5b</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vertebral fractures</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Many heterogeneous causes (e.g., metabolic, inflammatory, autoimmune, vascular, and renal diseases, and even drugs), collectively grouped as secondary causes of osteoporosis, may lead to bone loss or damage to architecture through a number of mechanisms. Although these secondary causes of osteoporosis are the most frequently observed causes of unexpected bone loss, they can only be diagnosed via a high degree of suspicion and clinical experience and by performing the appropriate investigations. In inflammatory disorders such as rheumatoid arthritis or chronic inflammatory bowel diseases, as well as vascular diseases, T-cell activation, and consequently pro-inflammatory cascades, trigger the increased expression of T-cell-derived RANKL. In addition, a new biomarker signature of bone-related miRNAs is promising in certain clinical features. Glucocorticoids, often used to control disease activity, decrease the number and function of osteoblasts and inhibit OPG expression. The ubiquitous occurrence of disease-related secondary changes in bone metabolism implies that numerous medical disciplines need to interact. Screening for secondary causes of osteoporosis and the search for new modes of action should present a substantial aspect of osteoporosis management. In the book, the current management of osteoporosis and related metabolic bone diseases is discussed.<br/><br/>Listed by <a href="https://unglue.it/work/567783/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/88/c1/88c174a2ba956ce92e88927f51a8eba9.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407190/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.580112.776123</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>776123</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Pathogenesis and Therapy of Oral Carcinogenesis</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Marko Tarle</PersonName><PersonNameInverted>Tarle, Marko</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ivica Lukšić</PersonName><PersonNameInverted>Lukšić, Ivica</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>4 NQO</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer stem cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Caveolin-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CC chemokine ligand 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CCL2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell polarization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cholesterol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cigarette smoke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating cell-free DNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical Trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Damage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>E2F2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EGFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epidermal growth factor receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erlotinib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Extracellular matrix</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Head and Neck Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hedgehog pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HS-173</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Human</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human papillomavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunocytochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunohistochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>integrin αvβ6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymph node metastases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lysyl oxidase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>margin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mast cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MCP-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MCs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>migration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-125b-5p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-155-3p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-214-5p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mouse model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nEGFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nucleophosmin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nutri-Jelly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral cavity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oropharyngeal squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>OSCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>p53</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pathogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PEITC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Periodontics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>periodontitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polymorphism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PRI-724</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SOD2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soluble factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>squamous cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synergism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tertiary chemoprevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tissue factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tooth loss: oral cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor suppressor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urokinase-type plasminogen activator receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vismodegib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WNT pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-catenin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>We present our reprint dedicated to the study of oral squamous cell carcinoma (OSCC). Despite advances in diagnosis and treatment, OSCC remains a challenge for scientists and clinicians worldwide. This compilation of articles addresses novel biomarkers and therapeutic targets for the prevention and treatment of OSCC. Articles cover topics such as the combined use of pathway inhibitors in cancer control, the role of genes and microRNAs, the interaction between smoking and HPV infection, and potential biomarkers for diagnosis and therapy. These publications provide insights into the latest research and inspire further innovation.<br/><br/>Listed by <a href="https://unglue.it/work/580112/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/414183/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.571422.764104</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>764104</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Pathogenesis of Pregnancy-Related Complication</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ilona Hromadnikova</PersonName><PersonNameInverted>Hromadnikova, Ilona</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>amino acid transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>assisted reproductive technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BeWo cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood–brain barrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular microRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD24</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell migration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chorionic villus sampling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic venous disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>congenital malformations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometriosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometrium immunomodulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Endothelium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FCN2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fetal growth restriction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fetal hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FGF2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ficolin-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>forensic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>galectin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gestational diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucagon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose uptake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Human</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypertensive vascular disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>idiopathic recurrent pregnancy loss</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IL-6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Il-8</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune Tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>implantation failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro preeclampsia models</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infertility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemic placental syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>JEG-3 cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>l-NAME</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal–fetal interface</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MenSCs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MicroRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-125a-5p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-23b-5p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miR-4732-5p</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neonate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuronal damage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>newborn</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathologic pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PGE2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Placenta</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>placental growth factor (PlGF)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>placental-derived immortalized cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Preeclampsia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pregnancy adverse outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy Complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pregnancy-induced CVD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prematurity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prenatal testing transcriptome sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Preterm Birth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary hyperparathyroidism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proinflammatory cytokines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pulmonary metastatic calcification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyroptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reproductive Immunology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sFlt-1/PlGF and sFlt-1*sEng/PlGF ratios</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Single nucleotide polymorphism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC2A1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC2A3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC38A1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC38A2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SLC38A4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small RNA sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>small RNA-seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soluble endoglin (sEng)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soluble fms-like tyrosine kinase-1 (sFlt-1)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sPTD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STOX1-A/B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tight junction proteins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tight Junctions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trophoblast invasion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>very low birthweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole peripheral venous blood</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>In this Special Issue, "Pathogenesis of Pregnancy-Related Complications", 4 reviews, 13 original papers, 1 communication, and 1 case report are compiled. These papers were published by scientific teams from 24 countries, including China, Tunisia, Canada, France, Serbia, Portugal, Spain, Chile, Singapore, Australia, the USA, Mexico, the Czech Republic, Germany, Sweden, Finland, the United Kingdom, Norway, Poland, Greece, Japan, Italy, Switzerland, and Israel, which is a really great achievement.<br/><br/>Listed by <a href="https://unglue.it/work/571422/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/51/ec/51ece6415d8197acfb7460d0f3197aa0.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407447/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.520047.696225</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>696225</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Perioperative Care</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Richard H. Parrish II</PersonName><PersonNameInverted>II, Richard H. Parrish</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>John Kortbeek</PersonName><PersonNameInverted>Kortbeek, John</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anesthesiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic prophylaxis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bio-monitoring system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Collaboration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>collaborative practice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Colorectal Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Critical Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enhanced recovery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gynecological</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heart transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>implementation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infection, surgical wound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignant hyperthermia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multimodal analgesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opioid stewardship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opioid-related adverse effects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain Management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pediatric</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pediatrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Perioperative Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative medication management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacy, clinical</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-operative nausea and vomiting</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preemptive analgesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prophylactic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prophylaxis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality improvement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regional anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgeon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical home</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical prophylaxis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical site infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>team-based care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>technology acceptance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thromboembolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transitions of care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tricuspid annuloplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tricuspid regurgitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venous</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vital sign monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wearable biosensors</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Perioperative care practices worldwide are in the midst of a seeing change with the implementation of multidisciplinary processes that improve surgical outcomes through (1) better patient education, engagement, and participation; (2) enhanced pre-operative, intra-operative, and post-operative care bundles; and (3) interactive audit programs that provide feedback to the surgical team. These improved outcomes include reductions in the frequency and severity of complications and improved throughput, which ultimately reduce operative stress. Practices in theatre as well as ward are becoming more collaborative and evidence-driven.This book is best utilized by perioperative care team members engaged in quality improvement, collaborative practice, and application of innovations in surgical care.<br/><br/>Listed by <a href="https://unglue.it/work/520047/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/0a/3e/0a3e07db6d51a2bbe89a766c13be27df.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368890/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.535072.716255</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>716255</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Personalized Care and Treatment Compliance in Chronic Conditions</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Fábio Teixeira</PersonName><PersonNameInverted>Teixeira, Fábio</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Catarina Godinho</PersonName><PersonNameInverted>Godinho, Catarina</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Júlio Belo Fernandes</PersonName><PersonNameInverted>Fernandes, Júlio Belo</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>advanced nursing practice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aerobic exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aged</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ageism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antidiabetic agents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autoimmune</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bibliometrics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>boot camp</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caregiver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Caregivers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child abuse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>child protective services</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic liver disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical psychology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognitive function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Compliance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Continuity of Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>decision</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Discrimination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual-tasking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Empowerment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>exercise prescription</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Fatigue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fibromyalgia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Glaucoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health promotion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hip Fracture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospital discharge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>informal caregiver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intentional nonadherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maltreatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medication acceptability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mental Disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mental illness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mortality risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>needs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neglect</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nursing Education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nursing students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older person</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Other branches of medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain acceptance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain catastrophizing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Parkinson Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient adherence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient compliance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-focused care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>performance-based test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalized care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalized medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>personalized therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical functioning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postural control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prejudice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Qualitative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rehabilitation nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>returning home</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>review literature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rheumatology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Safety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>self esteem</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sexuality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SGLT-2 inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>social stigma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stereotyping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stroke</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surface electromyography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>temporomandibular disorders</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapeutic exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transitional care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Virtual reality</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>People who have chronic diseases spend a significant amount of time in self-management in out-of-hospital environments, in their homes and in their community settings. These patients have different disease statuses and management requirements, so providing personalized care is key.Personalized care is a collaborative process that should be used in chronic condition management in which patients, caregivers, and healthcare providers identify and discuss problems caused by or related to the patient's condition and then develop plans and goals to empower patients.Personalized care can improve aspects of physical health, mental health, and the ability to self-manage conditions. Thus, a personalized care approach could greatly benefit patients with chronic conditions.In this book, we have included 20 articles that expand the current knowledge on the personalized care approach to diagnosing and treating chronically ill patients.<br/><br/>Listed by <a href="https://unglue.it/work/535072/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/379371/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.532188.711187</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>711187</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Personalized Medicine in the Field of Inflammatory Skin Disorders</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Mircea Tampa</PersonName><PersonNameInverted>Tampa, Mircea</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Monica Neagu</PersonName><PersonNameInverted>Neagu, Monica</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Constantin Caruntu</PersonName><PersonNameInverted>Caruntu, Constantin</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Simona Roxana Georgescu</PersonName><PersonNameInverted>Georgescu, Simona Roxana</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>AK</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alginate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>androgenic alopecia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidative stress strategies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atopic dermatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autoinflammatory disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomaterial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C57 BL/6 mice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calumenin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cannabinoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carbohydrate oxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD36</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical Trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>commercially available</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comorbidities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>corticosteroids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cSCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cutaneous melanoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cyclosporine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cytohesin 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA oxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dressing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drug resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eczema</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epigenetic regulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epigenetic therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>estrogen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Evidence-based medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fibers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gut-lung-skin barrier</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hair density</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>halo nevi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hydrogel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>IgY</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imiquimod</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune-mediated skin diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunosuppression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>JAK inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lipid Peroxidation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long-chain fatty acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lupus nephritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Menopause</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nanofibers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidized proteins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>platelet-rich plasma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proteome analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoriasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoriasis vulgaris</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psoriatic dermatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pyoderma gangrenosum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>S100A6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sea-buckthorn seed oil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sialidase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sialylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sialyltransferase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>signaling pathways</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin conditions and systemic inflammatory diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin dysplastic keratinocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skin tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SR-B2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sutton nevi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic lupus erythematous</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic sclerosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>target therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapeutic targets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UVA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wound care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Wound healing</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Skin inflammation is associated with a wide range of conditions which represent major health issues worldwide. Skin and mucosal surfaces represent the primary interface between the human body and the environment, susceptible to numerous factors whose action results in diseases produced by chemical substances, mechanical trauma, microbial agents, radiation, etc. Inflammation, a complex network of interactions between soluble molecules and cells, represents the main modality of the skin’s response to injuries. Numerous studies have revealed close links between chronic inflammation, oxidative stress, and carcinogenesis. Chronic inflammation induces the activation of various cell types and an increase in the production of reactive oxygen species, promoting the initiation of a malignant process. Identifying specific biomarkers is essential for understanding molecular mechanisms and developing therapies appropriate to the patient’s characteristics.Personalized medicine is an emerging field of medicine that has the potential to predict which therapy will be safe and efficacious for specific patients using an individual’s genetic profile to guide decisions regarding the diagnosis, treatment, as well as prevention of disease. This book gathers articles that present recent advancements in research involving the mechanisms that underlie the development of inflammatory skin disorders, skin and mucosal inflammation in general.<br/><br/>Listed by <a href="https://unglue.it/work/532188/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/0f/3d/0f3d7eb68d62d889aee1e32460b009cf.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/374990/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.455878.616917</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>616917</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039216543</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Pheochromocytoma (PHEO) and Paraganglioma (PGL)</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Karel Pacak</PersonName><PersonNameInverted>Pacak, Karel</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>David Taïeb</PersonName><PersonNameInverted>Taïeb, David</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>11C-hydroxy-ephedrine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>177Lu-DOTATATE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>18F-FDOPA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adaptive Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenal incidentaloma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenal tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenocortical carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adrenomedullary function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angiogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arrhythmia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>average real variability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>blood pressure variability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Calorimetry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Carotid Body</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>catecholamine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>catecholamines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromogranin A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromosomal alteration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CNV detection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Comparative genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cryoablation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dog</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ectopic secretion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Energy Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EPAS1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>erythropoietin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FGF21</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluorescence imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GAPP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>germline mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>global longitudinal strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GTV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hereditary</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIF</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Histology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypotension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxia-inducible factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunohistochemistry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>innate immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lL-6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metanephrines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic OR malignant pheochromocytoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimally invasive procedure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitochondria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mouse pheochromocytoma cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mutation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>net</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neural Crest</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroendocrine tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neutrophil</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>next-generation sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NF1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>normetanephrines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pan-cancer analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>paraganglioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PASS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathogen-associated molecular patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peptide receptor radiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>percutaneous ablation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>percutaneous ethanol injection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PET-CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PGL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pheochromocytoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pheochromocytoma and paraganglioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phosphorylation tyrosine hydroxylase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polycythemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PPGL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PRRT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pseudohypoxia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiofrequency ablation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiosensitization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SDHB</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SDHD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>somatostatinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>speckle-tracking echocardiography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spheroids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sporadic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stem-like tumor cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subclinical systolic dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>succinate dehydrogenase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>T cell</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TCA cycle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>therapy resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>toll-like receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transgenic mice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vasculogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VHL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weighted standard deviation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>xenograft</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This book outlines some new advances in genetics, clinical evaluation, localization, therapy (newly including immunotherapy) of pheochromocytoma and paraganglioma including their metastatic counterparts. Well-known and experienced clinicians and scientists contributed to this book to include some novel approaches to these tumors. This book will serve to various health care professionals from different subspecialties, but mainly oncologists, endocrinologists, endocrine surgeons, pediatricians, and radiologists. This book shows that the field of pheochromocytoma/paraganglioma is evolving and a significant progress has been made in last 5 years requiring that health care professionals and scientists will learns new information and implement it in their clinical practice or scientific work, respectively. This book should not be missed by anybody who is focusing on neuroendocrine tumors, their newest evaluation and treatment.<br/><br/>Listed by <a href="https://unglue.it/work/455878/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/80/f4/80f4a6604311df85447eedcf354b681e.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20191120</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/309066/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491892.659681</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659681</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Physical Activity in the Elderly and Orthopaedic Surgery</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Rocco Papalia</PersonName><PersonNameInverted>Papalia, Rocco</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Vincenzo Denaro</PersonName><PersonNameInverted>Denaro, Vincenzo</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Fabio Pigozzi</PersonName><PersonNameInverted>Pigozzi, Fabio</PersonNameInverted></Contributor><Contributor><SequenceNumber>4</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Chiara Fossati</PersonName><PersonNameInverted>Fossati, Chiara</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>active exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aquatic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caregiver</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caregiver strain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>caregiver stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cerebral Cortex</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic low back pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cycling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dyads</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynapenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>falls</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>global postural rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hip Arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Hydrotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hypertension</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knee</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Knee Arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>knee or hip osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>knee osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>land-based</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motor unit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Muscle strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neural</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroplasticity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>noncommunicable diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>old aged patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Older people</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orthopedic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physical Therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>replacement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>return to sport</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcopenia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Shoulder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social issues &amp; processes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sport</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tendinopathies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>unicompartimental knee arthroplasty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Walking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Yoga</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Old age is increasingly becoming the focus of research and development in Europe. Concerning orthopaedics and sports medicine, the elderly especially are considered as frail patients who need support to maintain the health of their musculoskeletal systems. For this reason, several interventions regarding physical activity have been investigated in recent years in order to understand whether some programs of physical activity are better than others as conservative treatments for degenerative musculoskeletal pathologies (i.e., osteoarthritis, rotator cuff arthropathy, and lower back pain). Furthermore, several investigations have been carried out to understand the best preoperative and postoperative protocols of physical activity to improve the results of orthopaedic surgery. The aim of this Special Issue was to collect the updated evidence concerning these topics in the form of a collection of systematic reviews of the literature.<br/><br/>Listed by <a href="https://unglue.it/work/491892/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/465376/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.519016.695163</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695163</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Physical Activity, Physical Fitness, and Exercise Interventions for Preserving Human Health and Preventing and Treating Chronic Conditions across the Lifespan</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Alberto Soriano-Maldonado</PersonName><PersonNameInverted>Soriano-Maldonado, Alberto</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>African circle dance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autoimmune disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Autonomic Nervous System</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body mass index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiac rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic low back pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Clinical Trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognition</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>construct validity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>core muscles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>depressive symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynamometer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>event-related potential</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>executive control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Fatigue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related physical fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>high intensity training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Internally displaced persons</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lupus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Martial arts</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Mental health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Muscle strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overweight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>peak torque</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical aptitude</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>QoL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference Data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rheumatic disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>schoolchildren</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Smoking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social issues &amp; processes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; culture: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Society &amp; Social Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::N History and Archaeology::NH History</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>trunk strength testing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>university staff</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight gain</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Increasing global physical activity levels is one of the most important public health goals of the 21st century. Physically active individuals present better sleep patterns, increased wellbeing and quality of life, as well as better physical function and fitness levels. In addition, physical activity might stimulate brain function and improve both cognition and mental health. The risk of many chronic diseases is also reduced in physically active individuals, and physical activity might counteract the detrimental metabolic effects of long sedentary periods. Physical fitness is not only a key marker of health in healthy individuals, but in people with chronic conditions. Compelling evidence indicates that low levels of both cardiorespiratory fitness and muscular strength are associated with an increased risk of morbidity and premature mortality for a variety of causes, including cardiovascular diseases and cancer. Consequently, preserving fitness levels throughout life is a major clinical and public health interest. Exercise interventions represent the most efficient form of physical activity to enhance physical fitness and improve health outcomes at all ages and chronic statuses. However, exercise prescription in many populations is underdeveloped and further insights are needed for practitioners and the research community to understand how exercise should be administered, depending on the health and clinical status of different populations. This Special Issue focuses on the influence of fitness and physical activity and the effects of exercise interventions on human health- and disease-related outcomes. This includes, but is not restricted to, the following article types: Observational studies assessing the association of physical fitness (alone or in combination with other risks/protective factors) with health- and disease-related outcomes. Observational studies assessing the association of physical activity (alone or in combination with other lifestyle behaviors) with health- and disease-related outcomes. This includes studies assessing physical activity through either objective or subjective means. Experimental studies assessing the effects of exercise interventions (alone or in combination with other interventions) on health- and disease-related outcomes across the lifespan. Systematic reviews and meta-analyses on the above-mentioned topics are also welcome.<br/><br/>Listed by <a href="https://unglue.it/work/519016/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/8e/51/8e5178a8ec4174b8cd4cd50758d0d481.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368390/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.646993.865443</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>865443</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Phytochemicals and Chronic Diseases Prevention</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Haixia Yang</PersonName><PersonNameInverted>Yang, Haixia</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jianjun Deng</PersonName><PersonNameInverted>Deng, Jianjun</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>11-O-(4?-O-methylgalloyl)-bergenin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>?-glucosidase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>A. tenuissimum flower flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Abl tyrosine kinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>affinity ultrafiltration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alcoholic liver disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Antioxidants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bilberry</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>botanical supplements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>by-products</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>c-myc</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cardiovascular Disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD1 mice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Child</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clarified apple juices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diabetes Mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary phytochemical index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNMTs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ESCC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fasting blood glucose</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Flavonoids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flaxseed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food processing degree</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>food supplement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit extract</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gastric cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ginsenoside Rh4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gut Microbiota</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HDACs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatic encephalopathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Korea National Health and Nutrition Examination Survey (KNHANES)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kratom</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lipid profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver fibrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lycopene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrophage polarization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microglial cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mitochondrial function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mitragyna speciosa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular docking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network pharmacology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroinflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic lipase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parkinson’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenolic compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Polyphenols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pomace</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postmenopausal woman</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preparative isolation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preschooler</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>qRT-PCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Rats</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>red clover</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>red currant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>redox homeostasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rosmarinic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rotenone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Saxifraga atrata</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Schisandrin B</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SIX1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TGF-?/Smad2/3 pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::P Mathematics and Science::PS Biology, life sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>type 2 diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WNT/?-catenin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>zerumbone</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>This Special Issue, entitled “Phytochemicals and Prevention of Chronic Diseases”, features a series of high-quality research articles that explore the isolation, identification, and bioactivities of phytochemicals, as well as the underlying molecular mechanisms implicated in chronic diseases via antioxidation, neuroprotection, and the modulation of the gut microbiota.<br/><br/>Listed by <a href="https://unglue.it/work/646993/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2024</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/466212/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.574694.768394</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>768394</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Plant Genomics 2019</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Frank M. You</PersonName><PersonNameInverted>You, Frank M.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2OGD family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABC transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABCDE model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abiotic stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abiotic stress tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Abscisic Acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acetolactate synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acteoside biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Agrobacterium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alien substitution line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alternative splicing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anthocyanin biosynthetic genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anthocyanins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apple</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aquaporin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aquaporins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Arabidopsis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aristolochia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>avocado</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>azafrin biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B3 superfamily</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biosynthesis pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biotic stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brachypodium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brassica rapa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brassinosteroid-signaling kinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BrBGLU10</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bright yellow-2 suspension cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium-dependent protein kinases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Camellia sinensis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Capsicum chinense</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotenoid biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cassava</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cassava (Manihot esculenta)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>catalpol biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CDPK-related kinases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Centranthera grandiflora Benth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cereals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chalcone synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chalcones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical fungicide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ChIP-sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chloroplast genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromatin accessibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromosome 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cis-elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cis-regulatory motifs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>citrulline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cold response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>common bean</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comparative chromosome barcoding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Comparative genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>compare analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cotton</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CRISPR/Cas9</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crop Improvement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CsWRKY7</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cucurbitaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cutin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokinins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>d60</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dasypyrum villosum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>de novo assembly from short read sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DEGs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>differentially expressed genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>directional improvement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drought</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drought stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drought tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>duplication pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>duplication/triplication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysploidy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epigenetic inheritance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Eucalyptus grandis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evolutionary analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evolutionary relationships</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression profiling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fabaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fatty acid synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferrochelatase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fine mapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonolignans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>floral organ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>floral speciation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flower organ identity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flowering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foxtail millet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fruit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>full-length transcript sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Functional analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fusarium oxysproum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GASR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GDSL lipase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene co-expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene dosage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene duplications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene families</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene recombination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene silencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genetic engineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome editing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome fractionation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome organization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome-wide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome-wide analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome-Wide Association Study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome-wide association study (GWAS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome-wide identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genomic selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genotype-to-phenotype association</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GISH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glutamine synthetase (GS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GPAT6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grain yield</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grapevine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GW2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>habaneros</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haplotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heat shock protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hormone biosynthetic and metabolism genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hst1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hub genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>identification of peroxidase genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intron retention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive weed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>karyopherin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>karyotype structure and evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kernel hardness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lagerstroemia indica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large grain gene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large grain-isogenic Koshihikari</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leaf coloration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leaf variegation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LIM genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linkage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linoleic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linseed flax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lupinus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MADS-box</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MADS-box genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Maize</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marker-assisted selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesocarp</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolite profiling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minor allele frequency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA156</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>missing data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>model grass genus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular cytogenetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular marker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple organellar RNA editing factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiplex genome editing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mutation hotspots</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Na+ accumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural variation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NB-LRR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neoscytalidium dimidiatum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NGS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nicotiana tabacum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oak species identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ODNs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ornamental value</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovule abortion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>PHI000000</SubjectCode><SubjectHeadingText>Philosophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phosphoenolpyruvate carboxylase (PEPC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogenetic analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogenetic relationship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogeny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytohormone signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phytohormones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pigment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pineapple</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pittosporum tobira</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plant breeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant defense</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plant hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant hormones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant–pathogen interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plastid genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pollen development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polygalacturonase (PGs), pectin methylesterase (PMEs), collinearity analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyploidy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pomegranate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Populus trichocarpa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction accuracy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein phosphatase (PP2C)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Puroindoline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Puroindoline b-2 variants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>qRT-PCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative trait loci (QTL)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative trait nucleotides (QTNs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Quercus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rapid generation advance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reddish purple Chinese cabbage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Régulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehmannia glutinosa L.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>repeat sequences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>replant disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rhizoctonia solani</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhizosphere microbes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA Editing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA-Seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA-sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNAi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ROS scavenging enzyme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>royal poinciana</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salicaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salinity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salt tolerant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seed development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semidwarf gene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sequence diversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sesame</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Silybum marianum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>silymarin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Single nucleotide polymorphism (SNP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>site-specific selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SNP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Solanum tuberosum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stem canker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stilbenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stress marker genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress Tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structural genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subcellular localization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subgroup IId</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>substrate specificity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>syntenic relationships</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synteny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic signal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TaCKX expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TaCKX1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TALEN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thema EDItEUR::Q Philosophy and Religion::QD Philosophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tobacco rattle virus (TRV)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tomato</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tomato fruit ripening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcription factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transcription Factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptional regulatory mechanism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transgenic rice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transient expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transposable elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>turnip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UAE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>variant annotation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virus-induced gene silencing (VIGS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitis vinifera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VQ genes family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VvGAST</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>watermelon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>wheat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wheat genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wheat spikes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole-genome duplication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole-genome sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>YABBY</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ZFN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ZmTCP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-glucosidase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Vols 1 and 2 contain 57 papers in the Special Issue of ‘Plant Genomics 2009’ and cover a wide range of topics, highlighting the significant progress that has been made in recent years in our understanding of the genetics and genomics of plants’ growth, development, and stress responses. These studies provide valuable insights into the potential applications of genomic tools and technologies for crop improvement and sustainable agriculture, as well as fundamental questions about the evolution and function of plant genes and genomes.<br/><br/>Listed by <a href="https://unglue.it/work/574694/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/0b/4c/0b4cb960438a408dc460d0f48ece341c.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407633/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.575199.768900</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>768900</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Plant Genomics 2019</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Frank M. You</PersonName><PersonNameInverted>You, Frank M.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>2OGD family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABC transporters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ABCDE model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abiotic stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abiotic stress tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Abscisic Acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acetolactate synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acteoside biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Agrobacterium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alien substitution line</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alternative splicing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anthocyanin biosynthetic genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Anthocyanins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apple</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aquaporin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aquaporins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Arabidopsis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aristolochia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>avocado</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>azafrin biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>B3 superfamily</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biosynthesis pathway</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biotic stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brachypodium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brassica rapa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>brassinosteroid-signaling kinase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BrBGLU10</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bright yellow-2 suspension cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium-dependent protein kinases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Camellia sinensis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Capsicum chinense</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>carotenoid biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cassava</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cassava (Manihot esculenta)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>catalpol biosynthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CDPK-related kinases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Centranthera grandiflora Benth</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cereals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chalcone synthase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chalcones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chemical fungicide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ChIP-sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chloroplast genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromatin accessibility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromosome 2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cis-elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cis-regulatory motifs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>citrulline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>co-integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cold response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>common bean</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>comparative chromosome barcoding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Comparative genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>compare analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cotton</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CRISPR/Cas9</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crop Improvement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CsWRKY7</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cucurbitaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cutin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cytokinins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>d60</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dasypyrum villosum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>data integration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>de novo assembly from short read sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DEGs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>differentially expressed genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>directional improvement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>disease control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drought</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drought stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>drought tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>duplication pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>duplication/triplication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dysploidy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epigenetic inheritance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Eucalyptus grandis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evolutionary analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>evolutionary relationships</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression pattern</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression profile</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>expression profiling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fabaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fatty acid synthesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ferrochelatase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fine mapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonolignans</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>floral organ</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>floral speciation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flower organ identity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flowering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>foxtail millet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fruit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fruit development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>full-length transcript sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Functional analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fusarium oxysproum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GASR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GDSL lipase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene co-expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene dosage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene duplications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene families</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gene recombination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene silencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genetic engineering</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome editing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome fractionation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome organization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome-wide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome-wide analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome-Wide Association Study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genome-wide association study (GWAS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genome-wide identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genomic selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genotype-to-phenotype association</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GISH</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glutamine synthetase (GS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GPAT6</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grain yield</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>grapevine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GW2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>habaneros</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>haplotype</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heat shock protein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hormone biosynthetic and metabolism genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hst1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hub genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Humanities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>identification of peroxidase genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intron retention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>invasive weed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>karyopherin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>karyotype structure and evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kernel hardness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lagerstroemia indica</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large grain gene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>large grain-isogenic Koshihikari</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leaf coloration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>leaf variegation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LIM genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linkage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linoleic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>linseed flax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lupinus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MADS-box</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MADS-box genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Maize</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>marker-assisted selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesocarp</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolite profiling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metabolome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>microRNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minor allele frequency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA156</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>missing data</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>model grass genus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular cytogenetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>molecular marker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple organellar RNA editing factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiplex genome editing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mutation hotspots</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Na+ accumulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>natural variation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NB-LRR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neoscytalidium dimidiatum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>network analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NGS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nicotiana tabacum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nutritional quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oak species identification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ODNs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ornamental value</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovule abortion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>PHI000000</SubjectCode><SubjectHeadingText>Philosophy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phosphoenolpyruvate carboxylase (PEPC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogenetic analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogenetic relationship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogeny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phytohormone signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phytohormones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pigment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pineapple</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pittosporum tobira</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plant breeding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant defense</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plant hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant hormones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plant–pathogen interaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plastid genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pollen development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polygalacturonase (PGs), pectin methylesterase (PMEs), collinearity analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyploidy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pomegranate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Populus trichocarpa</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prediction accuracy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein phosphatase (PP2C)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Puroindoline</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Puroindoline b-2 variants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>qRT-PCR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative trait loci (QTL)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quantitative trait nucleotides (QTNs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Quercus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rapid generation advance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reddish purple Chinese cabbage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Régulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehmannia glutinosa L.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>repeat sequences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>replant disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rhizoctonia solani</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rhizosphere microbes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA Editing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA-Seq</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNA-sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RNAi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ROS scavenging enzyme</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>royal poinciana</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salicaceae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Salinity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>salt tolerant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>seed development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>semidwarf gene</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sequence diversity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sesame</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Silybum marianum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>silymarin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Single nucleotide polymorphism (SNP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>site-specific selection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SNP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Solanum tuberosum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stem canker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stilbenes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stress marker genes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stress Tolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>structural genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subcellular localization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subgroup IId</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>substrate specificity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>syntenic relationships</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>synteny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systemic signal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TaCKX expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TaCKX1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TALEN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tobacco rattle virus (TRV)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tomato</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tomato fruit ripening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcription factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transcription Factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptional regulatory mechanism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transcriptome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transgenic rice</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transient expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transposable elements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>turnip</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UAE</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>variant annotation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virus-induced gene silencing (VIGS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitis vinifera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VQ genes family</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VvGAST</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>watermelon</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>wheat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wheat genome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wheat spikes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole-genome duplication</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole-genome sequencing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>YABBY</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ZFN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ZmTCP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-glucosidase</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Vols 1 and 2 contain 57 papers in the Special Issue of ‘Plant Genomics 2009’ and cover a wide range of topics, highlighting the significant progress that has been made in recent years in our understanding of the genetics and genomics of plants’ growth, development, and stress responses. These studies provide valuable insights into the potential applications of genomic tools and technologies for crop improvement and sustainable agriculture, as well as fundamental questions about the evolution and function of plant genes and genomes.<br/><br/>Listed by <a href="https://unglue.it/work/575199/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/d8/c7/d8c75c7c7561e8f261c794d286e7a6a7.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407720/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.455721.616604</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>616604</IDValue></ProductIdentifier><ProductIdentifier><ProductIDType>03</ProductIDType><IDValue>9783039214532</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY-NC-ND</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by-nc-nd/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Plug-in Hybrid Electric Vehicle (PHEV)</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>A01</ContributorRole><PersonName>Joeri Van Mierlo</PersonName><PersonNameInverted>Mierlo, Joeri Van</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>adaptive neuron-fuzzy inference system (ANFIS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Air quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial neural network (ANN)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attributional</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>battery power</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>capacity degradation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CO2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>consequential</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>convex optimization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dual inverter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dynamic programming</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>efficient energy management strategies for hybrid propulsion systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electric vehicle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electric vehicles (EVs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electricity mix</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emerging electric machines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emerging power electronics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Energy Efficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>energy management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>energy management strategy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Energy Storage systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>energy system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>engine-on power</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fuel consumption characteristics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>group method of data handling (GMDH)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>History of engineering &amp; technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hybrid electric vehicles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hybrid energy storage system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>including wide bandgap (WBG) technology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interleaved multiport converte</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LCA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Li(Ni1/3Co1/3Mn1/3)O2 battery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Li-ion battery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>life-cycle assessment (LCA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifetime model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lithium polymer battery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lithium-ion battery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lithium-ion capacitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>losses model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Marginal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Markov decision process (MDP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>measurements</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mobility needs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modified one-state hysteresis model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multi-objective genetic algorithm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>novel propulsion systems</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open-end winding</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>parallel hybrid electric vehicle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Paris Agreement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plug-in hybrid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plug-in hybrid electric vehicle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plug-in hybrid electric vehicles (PHEVs)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Plugin Hybrid electric vehicle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>power distribution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>power sharing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Q-learning (QL)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>range-extender</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regenerative braking</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reinforcement learning (RL)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>simulated annealing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>state of charge</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>state of health estimation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strong track filter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>system modelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology, engineering, agriculture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Technology: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>time-delay input</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>voltage vector distribution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Well-to-Wheel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>wide bandgap (WBG) technologies</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Climate change, urban air quality, and dependency on crude oil are important societal challenges. In the transportation sector especially, clean and energy efficient technologies must be developed. Electric vehicles (EVs) and plug-in hybrid electric vehicles (PHEVs) have gained a growing interest in the vehicle industry. Nowadays, the commercialization of EVs and PHEVs has been possible in different applications (i.e., light duty, medium duty, and heavy duty vehicles) thanks to the advances in energy storage systems, power electronics converters (including DC/DC converters, DC/AC inverters, and battery charging systems), electric machines, and energy efficient power flow control strategies. This book is based on the Special Issue of the journal Applied Sciences on “Plug-In Hybrid Electric Vehicles (PHEVs)”. This collection of research articles includes topics such as novel propulsion systems, emerging power electronics and their control algorithms, emerging electric machines and control techniques, energy storage systems, including BMS, and efficient energy management strategies for hybrid propulsion, vehicle-to-grid (V2G), vehicle-to-home (V2H), grid-to-vehicle (G2V) technologies, and wireless power transfer (WPT) systems.<br/><br/>Listed by <a href="https://unglue.it/work/455721/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/e7/1e/e71eea9bb49a00281fa48137d0247934.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>20190827</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/427563/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518918.695065</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695065</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Policies and Strategies in Sexual and Reproductive Health</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Juan Miguel Martínez Galiano</PersonName><PersonNameInverted>Galiano, Juan Miguel Martínez</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Miguel Delgado-Rodríguez</PersonName><PersonNameInverted>Delgado-Rodríguez, Miguel</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Abortion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adolescents</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apgar score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Attitudes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>birth attention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>China</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic fatigue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community pharmacies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>condom use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>consultation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic targets</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>economic recession</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ELISA-enzyme linked immunosorbent assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>emergency contraception</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometriosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epitopes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Equality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ethnic disparity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Family Planning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>female genital mutilation (FGM)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Germany</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gestational gain weight</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>government health expenditure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health professionals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV/AIDS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immunogens</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Infant Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>International Collaboration</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intimate partner violence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>labor stage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Latins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal and child health services</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal dietary patterns</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>maternal health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>midwifery continuity of care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>migrant women</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal intensive care unit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neonatal morbidity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>newborn care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-prescription drugs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Nursing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>offspring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient and public involvement</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient satisfaction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient simulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Post-traumatic stress disorder</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pre-post evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>predictive model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychometric</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosocial status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Public Health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality of maternity care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>reproductive behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Research</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risk groups</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>satisfaction questionnaire</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Second</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sera</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>serodiagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sexual Behavior</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sexual behaviour</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>sexual health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sexual risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sexually transmitted diseases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sexually transmitted infections</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>son preference</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STI prevention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Students</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>subsequent parity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Thailand</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transients and Migrants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Trichomonas vaginalis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ulipristal acetate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>umbrella review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>unintended pregnancies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>unplanned pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>US state laws</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Utilization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Validation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>validation study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>validity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Women</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>women’s health needs</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The topics covered in the book cover different aspects of sexual and reproductive health. This book provides novel research results that may be essential as a basis for the development of health policies and strategies in sexual and reproductive health. These policies are necessary to achieve greater health protection. Among others, issues as important as the increase in STIs, their risk factors, vulnerable situations and populations, as well as the issue of priority in reproductive health, such as the care that must be provided during pregnancy and childbirth in order to guarantee healthy women and children, are developed in the book. There is no doubt that women should be the preferential recipients of these health policies and strategies and, therefore, pathologies that have an impact on their quality of life as well as the situations of gender violence that these women experience also occupy a place within the content of this book. In this book, you can find interesting results allowing researchers to take into account in proposing new lines of research, students and academics to receive and transmit the most current and relevant knowledge, political leaders to develop adequate and efficient health policies and strategies, and clinical health professionals to work in clinical practice with the best available scientific evidence.<br/><br/>Listed by <a href="https://unglue.it/work/518918/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/d8/c5/d8c59301cd5b5c49fd5cacbbff36283e.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368340/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.543744.727776</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>727776</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Prevention and Management of Frailty</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Haewon Byeon</PersonName><PersonNameInverted>Byeon, Haewon</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jaewon Nah</PersonName><PersonNameInverted>Nah, Jaewon</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>accidental falls</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Aged</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Aging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Baduanjin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BDI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Brain stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical dementia rating</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognitive function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>color-changing chewing gum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community-based</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>community-dwelling older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>convergence rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cross-sectional study</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Data mining</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>depressive symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>determinants</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>driving cessation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly patients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endurance training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>explainable artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fall</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fall assessment sheet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frail</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FRAIL scale</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Frailty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frailty profiles</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>frailty syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gait analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gait speed</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Healthcare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospitalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>indicators</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>instrumental activities of daily living</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>latent class analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meaningful activities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Medicine: General Issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>middle-aged and older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mild Cognitive Impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mixing ability</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mood</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>motoric cognitive risk syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multiple risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Muscle strength</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>naming</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuropsychiatric symptoms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuropsychological test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neuropsychological Tests</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-robust</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nursing Homes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>older adults</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Parkinson’s disease dementia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Parkinson’s disease with mild cognitive impairment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perceived health</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical fitness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical frailty</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical functional performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prevalence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>primary progressive aphasia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychometric properties</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychosomatic functions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Public health &amp; preventive medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>qualitative evaluation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>random forest</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk factors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Risk management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>screening tool</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Self-Rating Anxiety Scale</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sleep quality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social isolation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social networks</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social participation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Social Support</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spousal concordance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>stacking ensemble</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STAI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>strength training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SUNFRAIL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SWLS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>three-item recall</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tilburg Frailty Indicator</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>It is important to prevent and manage the frailty of the elderly because their muscle strength and physical activity decrease in old age, making them prone to falling, depression, and social isolation. In the end, they need to be admitted to a hospital or a nursing home. When successful aging fails and motor ability declines due to illness, malnutrition, or reduced activity, frailty eventually occurs. Once frailty occurs, people with frailty do not have the power to exercise or the power to move. The functions of the heart and muscles are deteriorated more rapidly when they are not used. Consequently, frailty goes through a vicious cycle. As one’s physical fitness is deteriorated, the person has less power to exercise, poorer cognitive functions, and inferior nutrition intake. Consequently, the whole body of the person deteriorates. Therefore, in addition to observational studies to identify risk factors for preventing aging, various intervention studies have been conducted to develop exercise programs and apply them to communities, hospitals, and nursing homes for helping the elderly maintain healthy lives.  Until now, most aging studies have focused on physical frailty. However, social frailty and cognitive frailty affect senile health negatively just as much as physical frailty. Nevertheless, little is known about social frailty and cognitive frailty. This special issue includes original experimental studies, reviews, systematic reviews, and meta-analysis studies on the prevention of senescence (physical senescence, cognitive senescence, social senescence), high-risk group detection, differentiation, and intervention.<br/><br/>Listed by <a href="https://unglue.it/work/543744/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/388533/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.568665.760701</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>760701</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Prostate Cancer</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ana Faustino</PersonName><PersonNameInverted>Faustino, Ana</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Paula A. Oliveira</PersonName><PersonNameInverted>Oliveira, Paula A.</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>androgen receptor signaling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>androgen-deprivation therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bioinformatics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biopsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Circulating Tumor Cell (CTC)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Classification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Cognitive function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computed Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Depression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic algorithm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dkk1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DNA Methylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>focal adhesion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gene expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gleason pattern 4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Gleason score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>histone deacetylation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laser capture microdissection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Liquid Biopsy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>long noncoding RNA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymph node invasion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymph node metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnetic resonance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NEAT1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic lymph node dissection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>positron emission tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preoperative nomogram</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prostate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate cancer (PCa)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate health index</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate-specific membrane antigen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protein filament</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PUR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PUR-4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radical prostatectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiomic features</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Reference, information &amp; interdisciplinary subjects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Research &amp; information: general</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risk stratification</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Sleep</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>STEAP1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Testosterone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Wnt</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>WNT5A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>β-catenin</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The prostate is the largest accessory gland of the male reproductive tract. Together with seminal vesicles and bulbourethral glands, the prostate is responsible for the production of an alkaline fluid that forms part of the seminal fluid. The prostates of men over 40 years of age are commonly affected by several pathologies, such as benign prostate hyperplasia and cancer. Prostate cancer is one of the most frequently occurring cancers among men population worldwide. According to the World Health Organization (WHO), in the year 2018, prostate cancer affected approximately 1.28 million men and was responsible for the death of 358,989 of them. Prostate cancer development is associated with several risk factors, such as older age, black ethnicity, a family history of disease, an increased body mass index and obesity. In this way, the risk of prostate cancer development may be reduced through the consumption of a healthy diet full of fruits and vegetables, practice of physical exercise and maintenance of a healthy weight.Despite several approaches being available for prostate cancer treatment, the number of prostate cancer deaths is continuously increasing, which emphasizes the need to search for new methods for precocious diagnosis and more effective treatment. Animal models, including rodents, have greatly contributed to the study of biopathology and the prevention and treatment of prostate cancer.This Special Issue presents original research works, case reports and reviews concerning the diagnosis, treatment and prognosis of prostate cancer, highlighting new advances in this field.<br/><br/>Listed by <a href="https://unglue.it/work/568665/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2023</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/407197/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491568.659356</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659356</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Recent Advances and Clinical Outcomes of Kidney Transplantation</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Wisit Cheungpasitporn</PersonName><PersonNameInverted>Cheungpasitporn, Wisit</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Charat Thongprayoon</PersonName><PersonNameInverted>Thongprayoon, Charat</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Napat Leeaphorn</PersonName><PersonNameInverted>Leeaphorn, Napat</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute humoral rejection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute rejection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adaptive Immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADPKD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>all-cause mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>allograft survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alport syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibody-mediated rejection (AMR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arsenic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atypical hemolytic uremic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autosomal dominant polycystic kidney disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Belatacept</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>beliefs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BK virus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BK virus nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BKV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BKVAN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Branched chain amino acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C/D ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C/D-ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C3d-binding assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcineurin inhibitor nephrotoxcity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcineurin inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular high risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD45RC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>creatinine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>delayed graft function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>donor-specific antibodies (DSA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eculizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epidermal growth factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ethnicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fast tacrolimus metabolizers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>first-line therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fish consumption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FK506</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluid management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genetic relationship donor/recipient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glomerulus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose intolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>goal-directed fluid therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>graft failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>graft survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>growth hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy subject</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospitalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperchloremia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperoxaluria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypomagnesaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypothermic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxic inducible factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunosuppression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inequity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infectious mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Innate immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin secretion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin-like growth factor 1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemia reperfusion injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kidney</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney allograft</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney graft dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplant (KT)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplant recipients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living donor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living donor kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living kidney donation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living-donor kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphocyte</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machine perfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnesium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malondialdehyde</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methanogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methanosphaera stadtmanae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle mass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mycophenolic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N1-methyl-2-pyridone-5-carboxamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N1-methylnicotinamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>native nephrectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>necrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nephrotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>new onset diabetes after renal transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>new-onset diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>niacin status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>night-time renal transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>normothermic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opportunistic infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral glucose tolerance test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>organ preservation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxalate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidative stress.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient survival/outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacokinetic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacokinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogeny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasmapheresis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyomavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-transplant diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-transplant malignancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-transplantation diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>posttransplant diarrhea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proteasome inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proton pump inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proton-pump inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplant recipients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplantation.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single nucleotide polymorphisms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Subarachnoid Hemorrhage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfate-reducing bacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Systematic Reviews</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tacrolimus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tacrolimus metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>temperature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>timing of removal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transplant recipients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transplant rejection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tryptophan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UPEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ureteric stent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary excretion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary excretion of N1-methylnicotinamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary tract infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urological complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Uropathogenic E. coli</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virulence traits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin B3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-GST</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>π-GST</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.<br/><br/>Listed by <a href="https://unglue.it/work/491568/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381703/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491723.659511</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659511</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Recent Advances and Clinical Outcomes of Kidney Transplantation</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Wisit Cheungpasitporn</PersonName><PersonNameInverted>Cheungpasitporn, Wisit</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Charat Thongprayoon</PersonName><PersonNameInverted>Thongprayoon, Charat</PersonNameInverted></Contributor><Contributor><SequenceNumber>3</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Napat Leeaphorn</PersonName><PersonNameInverted>Leeaphorn, Napat</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute humoral rejection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>acute rejection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adaptive Immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ADPKD</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Age</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>all-cause mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>allograft survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alport syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibiotic resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antibody-mediated rejection (AMR)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>arsenic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>atypical hemolytic uremic syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autosomal dominant polycystic kidney disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Belatacept</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>beliefs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BK virus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BK virus nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BKV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BKVAN</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Branched chain amino acids</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C/D ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C/D-ratio</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>C3d-binding assay</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcineurin inhibitor nephrotoxcity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcineurin inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cancer mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular high risk</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cardiovascular mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD45RC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Children</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>creatinine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>delayed graft function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Diet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dietary intake</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>donor-specific antibodies (DSA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eculizumab</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endothelial dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epidemiology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>epidermal growth factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ethnicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fast tacrolimus metabolizers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>first-line therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fish consumption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FK506</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fluid management</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genetic relationship donor/recipient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GFR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glomerulus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>glucose intolerance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>goal-directed fluid therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>graft failure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>graft survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>growth hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>healthy subject</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hospitalization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperchloremia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hyperoxaluria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypomagnesaemia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypothermic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hypoxic inducible factor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunosuppression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inequity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>infectious mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Innate immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Insulin Resistance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin secretion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>insulin-like growth factor 1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Iron deficiency</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ischemia reperfusion injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kidney</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney allograft</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney graft dysfunction</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplant (KT)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplant recipients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living donor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living donor kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living kidney donation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>living-donor kidney transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphocyte</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>machine perfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>magnesium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malondialdehyde</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>methanogenesis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Methanosphaera stadtmanae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucins</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>muscle mass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mycophenolic acid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N1-methyl-2-pyridone-5-carboxamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>N1-methylnicotinamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>native nephrectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>necrosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nephropathy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nephrotoxicity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>new onset diabetes after renal transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>new-onset diabetes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>niacin status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>night-time renal transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>normothermic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Obesity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>opportunistic infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oral glucose tolerance test</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>organ preservation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>outcomes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxalate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Oxidative Stress</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oxidative stress.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient survival/outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perioperative complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacokinetic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacokinetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phylogeny</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>physical activity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>plasmapheresis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>polyomavirus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-transplant diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-transplant malignancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>post-transplantation diabetes mellitus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>posttransplant diarrhea</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proteasome inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proton pump inhibitor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>proton-pump inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal cell carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplant recipients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal transplantation.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single nucleotide polymorphisms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Subarachnoid Hemorrhage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sulfate-reducing bacteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Systematic Reviews</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tacrolimus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tacrolimus metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>temperature</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>timing of removal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transplant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transplant recipients</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transplant rejection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Transplantation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tryptophan</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>UPEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ureteric stent</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary excretion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary excretion of N1-methylnicotinamide</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urinary tract infection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urological complications</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Uropathogenic E. coli</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>virulence traits</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vitamin B3</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Vitamin C</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>α-GST</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>π-GST</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Advances in immunosuppression and kidney transplant techniques have led to significant improvements in the short-term survival of the renal allograft. Long-term graft survival, however, has relatively lagged behind and has now become one of the main problems in kidney transplantation. In this Special Issue, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored.<br/><br/>Listed by <a href="https://unglue.it/work/491723/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2020</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381850/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.518962.695109</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>695109</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Recent Advances in Minimally Invasive Surgery</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Matthias Biebl</PersonName><PersonNameInverted>Biebl, Matthias</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Ibrahim Alkatout</PersonName><PersonNameInverted>Alkatout, Ibrahim</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>3D printing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Anesthetics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-Müllerian hormone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>augmented reality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>autonomic pelvic nerves</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biliopancreatic diversion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>body donors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cervical cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cholangiocarcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic pelvic pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>clinical anatomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>colorectal liver metastases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>conversion rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Counseling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>COVID-19</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cysts of the canal of Nuck</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>da Vinci</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diaphragmatic hernia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>embryologic development</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Embryology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometrial cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometrial neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometrioma surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>endometriosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Endoscopic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Endoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>enterothorax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>esophageal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>esophagectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fetal surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>general anesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genital nerves stimulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Gynecology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>health-related quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatic metastasis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hernia repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hydrocelectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hysterectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hysteroscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>indocyanine green</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intercostal catheter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intraoperative imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Ivor-Lewis procedure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laparoscopic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laparoscopic hysterectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laparoscopic liver surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laparoscopic repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Laparoscopic Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>laparoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>learning curve</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Lichtenstein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LION procedure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>live surgery events</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver resection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>local recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lymphadenectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malabsorption</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesh</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesh use</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mesorectal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimal invasive surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimally invasive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimally invasive surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>minimally invasive surgical procedures</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mortality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>native tissue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuropelveology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>notes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Nuck hydrocele</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>oncologic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>one-anastomosis gastric bypass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>open surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Opioid</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovarian cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovarian neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovarian reserve</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreaticoduodenectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>patient-doctor-relationship</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pectopexy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pediatric surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic compartments</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic floor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic floor repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvic lymphonodectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pelvitrainer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Perioperative Care</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Platelet-Rich Plasma (PRP)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PMMR</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>postoperative pain control</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prolapse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Quality of life</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiofrequency pre-coagulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>real-life imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rectal cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence rate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>regional anaesthesia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>risk score</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic assisted surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic liver resection</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic radical hysterectomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>robotic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Roux-en-Y gastric bypass</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SADI-S</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SARS-CoV-2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sentinel lymph node mapping</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sexuality</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-incision surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>single-port laparoscopy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>skill assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>snorkel mask</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spontaneous pregnancy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical devices</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical education</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical performance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Surgical techniques</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>surgical training</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival Analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TAPP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>technical aspects</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thin endometrium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>thoracic surgery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>topographic anatomy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transanal</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>uterine cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>uterine cervical neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vaginal neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vaginal repair</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VATS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video feedback</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>video modeling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>vulvar neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>weight regain</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>Minimally invasive surgery has become a common term in visceral as well as gynecologic surgery. It has almost evolved  into its own surgical speciality over the past 20 years. Today, being firmly established in every subspeciality of visceral surgery, it is now no longer a distinct skillset, but a fixed part of the armamentarium of surgical options available. In every indication, the advantages of a minimally invasive approach include reduced intraoperative blood loss, less postoperative pain, and shorter rehabilitation times, as well as a marked reduction of overall and surgical postoperative morbidity. In the advent of modern oncologic treatment algorithms, these effects not only lower the immediate impact that an operation has on the patient, but also become important key steps in reducing the side-effects of surgery. Thus, they enable surgery to become a module in modern multi-disciplinary cancer treatment, which blends into multimodular treatment options at different times and prolongs and widens the possibilities available to cancer patients. In this quickly changing environment, the requirement to learn and refine not only open surgical but also different minimally invasive techniques on high levels deeply impact modern surgical training pathways. The use of modern elearning tools and new and praxis-based surgical training possibilities have been readily integrated into  modern surgical education,which persists throughout the whole surgical career of modern gynecologic and visceral surgery specialists.<br/><br/>Listed by <a href="https://unglue.it/work/518962/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>https://tieulgnu.s3.amazonaws.com/cache/9c/0f/9c0f6f05abaf65a93745c2c36440e24d.jpg</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/368367/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.492203.659992</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659992</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Rehabilitation for Persistent Pain Across the Lifespan</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Jo Nijs</PersonName><PersonNameInverted>Nijs, Jo</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Kelly Ickmans</PersonName><PersonNameInverted>Ickmans, Kelly</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>action observation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attachment theory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attachment-informed intervention</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>attentional biases</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>best evidence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biology, Life Sciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>children pain rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic neck pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Chronic Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cost-effectiveness</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cost–utility</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dissociation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>early change</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>electric stimulation therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>eye gaze</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Fibromyalgia</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hierarchical structure</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>individualisation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interdisciplinary multimodal pain therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>interdisciplinary pain treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Life sciences: general issues</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lifestyle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Low back pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>low-back pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>manual therapies</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mathematics &amp; science</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mind-body medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mind-body therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Motor Imagery</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>musculoskeletal pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neck pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Neurosciences</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-pharmacological</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain acceptance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain modulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain neuroscience</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pain-catastrophizing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Patient Care Team</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Physiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>programme dosage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>10</SubjectSchemeIdentifier><SubjectCode>PSY000000</SubjectCode><SubjectHeadingText>Psychology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>psychology review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Qigong</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quality-adjusted life years</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>range of motion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Rehabilitation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rehabilitation medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>shoulder pain</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tai chi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>total knee arthroplasty (TKA)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Treatment Outcome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Yoga</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>The area of rehabilitation research for patients having persistent pain is on the move. The rapid growth in pain science has inspired rehabilitation clinicians and researchers around the globe. This has led to breakthrough research and implementation of modern pain science in rehabilitation settings around the world. Still, our understanding of persistent pain continues to grow, not in the least because of fascinating discoveries from areas such as psychoneuroimmunology, exercise physiology, clinical psychology and nutritional (neuro)biology. This offers unique opportunities to further improve rehabilitation for patients with chronic pain across the lifespan. Also, the diversity of health care disciplines involved in the rehabilitation of chronic pain (e.g. physicians, psychologists, physiotherapists, occupational therapists, nurses, coaches) provides a framework for upgrading rehabilitation for chronic pain towards comprehensive lifestyle approaches.<br/><br/>Listed by <a href="https://unglue.it/work/492203/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/382321/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.534441.715623</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>715623</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Research Topics in Medicines and How Our Board Members Are Engaged in Them</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Hiroshi Sakagami</PersonName><PersonNameInverted>Sakagami, Hiroshi</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>abdominal breathing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>alkaline extract of Sasa sp.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>allergic rhinitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Angelicae Sinensis Radix</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-acetylcholinesterase</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>anti-inflammatory</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antidiabetic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antifouling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antimicrobial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antioxidant</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>antitumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>aphthous stomatitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Apoptosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>artificial intelligence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>auricular acupuncture</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biliary tract cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bioactive compounds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biochanin A</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Biofilm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>boiogito</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>bone metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>BRCA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>breathing exercise</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>calcium metabolism</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cell cycle analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cholangiocarcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chromone</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>chronic liver disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cobblestoning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>contrast-enhanced ultrasound</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>coronarin D</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CRBSI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Crohn’s disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CVC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>daidzein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Danggui</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>detection of the precursory signs of decompensation of geriatric syndromes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diagnostic algorithm</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diaphragmatic breathing</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Dili</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>elderly patient</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>extra-intestinal manifestations</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>fentanyl</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>flavonols</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Genista tridentata</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genistein</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>genomic landscape</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>GER-e-TEC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>geriatric syndromes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>granules</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>granuloma annulare</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>granulomatous disorders of the skin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hedychium</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>hepatocellular carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Herb</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>herb induced liver injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>herbal medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HILI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HIV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HSV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>human CD4+ T cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iDILI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>iDrug induced liver injury</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immune system</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>in vitro</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Inflammation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory bowel disease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>inflammatory skin conditions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intravascular catheter</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>isoflavones</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Kampo formulae</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>knee osteoarthritis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LI-RADS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>lip swelling</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>liver cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>loss of infectivity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>LPS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>macrophage</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>medical dermatology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>modulation</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mucogingivitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>multivariate analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>olaparib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>orofacial granulomatosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>osteoclast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic adenocarcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pancreatic Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PARP</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pharmacological activities</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>phosphorylated extracellular signal-regulated kinase (pERK)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Phytochemicals</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pine cone extract</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>povidone-iodine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>preoperative anxiety</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protease</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>protocol</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Pterospartum tridentatum</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Qigong</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>QSAR analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>quercetin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trial</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>randomized controlled trials</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RANKL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rat</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>remote monitoring</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>renal cell cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>respiratory function</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Roussel Uclaf Causality Assessment Method</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>RUCAM</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rucaparib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>rutin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Sarcoidosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>solubilization method</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Stachys L.</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>superior vena cava syndrome</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>systematic review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tag-like lesions</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Tai chi</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Telemedicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Th1/Th2 cytokine balance</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TLR4</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Traditional medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>traditional uses</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>transient receptor potential ankyrin 1 (TRPA1) channel</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>TREM2</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor evolution</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor heterogeneity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>tumor specificity</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ulcerative colitis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ultra-performance liquid chromatography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>venous thrombosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>villosin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>whole-cell patch-clamp recording</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Yokukansan</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>With the development of analytical instruments, the academic system has become more complicated, producing new journals one after another. Therefore, it became much important to clarify what is original of “Medicines”. As the name Medicines indicates, it includes science and practice of caring for a patient and managing the diagnosis, prognosis, prevention, treatment or palliation of their injury or disease. Therefore, Medicines differs from other journals with similar title in that it covers a wide range of fields, from traditional medicine to rapidly developing molecular-targeted drugs, focusing on their pharmacological effects, structure–activity relationships, metabolic pathways, gene expression, using cultured cells, animals, and clinical trials. Most parts of this Special Issue were written by our editorial board members, who described the research topics and how they are engaged in their field of research. All of these articles are their life-long story. We collected a total number of 22 original works by basic researchers and clinical doctors. We hope that readers can get a chance to know the current status of diverse fields of medicines, and what your most important research themes are after reading these articles.<br/><br/>Listed by <a href="https://unglue.it/work/534441/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2022</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/379291/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product><Product><RecordReference>it.unglue.work.491622.659410</RecordReference><NotificationType>03</NotificationType><ProductIdentifier><ProductIDType>01</ProductIDType><IDTypeName>unglue.it edition id</IDTypeName><IDValue>659410</IDValue></ProductIdentifier><DescriptiveDetail><ProductComposition>00</ProductComposition><ProductForm>ED</ProductForm><ProductFormDetail>E107</ProductFormDetail><EpubLicense><EpubLicenseName>CC BY</EpubLicenseName><EpubLicenseExpression><EpubLicenseExpressionType>01</EpubLicenseExpressionType><EpubLicenseExpressionLink>https://creativecommons.org/licenses/by/3.0/</EpubLicenseExpressionLink></EpubLicenseExpression></EpubLicense><TitleDetail><TitleType>01</TitleType><TitleElement><TitleElementLevel>01</TitleElementLevel><TitleText>Role of Medical Imaging in Cancers</TitleText></TitleElement></TitleDetail><Contributor><SequenceNumber>1</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Stefano Fanti</PersonName><PersonNameInverted>Fanti, Stefano</PersonNameInverted></Contributor><Contributor><SequenceNumber>2</SequenceNumber><ContributorRole>B01</ContributorRole><PersonName>Laura Evangelista</PersonName><PersonNameInverted>Evangelista, Laura</PersonNameInverted></Contributor><Language><LanguageRole>01</LanguageRole><LanguageCode>eng</LanguageCode></Language><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>18F-FACBC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>18F-FDG PET/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>68Gallium-PSMA PET/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adipose Tissue</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Adoptive</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biochemical recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>biomarkers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Bladder cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>Breast</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>castrate resistant prostate cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CD8-Positive T-Lymphocytes</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating miRNAs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>circulating tumor cells</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computed Tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Computer-assisted diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>concurrent chemoradiotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Consensus</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>CTLA-4 Antigen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>cystic tumor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DCFBC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>DCFPyL</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Deauville criteria</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diagnostic imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diffuse large B-cell lymphoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diffusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>diffusion kurtosis imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diffusion Tensor Imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Diffusion-weighted imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynamic 18F-FDG PET/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>dynamic contrast-enhanced magnetic resonance imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>EBV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>empyema</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Epistemology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FDG</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>FDG-PET/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>follow up</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Glioblastoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>gold nanoparticle</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>guidelines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Head and Neck Cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>head and neck neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>heat shock protein 70</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hodgkin lymphoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Hounsfield unit</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>HPV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>imaging parameters</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>immune checkpoint inhibitors</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Immunotherapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>International Consensus Guidelines</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>intraductal papillary mucinous neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>locally advanced cervical cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Machine learning</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Magnetic Resonance Imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>malignant pleural mesothelioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mantle cell lymphoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Märker</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>mCRPC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>04</SubjectSchemeIdentifier><SubjectHeadingText>medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>meningioma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Mesothelin</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Meta-analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>metastatic breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>miRNA expression</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Molecular imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>n/a</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neovascularization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>neuroimaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>non-small-cell lung cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>noninvasive imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>NSCLC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>nuclear medicine</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>optimal cutoff level</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>ovarian cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>overutilization</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>p16</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pancreatic neoplasms</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pathologic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pazopanib</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PD-L1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PDAC</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PERCIST</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>perfusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pet</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PET/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PET/MRI</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PI-RADS</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pleural dissemination</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>pleural effusion</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>positron emission tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>positron-emission tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>precision oncology</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prognosis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>programmed cell death 1 receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Prostate</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>prostate-specific-antigen</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PSA kinetics thresholds</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PSMA</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>PSMA-1007</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiation therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radioactive tracers</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiogenomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiomic</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radiomics</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radionuclide imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>radionuclide therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Radium-223</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>receptor status</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>recurrence</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>relapse</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>response assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>response to therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>response to treatment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>review</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>sdAbs</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Single-photon emission computed tomography</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>soft tissue sarcoma (STS)</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>somatostatin receptor</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SPECT imaging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SPECT/CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>spectral-CT</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>squamous cell carcinoma of the head and neck</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Staging</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Survival</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SUV</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>SUVmax</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>targeted therapy</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>texture analysis</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Therapy response assessment</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>treatment response</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>triple negative breast cancer</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>two-tissue compartment model</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>upper tract urothelial carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>urothelial carcinoma</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>VCAM-1</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>XOFIGO</SubjectHeadingText></Subject><Subject><SubjectSchemeIdentifier>20</SubjectSchemeIdentifier><SubjectHeadingText>Yin Yang 1</SubjectHeadingText></Subject><AudienceRange><AudienceRangeQualifier>17</AudienceRangeQualifier><AudienceRangePrecision>03</AudienceRangePrecision><AudienceRangeValue>18</AudienceRangeValue></AudienceRange></DescriptiveDetail><CollateralDetail><TextContent><TextType>03</TextType><ContentAudience>00</ContentAudience><Text textformat="05"><div>undefined<br/><br/>Listed by <a href="https://unglue.it/work/491622/">Unglue.it</a>.</div></Text></TextContent><SupportingResource><ResourceContentType>01</ResourceContentType><ContentAudience>00</ContentAudience><ResourceMode>03</ResourceMode><ResourceVersion><ResourceForm>01</ResourceForm><ResourceVersionFeature><ResourceVersionFeatureType>01</ResourceVersionFeatureType><FeatureValue>D502</FeatureValue></ResourceVersionFeature><ResourceLink>/static/images/generic_cover_larger.png</ResourceLink></ResourceVersion></SupportingResource></CollateralDetail><PublishingDetail><Publisher><PublishingRole>01</PublishingRole><PublisherName>MDPI - Multidisciplinary Digital Publishing Institute</PublisherName></Publisher><PublishingStatus>00</PublishingStatus><PublishingDate><PublishingDateRole>01</PublishingDateRole><Date>2021</Date></PublishingDate></PublishingDetail><ProductSupply><Market><Territory><RegionsIncluded>WORLD</RegionsIncluded></Territory></Market><SupplyDetail><Supplier><SupplierRole>11</SupplierRole><SupplierName>Unglue.it</SupplierName><Website><WebsiteRole>29</WebsiteRole><WebsiteDescription textformat="06">pdf file download</WebsiteDescription><WebsiteLink>https://unglue.it/download_ebook/381756/</WebsiteLink></Website></Supplier><ProductAvailability>20</ProductAvailability><Price><PriceType>01</PriceType><PriceAmount>0.00</PriceAmount><CurrencyCode>USD</CurrencyCode></Price></SupplyDetail></ProductSupply></Product></ONIXMessage>